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ABSTRACT 
Human Papillomavirus (HPV) vaccination among adolescents lags behind 
those of other adolescent vaccines, including the tetanus-diphtheria-acellular 
pertussis (Tdap) and the meningococcal conjugate vaccine (MCV4). This research 
sought to understand barriers to recommending and administering the HPV vaccine 
to adolescents in Colorado, with focus on providers serving low-income populations 
who are at high risk for HPV related cancer and other diseases.  
Colorado’s Vaccine for Children (VFC) and primary care service area data 
were used to identify high and low HPV vaccine ordering practices compared to 
Tdap vaccine and compared to neighboring practices. Using adapted grounded 
theory, semi-structured interviews were conducted with 26 providers from these 
practices. This study identified barriers and facilitators to HPV vaccine uptake 
among VFC participating providers. Hypotheses generated using qualitative findings 
were tested for generalizability using All Payer Claims Database data. Logit 
regression was used to model likelihood of HPV vaccine initiation and completion 
among children ages 11-18. Oaxaca-Blinder (OB) regression decomposition was 
used to identify explained and unexplained factors between ethnicity and public- 
versus privately-insured groups.  
Qualitative research results described parental, provider, and policy level 




hesitancy and lack of consistent recommendation by providers. Steps taken to 
improve HPV vaccine acceptability included creative communications with parents 
and adolescents about HPV and extended office hours to administer vaccines.  
Quantitative analysis showed that males, adolescents with male providers, 
and patients who saw providers other than primary care providers were significantly 
less likely to initiate the HPV vaccine and less likely to complete the full dose. 
Hispanics were more likely to initiate and complete the three dose HPV vaccine 
series. A 12.15 percentage point of disparity in initiating and 2.99 percentage point in 
completing the HPV vaccine existed between non-Hispanics and Hispanics. 
Additionally, publicly insured adolescents were more likely to initiate (3.99 
percentage point disparity) where as non-publicly insured were more likely to 
complete (5.4 percentage point disparity) the three dose HPV vaccine series. OB 
decomposition showed explained and unexplained factors in driving the observed 
disparity in HPV vaccine initiation and completion between the groups. Patient and 
provider gender, provider type, and insurance status influenced explained 
differences in HPV vaccine uptake.  
Even though higher vaccination rates among low income groups than non-low 
income groups are observed, significant challenges to HPV vaccine initiation and 
completion remain. Efforts to improve HPV vaccine uptake should target amenable 
factors that influence and explain HPV vaccine uptake. The findings from this 
research quantify explainable factors in variation that could be influenced to improve 
HPV vaccine uptake. Researchers, policy makers, and practitioners could use this 




done to understand unexplained patient, provider, and population level factors that 
influence HPV vaccine uptake.  
The form and content of this abstract are approved. I recommend its publication. 
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Human Papillomavirus (HPV) is the most common sexually-transmitted virus 
in the United States, and it is transmitted through intimate skin-to-skin contact (CDC, 
2015). Some HPV strains can cause warts (papillomas) while other types can lead to 
cancer, especially cervical cancer (CDC, 2015). About 79 million Americans are 
currently infected with HPV and about 14 million people become newly infected each 
year (Centers for Disease Control and Prevention [CDC], 2015). The annual overall 
direct medical cost of preventing and treating HPV-associated disease was 
estimated to be $8 billion (2010 U.S. dollars) (Chesson et al., 2012). 
Vaccines given in three doses over six months or two doses over six months, 
depending on age of initial vaccination, can prevent infection with the most common 
strains of HPV. Three types of HPV vaccines are licensed by the Food and Drug 
Administration (FDA) to prevent infections related to the most common types of 
HPV: the quadrivalent HPV vaccine for HPV types 6,11,16,18 (Gardasil), the 
bivalent HPV vaccine for types 16, 18 (Cervarix), and the 9-valent vaccine for HPV 
types 6,11,16,18, 31, 33, 45, 52, 58 (9vHPV). As of this writing, essentially all the 
HPV vaccines delivered in the US in the near term will be 9vHPV. The bivalent HPV 
vaccine can be given for ages 9-26, quadrivalent vaccine for ages 9-26, and 9-valent 
for girls and boys aged 9-26.  The HPV vaccine is currently recommended for 
adolescent children 11 through 12 years of age primarily because the vaccine is 
most effective when administered before the onset of sexual activity, when exposure 




frequently than younger adolescents. The vaccine is ineffective against HPV types 
previously acquired by the vaccine recipient (Committee on Infectious Diseases, 
2012). Antibody responses are also higher among children ages 9 through 15 
compared to 16-24 year-olds, though the clinical significance of this is unclear. 
Although geometric mean titers (GMTs) are lower in the older age groups, the 
immune response is still likely protective (Centers for Disease Control and 
Prevention [CDC], 2012).  
Three dose of the HPV vaccine were originally recommended until a change 
in dosage was announced in October 2016. The current recommended 
immunization schedule is 2 doses of the HPV vaccine for those initiating the HPV 
vaccine before age 15. The second dose should be administered 6-12 months after 
the first dose. However, for those initiating HPV vaccinations after their 15th 
birthday, the recommended immunization schedule is 3 doses. The second dose 
should be administered one to two months after the first dose, and the third dose 
should be administered six months after the first dose. Three doses of the HPV 
vaccine for all age groups was the standard until October 2016 (Meites, Kempe, & 
Markowitz, 2017).  
The National Immunization Survey–teen (NIS-teen) in the United States 
showed that the HPV vaccination rate lags behind that of other recommended 
adolescent vaccines such as tetanus-diphtheria-acellular pertussis (Tdap), and the 
meningococcal conjugate vaccine (MCV4). In Colorado, only 58% of females and 
33.5% of males have received one dose of the HPV vaccine (NIS teen, 2013). In 




boys in Colorado (Colorado Department of Public Health & Environment [CDPHE], 
2017). Although this is an increasing trend, it is significantly lower than Tdap and 
other adolescent vaccine rates. Healthy People 2020 vaccination targets for 
adolescent children aged 13-15 years were reached in many states for Tdap (target: 
80%) and meningococcal (target: 80%) vaccines. However, no state met the Healthy 
People 2020 target of 80% for HPV vaccine doses (Elam-Evans et al., 2014; Healthy 
People 2020).  
Several barriers have been identified to explain the low HPV vaccination 
rates. A systematic review of barriers to HPV vaccination among U.S. adolescents 
found that health care professionals and parents cited financial concerns as one of 
the primary barriers to provision and receipt of the HPV vaccine, although this barrier 
appears to have been mitigated in recent years (Holman et al., 2014). In addition, 
parents consistently cited health care professional recommendations as one of the 
most important factors in their decision to vaccinate their children. In 2013 parents 
indicated that one of the top reasons they had not vaccinated their adolescent 
children with HPV vaccine was that there had not been a provider recommendation 
for the vaccination (Elam-Evans et al., 2014).  
 The perceived high cost of the HPV vaccine, combined with too few provider 
recommendations, might have slowed current vaccine dissemination. The drug 
company price for the HPV vaccine is around $130-$140 per dose, not including the 
cost of giving the shots or the provider’s fee. As a result, three shots over six months 
could cost $500 or more for uninsured individuals, making it one of the most 




[CDC], 2016). Expensive vaccines may present financial challenge for families. 
However, the Vaccine for Children (VFC) program offers vaccines, including HPV, 
free of charge for qualifying individuals. The program removes the cost barrier for 
obtaining immunizations among children 18 years of age and younger. However, 
even among VFC providers, the HPV vaccine coverage rate is lower than other 
adolescent vaccines. Furthermore, a 2009 study compared VFC and non-VFC 
eligible adolescent immunization rate and found that coverage among non-VFC 
eligible adolescents was about 43% for at least one dose and about 46.6% for VFC 
eligible adolescents between ages 13-17 (Lindley, Smith, & Rodewald, 2011). HPV 
vaccine coverage in the adolescent population is a few percentages higher in the 
VFC-eligible population, but not adequate. This research study will focus on VFC 
program-participating providers in Colorado to understand barriers to HPV vaccine 
recommendation and provision. VFC providers serve low-income populations who 
are at higher risk for HPV infection and related disease, making this a very important 
focus area. Findings from VFC providers will further be explored to explore the 
generalizability of findings to HPV vaccine landscape in Colorado. 
 The overall objective of this study is to identify VFC provider barriers to 
providing the adolescent HPV vaccine, and to understand provider barriers, 
attitudes, and practices towards HPV vaccination, which will help researchers and 
policy makers to target interventions to increase HPV vaccine uptake and decrease 




Specific Aims and Hypotheses 
Aim 1 
Identify geographic areas and VFC provider sites that are high and low 
performing in terms of HPV vaccine relative to Tdap vaccine ordering ratio.  
Hypothesis. Providers who are less likely to administer HPV vaccinations 
than Tdap will have a lower HPV vaccine ordering ratio due to low anticipated usage 
of the HPV vaccine.   
Rationale. The VFC program, which is aimed at removing cost barriers to 
vaccination, provides free vaccines for eligible patients under participating providers. 
However, HPV vaccine coverage in the VFC-eligible adolescent population is 
inadequate, as it is among the non-VFC eligible population. At the time of this 
study’s conception, the recommended three-dose HPV vaccination rate was quite 
low and the two-dose recommendation was just starting. To focus on HPV-specific 
barriers and precursors rather than issues surrounding the vaccine in general, we 
identified practices that have either a high or low HPV vaccine-ordering ratio relative 
to Tdap. This allowed us to identify providers for qualitative interviews about the 
provision of the HPV vaccine. Focusing on the low performers provided information 
that could be used for vaccine uptake improvement efforts whereas high performing 
sites could share their best practices that helped them.   
Existing VFC provider ordering data was analyzed to identify providers and 
primary care service areas (PCSAs) with high and low HPV vaccine-ordering ratios 
relative to Tdap. This information was used to develop a qualitative interview sample 




asked if they were interested participating in key informant interviews to identify 
barriers to providing the HPV vaccine to adolescents in their practice.  
Aim 2 
Use key informant interviews to identify the root causes of provider variations 
and barriers to recommending and administering the HPV vaccine to adolescents in 
Colorado. 
Hypothesis. Significant provider variation and barriers to recommending and 
administering HPV vaccine for adolescents exist in Colorado among VFC providers 
due to provider concerns such as their personal discomfort discussing sexually 
transmitted infections with teens.  
Rationale. Because the VFC program provides vaccines free of charge to 
children, removing the cost burden of the HPV vaccine series, understanding 
additional factors that influence HPV vaccine ordering and recommendation 
variations will lead to a better understanding of the challenges providers face in 
Colorado. Analysis of this qualitative information will provide key information in 
Colorado that could be used to focus interventions to increase HPV vaccine uptake. 
Furthermore, hypotheses that emerged from our qualitative results were used to 
inform Aim 3 analyses. 
Aim 3  
Understand the contribution of provider, patient, and PCSA characteristics to 




Hypothesis. We expected testable hypotheses to emerge from the qualitative 
interviews related to patient, provider, and population level factors that could be 
tested using our quantitative data.   
Rationale. The analysis of quantitative data will provide a more general 
description of how patient, provider, and population level factors influence HPV 
vaccination rates among adolescents in Colorado. It provides more generalizable 
information across Colorado to assess whether findings from the qualitative sample 
pertain to the rest of Colorado. In doing so, the analysis will support or refute some 
of the conclusions and hypotheses that arise from the qualitative inquiry. In addition, 
it allows us to control for patient characteristics in a way that was not possible in our 
qualitative analysis. We can also measure patient trend in HPV vaccination and 
control for other factors that were not the focus of our qualitative interviews. 
Impact 
 
Of all cancers in the world, 7.7% are attributable to HPV (Parkin, 2006). HPV 
infection causes a significant health and economic burden — about 8 billion dollars 
annually in the United States — that can be prevented with adequate HPV 
vaccination (Chesson et al., 2012). Providing immunization for adolescents before 
their sexual debut is currently the best way to prevent HPV infection and illness. 
Providers play a central role in the initiation and completion of the HPV vaccination 
series through conversations with parents and  recommendations to vaccinate 
adolescents with the recommeded three dose of the HPV vaccine series. 
Understanding barriers, attitudes, and the practice of adolescent HPV vaccination is 




sources of variations among providers and variations in different regions is 
paramount to determine and inform policy level interventions.  
Significance 
 
HPV-related disease and infection presents a significant amount of cost 
burden. Of a total cost of 8 billion U.S dollars, about $6.6 billion (82.3%) was for 
routine cervical cancer screening and follow-up, $1.0 billion (12.0%) was for cancer 
(including $0.4 billion for cervical cancer and $0.3 billion for oropharyngeal cancer), 
$0.3 billion (3.6%) was for genital warts, and $0.2 billion (2.1%) was for recurrent 
respiratory papillomatosis (RRP) (Chesson et al., 2012). Several studies showed 
that routine HPV vaccination program implementation for adolescents is instrumental 
in reducing HPV incidence, precancerous lesions, and cervical cancer rates over 
time (Dee & Howell, 2009; Insigna, Dasbach, & Elbasha, 2007; Shobert, 2012). 
Economic evaluations also showed that quadrivalent HPV vaccination programs are 
cost effective compared with cervical cancer screening alone or no vaccination 
(Elbasha, Dasbach, & Insigna, 2007). Additionally, a study that compared the 
population-level effectiveness and cost effectiveness of 9- and 4-valent HPV 
vaccination in the United States found that switching to the 9-valent gender-neutral 
HPV vaccination program saves money (Brisson et al., 2016). The economic burden 
of HPV disease can be lessened if providers increase their recommendations or 
provide high-quality recommendations to parents to vaccinate their adolescents 
(Gilkey et al., 2016).  
Vaccines are a great tool in our fight against infectious diseases. However, 




and delivery system related factors. For an immunization delivery system to be 
effective, it must address the needs of both the target populations and primary care 
practitioners (Orenstein, Douglas, Rodewald, & Hinman, 2005). As frontline 
personnel, providers can influence parents and adolescents in their decision to 
vaccinate, provide information, and offer advice and vaccinations. From the 
provider's perspective, factors that influence their delivery of adolescent 
immunization include: organizational recommendations, vaccine cost and 
reimbursement, and disease and vaccine characteristics (Humiston et al., 2009). In 
2013, parents indicated that one of the top reasons for not vaccinating their 
adolescent children with HPV vaccine was a lack of provider recommendation for 
vaccination (Elam-Evans et al., 2014). In addition, data about missed opportunities 
(during which a teen received at least one vaccine but did not receive the HPV 
vaccine) demonstrated that if the HPV vaccine was given every time a provider gave 
the Tdap or meningococcal vaccine, HPV vaccine initiation would be more than 
80%. In 2012, if all missed opportunities for HPV vaccination had been eliminated, 
coverage with ≥ 1 dose of HPV vaccine could have reached 92.6% (CDC, 2013). 
Therefore, understanding and addressing provider barriers to recommendating the 
HPV vaccine for their adolescent patient population is critical for increasing HPV 
vaccination, lowering the HPV infection and disease burden, and lowering the 
economic burden of HPV. Although provider barriers have been examined in several 
prior research, this work takes a unique approach by identifying practice level HPV 
vaccine ordering trends among VFC providers compared to Tdap to capture the 




supply differences between practices, asked provider perspectives, and compared 
that data to actual vaccine uptake among adolescents in Colorado. The VFC 
Program is a vaccine supply program intended to remove cost barriers for obtaining 
immunizations among children 18 years of age and younger. This research study will 
focus on the VFC provider population to understand barriers they face in 
recommending the 3-dose HPV vaccine to their adolescent population via mixed 
methods and further test generalizability of findings to different types of providers in 
Colorado. The literature review in chapter three details currently known research 
about VFC providers and the gap in knowledge about HPV vaccine trends.  
Theoretical Framework and Conceptual Model 
 
Theories of behavioral change provide a framework to understand, design, 
and evaluate health promotion and disease prevention efforts. We considered 
several different theoretical models to guide our aims. The Theory of Planned 
Behavior proposes that the most important determinant of behavior is an individual’s 
intention to perform that behavior (Millstein, 1996). Several studies have shown that 
there is a strong association between intention and actual behavior (Godin & Kok, 
1996; Sheeran & Orbell, 1998). The Theory of Planned Behavior has been used to 
predict healthcare provider behaviors in preventive health services such as 
immunization practices (Prislin et al., 1999; Millstein, 1996). Determinants of 
behavioral intention include the individual’s attitudes about performing the behavior, 
perceptions about the attitudes of other people who are important to that individual, 
and perceived control over performing the behavior (including barriers to performing 




This theory has been used to predict HPV vaccine uptake among adult men and 
women. One study surveyed women aged 18-26 using the Theory of Planned 
Behavior constructs and assessed their HPV vaccine uptake 10 months later. It 
found that the Theory of Planned Behavior showed key predictors of uptake (Gerend 
& Shepherd, 2012). Another study looked at the mother’s intentions to vaccinate 
their daughters against HPV and found that attitudes were the strongest predictor of 
mothers’ intentions to vaccinate, but intentions were low. They also found that risk 
perceptions were unrelated to intention and that mother’s perceptions of their 
daughter’s risk were low (Askelson et al., 2010). Although the Theory of Planned 
Behavior has some utility in predicting behavior, it has several drawbacks, including 
assumptions that an individual has acquired the opportunities and resources 
necessary to be successful in performing the desired behavior, regardless of the 
intention. It does not account for other variables that factor into behavior intention, 
such as past experiences. While it does consider normative influences, the theory of 
planned behavior does not take into account other factors that influence a person's 
intention to perform a behavior such as economic factors. We examined alternative 
models because the theory of planned behavior was too restrictive to guide our 
understanding of variations in HPV vaccine recommendations. First, HPV vaccine 
recommendations are repetitive rather than a periodic behavior. They are not the 
result of a simple, one-time linear decision-making process, because the behavior 
can change over time.  
It is essential to understand provider intentions as well as factors that closely 




Consequently, we looked at the Competing Demands Model, which was originally 
developed to understand delivery of preventive health services in the primary care 
setting (Jaén, Stange, & Nutting, 1994). This model was previously used to explain 
factors that influence physicians’ HPV vaccine recommendations (Vadaparampil et 
al., 2011; Vadaparampil et al., 2014). This model proposes three domains of factors 
influencing physicians’ HPV vaccine recommendations: physician, patient, and 
practice factors. Physician factors include personal characteristics, knowledge, 
beliefs, attitudes, and experiences. Patient factors include characteristics such as 
payment amount and vaccine preferences. Practice factors are the immediate 
setting in which a physician delivers care (practice size, geographic location, single 
vs. multi-specialty group). Practice factors can also include issues outside the 
immediate practice environment, such as state/policy factors that may affect HPV 
vaccine recommendation (e.g., physician participation in the VFC program). Taken 
together, these theories provide a useful theoretical framework for identifying key 
attitudinal and normative beliefs that shape HPV vaccination intentions and 
ultimately behavior among providers.  
This study is grounded in a conceptual model represented in Figure 1, which 
was adapted from a previously developed conceptual model by Kahn et al. (2007). 
The model depicts the interrelated factors that impact HPV vaccine recommendation 
to adolescents. These include professional and personal characteristics, vaccine 
policies and procedures, awareness of HPV vaccine policies and guidelines, 
communication about and endorsement of HPV vaccines, perception of likely 




actual vaccine recommendations. We adapted this conceptual framework by adding 
an essential element of provider perception of likely parental refusal/acceptance of 
vaccine that could influence communication about and endorsement of the HPV 
vaccine as well as intention to recommend HPV vaccine. In our aims, we assessed 
these factors and how they impact HPV vaccine ordering and actual 
recommendation. We hypothesized that initiation of the HPV vaccine series might 
depend on VFC provider characteristics (left side of the conceptual model) such as 
awareness of the vaccine, perception of likely parental refusal/acceptance of 
vaccine, and consequently recommendation. Additionally, we hypothesized that the 
completion of the three dose HPV vaccine series might be mainly due to 
parental/patient factors such as request for vaccines, vaccine cost and insurance 
coverage (bottom of the conceptual model). Because of these hypothesized different 
factors affecting initiation and completion of the HPV vaccine, we analyzed these 





Figure 1: Conceptual model explaining factors influencing provider’s intention to 
recommend the HPV vaccine. Adapted from “Factors influencing pediatricians’ 
intention to recommend human papillomavirus vaccines,” by J. A. Kahn, S. L., 
Rosenthal, A. M.  Tissot, D. I. Bernstein, C. Wetzel, & G. D. Zimet, 2007, Ambulatory 








This chapter begins by describing human papillomavirus, HPV-associated 
diseases, current prevention methods for these diseases, and the safety, efficacy, 
and cost effectiveness of these prevention methods. Next, this chapter discusses 
previous research that was done related to the three aims of the dissertation 
proposal, and includes a comprehensive review of literature in the realm of HPV 
vaccine delivery and patient and provider characteristics that facilitate or hinder the 
three-dose HPV vaccine receipt among adolescents. The chapter continues by 
describing the inclusion criteria used to select articles for the different aims. Content 
of these relevant articles will be summarized. This chapter will conclude with a 
summary of what is known about the three aims from previous research literature 
review and how this proposal will fill gaps in the literature.  
Literature Search Method 
This literature review looked at published articles that focused on the three 
aims of the proposal. PubMed and Google Scholar were used to search existing 
published research in the realm of HPV vaccination in the VFC provider population, 
qualitative research that explored provider challenges and facilitators in HPV vaccine 
ordering and administration to adolescents, and research that explored regional, 
patient, and provider level variations in the provision and receipt of the HPV vaccine 





Searches were performed using combinations of the following keywords: 
 HPV infection, HPV infection related disease, HPV infection 
prevention, HPV vaccine, HPV vaccine in Colorado, Barriers to HPV 
vaccine, Barriers to HPV vaccine in Colorado 
 HPV vaccine trends in Colorado, variation in HPV vaccine uptake in 
Colorado 
 HPV vaccine safety, HPV vaccine effectiveness  
 Differences in HPV vaccine uptake, disparities in HPV vaccine uptake, 
HPV vaccine cost effectiveness  
 Provider barriers to HPV vaccine recommendation, provider barriers to 
HPV vaccine recommendation in Colorado 
This search yielded hundreds of citations. To further examine this evidence base 
and identify foundational work for this research study, only studies published in the 
past 10 years were reviewed. This criterion was established because more recent 
studies tend to employ more rigorous research methods and present a more 
accurate assessment of contemporary patterns of variation in the HPV vaccine. 
Furthermore, the HPV vaccine has been in the market since 2006, making the 
existing research relatively current by default. We ensured that the research articles 
were: 
 Publications in peer-reviewed journals 





 Only studies whose primary purpose was to examine variation in 
HPV vaccine compared to other adolescent vaccines  
Research studies and publications that met these criteria were selected. The 
researcher read the abstracts to ensure it would be of interest and proceeded. Many 




There are nearly 200 recognized, distinct strains of HPV, and each is 
associated with a specific set of clinical lesions that are associated with a spectrum 
of diseases (Ljubojevic & Skerlev, 2014). Infections with different strains result in 
different skin appearances and malignancies. Some HPV strains can cause warts 
(papillomas), while other types can lead to cancer, especially cervical cancer (CDC, 
2015). HPV can affect any area on the skin and mucous membranes. HPV is the 
most common sexually transmitted virus in the United States and is transmitted 
through intimate skin-to-skin contact (CDC, 2015). A person can get HPV by having 
vaginal, anal, or oral sex with someone who has the virus. HPV is so common that 
nearly all sexually active men and women are infected with it at some point in their 
lives (CDC, 2015). HPV can be passed even when an infected person has no signs 
or symptoms. One can develop symptoms years after having sex with someone who 
is infected, making it hard to know when one first became infected (CDC, 2015). 
About 79 million Americans are currently infected with HPV and about 14 million 







Most HPV infections resolve spontaneously on their own but some persist 
and can cause cell changes in the infected area. There is no way to pre-determine 
whether individuals infected with HPV will develop diseases, such as warts or 
cancer, or remain asymptomatic. (CDC, 2015). When the HPV infection is 
symptomatic, the majority of clinically apparent anogenital warts are caused by HPV 
genotypes 6 or 11 and are infrequently associated with high risk types of HPV. If left 
untreated, warts can spontaneously regress or continue to increase in size 
(Ljubojevic & Skerlev, 2014). 
The most common HPV-associated cancer among women is cervical cancer, 
whereas among men it is oropharyngeal cancers (cancers of the back of the throat, 
including the base of the tongue and tonsils) (CDC, 2015). From 2006-2010, about 
33,000 HPV-associated cancers (22,000 among women and 12,000 among men) 
occurred in the United States each year. In general, it is believed that HPV also is 
associated with approximately 91% of cervical cancers; 90% of anal cancers; 40% of 
penile, vaginal, and vulvar cancers; 25% of oral cavity cancers; and 35% of 
oropharyngeal cancers (Parkin, 2006; Gargano et al., 2006; Steinau et al., 2013).  
Significantly increased trends in HPV-associated oropharyngeal cancers have 
been shown between years 1983 to 2002, mostly in developed countries and at 
younger ages (Chaturvedi et al., 2013). The prevalence of oral HPV infection in the 
United States was 6.9% in 2010, and the prevalence was higher among men than 
among women (Gillison et al., 2012). Incidence rates for most cancers are on the 




(Jemal et al., 2013). These numbers emphasize the role HPV infection plays in 
increasing the incidence of oropharyngeal cancers, particularly among men 
(Chaturvedi et al., 2013). 
Disparities in HPV Infection 
There are documented racial, ethnic, and income disparities in the rates of 
HPV and high-risk HPV (cancer-causing) infection. A previous study that looked to 
examine whether socio-demographic characteristics were associated with HPV 
prevalence found that poor women, Mexican American women, and unmarried 
women were more likely to test positive for HPV (Kahn et al., 2007). This disparity in 
infection shows the need for attention in this population to ensure HPV vaccine 
coverage reaches optimal levels. This study underlined the need for focused 
intervention efforts to ensure low-income men and women have access to 
preventive services, including HPV vaccination.  
HPV causes several types of cancers, and some ethnic minorities have 
higher rates of these cancers. Black men have higher rates of anal cancer than 
white men, Hispanic men have higher rates of penile cancer than non-Hispanic men, 
and women of color are often diagnosed with cervical cancer at a later stage than 
white women, which makes it difficult to treat (Freeman & Wingrove, 2005).  
Hispanic women get cervical cancer at the highest rate compared to other 
groups, but Black women have the highest rates of dying of cervical cancer (U.S. 
Cancer Statistics Working Group, 2013), and they also have higher rates of vaginal 
cancer than women of other races (McCarthy, Dumanovsky, Visvanathan, Kahn, & 




developments rates, providing increased HPV vaccination is vital to prevent HPV 
infection and further disease (CDC, 2016). Fewer HPV infections mean healthier 
communities — especially in those communities most impacted by HPV — and that 
can be achieved by high HPV vaccination rates.   
Current HPV Infection Prevention Methods 
 
Currently, there are vaccinations to prevent infection with HPV, screening 
tests to identify if cells are infected with HPV, and counseling regarding safe sex to 
decrease risk of infection with HPV. However, condoms are not fully protective of 
HPV infection because of the skin-to-skin contact transmission of the virus.  
Vaccination 
There are three vaccines that can prevent infection with the most common 
types of HPV, and these are given in three doses over a six-month time period or 
two doses if initiated before a patient’s 15th birthday. The three types of HPV 
vaccines are licensed by the Food and Drug Administration (FDA) and include the 
quadrivalent HPV vaccine for HPV types 6,11,16,18 (Gardasil-licensed for females 
in June 2006 and males in October 2009), bivalent HPV vaccine for types 16, 18 
(Cervarix-licensed in October 2009), and 9-valent vaccine for HPV types 6,11,16,18, 
31, 33, 45, 52, 58 (9vHPV-licensed December 2014). Currently, the 9vHPV vaccine 
is used widely in the United States, which protects against more HPV strains. 
The Advisory Committee on Immunization Practices (ACIP) originally 
recommended administration of a 3-dose series of the HPV vaccine on a schedule 
of 0, 1-2, and 6 months to all adolescents aged 11 through 12 years. Currently, two 




before the 15th birthday. The second dose is recommended 6-12 months after the 
first dose (0, 6-12 month schedule). Catch-up regimens of the vaccine series are 
recommended for females with the bivalent, quadrivalent or 9-valent vaccine, and for 
males with the quadrivalent and 9 valent vaccines at age 13 through 26 years for 
females and males through age 21 and up to age 26 in high risk males, if not 
previously vaccinated (CDC, 2016; Petrosky et al., 2015). The bivalent, quadrivalent, 
and 9-valent HPV vaccines may be used for females, and only the 9-valent or 
quadrivalent HPV vaccines may be used for males. In June 2006, Gardasil, a 
recombinant HPV vaccine for protection against HPV types 6, 11, 16, and 18, was 
licensed for use among females aged 9-26 years for the prevention of HPV-type-
related cervical cancer, cervical cancer precursors, vaginal and vulvar cancer 
precursors, and anogenital warts (Markowitz et al., 2007). The bivalent vaccine 
prevents against infection with HPV types 16 and 18, which cause 70% of cervical 
cancers, and it is licensed for use in females aged 9 through 25 years (Markowitz et 
al., 2014). In 2014, the FDA approved the use of the 9-valent vaccine for HPV types 
6,11,16,18, 31, 33, 45, 52, and 58 for girls 9-26 years of age and boys 9-15 years of 
age.  
HPV vaccines are most effective when given at 11 or 12 years of age for both 
boys and girls. This is because optimal vaccine efficacy is derived if the vaccine is 
administered before the onset of sexual activity when exposure is likely to occur. 
Also, antibody responses are highest among children ages 9 through 15 years, 
although the clinical significance of this is not known (CDC, 2002). The HPV vaccine 




(Committee on Infectious Diseases, 2012). Because of this, early vaccination of 
adolescents is important to ensure protection. 
Screening for HPV-Associated Infections 
Other than vaccination, the other method of HPV-associated severe disease 
prevention is regular screening tests for early detection of precursors to cervical 
cancer (Hairi, Dunne, Saraiya, Unger, & Markowitz, 2014). Cervical cancer is the 
easiest gynecologic cancer to prevent with regular screening tests and follow-up. 
However, cervical cancer screening guidelines by the American Cancer Society 
recommend that for average-risk women, screening should begin at age 21 
regardless of the age of sexual initiation or other risk factors (CDC, 2016). Two 
screening tests can help prevent cervical cancer or find it early. One is the Pap test, 
which looks for pre-cancers or cell changes on the cervix that might become cervical 
cancer if not treated appropriately. Pap tests are recommended for all women ages 
21-65 years old. According to a 2016 CDC report, the Pap test is one of the most 
reliable and effective cervical cancer screening tests available. The second test is 
the HPV test that specifically looks for the virus that can cause these cell changes. 
Pap test samples can be used to test for HPV-associated cancers and can be 
specifically requested if an individual is interested in knowing their status (CDC, 
2016). However, these screening tests do not prevent individuals from acquiring the 
HPV infection, leaving vaccination as the best strategy to prevent HPV infection. The 
fact that the screening test is only recommended for women 21 years of age and 
older means that younger individuals with an HPV infection might not be identified 




Other HPV Prevention Methods 
Other methods that may reduce likelihood HPV infection include counseling 
adolescents about abstinence, and safe sex practices, including proper condom use. 
However, because of the skin-to-skin contact transmission of HPV, condoms are not 
reliable in preventing HPV infection. There is also evidence that indicates 
circumcision of males reduces the risk of HPV infection. However, these methods 
are imperfect because HPV is transmitted through skin-to-skin contact (American 
Academy of Pediatrics [AAP] Task Force on Circumcision, 2012; AAP Committee on 
Adolescence, 2001). 
Vaccine Safety and Efficacy 
 
HPV vaccine safety and efficacy has been established by several studies. 
Among women who had not been previously exposed to targeted HPV types, the 
bivalent vaccine efficacy study showed 93% vaccine efficacy in preventing cervical 
precancers due to HPV 16 or 18. Bivalent vaccine efficacy was 91.6% against 
incident infection and 100% against persistent infection. All studies of the bivalent 
HPV vaccine showed that 99% of females developed HPV 16 and 18 antibody 
response one month after completing the 3-dose series. Over 99% of vaccinated 
girls in these studies developed antibodies after vaccination. The vaccine was 
generally safe and well tolerated (Harper et al., 2004). 
Another study looked at the efficacy of the quadrivalent HPV vaccine and 
concluded that the vaccine could substantially reduce the acquisition of infection and 




these four types of HPV (Villa et al., 2005). The vaccine was generally considered 
safe and well tolerated.  
Joura and colleagues looked at the efficacy and immunogenicity of the 9-
valent HPV vaccine and concluded that the vaccine prevented infection and disease 
related to HPV-31, 33, 45, 52, and 58 in a susceptible population, and generated an 
antibody response to HPV-6, 11, 16, and 18 that was non-inferior to that generated 
by the quadrivalent HPV vaccine (Joura et al., 2015; Petrosky et al., 2015). Safety 
also has been evaluated in this vaccine and was well tolerated other than injection 
site pain, swelling, and mild to moderate erythema (Petrosky et al., 2015). 
Cost Effectiveness of Current Vaccinations 
 
Several studies assessed the cost effectiveness of providing quadrivalent or 
bivalent vaccines compared to cervical cancer screening or no vaccination at all, and 
concluded that vaccinating with either vaccine is cost effective compared to no 
vaccination (Elbasha, 2007). Furthermore, studies that compared the cost 
effectiveness of the bivalent to the quadrivalent HPV vaccine concluded that the 
bivalent HPV vaccine needs to be 22% cheaper than the quadrivalent vaccine 
because it protects against fewer HPV types than the quadrivalent vaccine (Dee & 
Howell, 2010; Jit, Chapman, Hughes, & Choi, 2011). 
Because the quadrivalent vaccine was primarily a female-only vaccine and 
males were added later, the cost effectiveness of male vaccination is affected by 
different conditions, including the vaccine coverage of females, different health 
outcomes, vaccine efficacy, and quality of life impacts from HPV disease (Kim & 




Markowitz, 2011). With low vaccine uptake among females and majority 
heterosexual transmission of HPV, immunization of males is a cost-effective solution 
for preventing HPV-associated disease in both genders.  
A recent study that looked at incremental costs and benefits of the 9-valent 
HPV vaccine compared with the quadrivalent HPV vaccine for both sexes concluded 
that a vaccination program of the 9-valent vaccine for both sexes can improve health 
outcomes and can be cost-saving (Chesson, Markowitz, Hariri, Ekwueme, & 
Saraiya, 2016). In 2015, the ACIP recommended the 9-valent HPV vaccine for 
routine immunization. Therefore, the cost effectiveness of HPV vaccines compared 
to no vaccination at all has been established, and vaccinating with any of the three 
vaccines is considered beneficial compared to not vaccinating or relying only on 
available screening tests. 
HPV Vaccination Rate 
 
The national immunization survey for teens in the United States showed that 
in 2016, the HPV vaccination rate lags behind that of the other two recommended 
adolescent vaccines, Tdap and MCV4. In Colorado, only 58% of females and 33.5% 
of males have received ≥ 1 dose of HPV vaccine (Centers for Disease Prevention 
and Control [CDC], 2013b). In 2015, the three-dose HPV vaccine has been received 
by 46% of girls and 37% of boys in Colorado (CDPHE, 2017). Healthy People 
2020 vaccination targets for adolescents aged 13–15 years were reached in 42 
states for Tdap and 18 states for meningococcal. However, no state met the target 
for three HPV doses (Elam-Evans et al., 2014). There is a significant gap in 




vaccine. In 2013, one of the top five reasons parents discussed for not vaccinating 
their adolescents with the HPV vaccine was because it was not recommended by a 
provider (Stokley et al., 2014). This gap shows a need to focus efforts to increase 
immunization with the recommended 3-dose HPV vaccine to protect individuals 
against HPV infection, and to find ways to support providers to improve vaccine 
coverage by providing strong recommendations to parents of adolescents.  
Low vaccination coverage among adolescents and documented increases in 
incidence rates of some HPV-associated cancers underscore the need for additional 
prevention efforts for HPV-associated cancers, and especially for efforts to increase 
vaccination coverage. This is of additional importance in minority and poor 
communities due to the prevalence of high-risk HPV infections and associated 
increased death. In these communities, improved HPV vaccine coverage is essential 
for protection from HPV associated infection and further diseases.  
Vaccines for Children Program 
 
The VFC Program is a vaccine supply program that allows enrolled health 
care providers to give ACIP-recommended vaccines to eligible children. The intent is 
to remove cost as a barrier from receiving timely immunizations. VFC is considered 
one of our nation’s most successful public-private partnerships for improving public 
health (CDC, 2015). A child is eligible for the VFC Program if he or she is younger 
than 19 years of age and is one of the following: Medicaid-eligible, uninsured, 
underinsured (FQHC only), and Native American or Alaska Native (CDC, 2015). 
VFC was created by the Omnibus Budget Reconciliation Act of 1993 and was 




for the program do not contract vaccine preventable diseases due to their inability to 
afford the vaccine. This program was created in part due to the 1989-1991 measles 
resurgence in the United States.  
A 2014 analysis looked at the benefits of immunization during the VFC 
program era from 1994-2013 and found that among 78.6 million children born during 
this time period, routine childhood immunization was estimated to prevent 322 
million illnesses (averaging 4.1 illnesses per child) and 21 million hospitalizations 
(0.27 per child) over the course of their lifetimes, and avert 732,000 premature 
deaths from vaccine-preventable illnesses (Whitney, Zhou, Singleton, & Schuchat, 
2014). Routine childhood vaccines that were introduced during the VFC era 
(excluding influenza and hepatitis A) together will prevent 1.4 million hospitalizations 
and thousands of deaths (Whitney et al., 2014). VFC program has been instrumental 
in attempting to remove cost of vaccines as a barrier and making vaccines 
affordable for children who need and qualify for it.  
Enrollment in VFC. Providers who are interested in becoming a VFC 
provider must agree to follow VFC program requirements. There are requirements 
about vaccine handling and storage as well as about screening and documentation 
of individuals for eligibility at each immunization visit. The program requirements 
around storage and handling reflect best practices to protect and safeguard 
vaccines. Additional requirements to screen and document eligibility for VFC 
vaccines ensure stewardship and accountability for vaccines purchased with federal 




Providers enrolled in the VFC program are responsible for ordering 
appropriate amounts of vaccines and maintaining proper vaccine inventory. The 
amount of vaccines needed for a practice is based on the number of VFC-eligible 
children seen in a practice as reported on the Medical Practice Profile and validated 
by KIDS Plus Immunization Information Systems. This is a confidential, population-
based, computerized system that collects and disseminates consolidated 
immunization information.    
Opportunities with the VFC Program. The ability of the VFC program to 
remove financial and logistical barriers hindering vaccination for low-income children 
likely played a significant role in obtaining the current coverage rates, near or above 
90% coverage for many vaccines (Whitney et al., 2014). However, there is room to 
improve when it comes to HPV vaccines. A 2009 study looked at the vaccination 
coverage among U.S. adolescents eligible for the VFC program and found that 
vaccination coverage was only 46.6% for at least 1 dose of the quadrivalent HPV 
vaccine compared to 43.2% for the non-VFC-eligible population (Lindley, Smith, & 
Rodewald, 2011). Even though there is a slightly increased coverage among the 
VFC eligible population, it is nowhere near the desired immunization coverage of 
90% or more. Additionally, VFC program also serves low-income communities who 
are at high risk for HPV infection and associated morbidity and mortality. 
Furthermore, this 2009 study shows that there is more to be explored than the cost 
of the vaccine alone in the VFC population to explain the low vaccine coverage. 
VFC’s ability to provide vaccines for poor families makes it an invaluable program 




colleagues found in the systematic review about barriers to HPV vaccine coverage, 
both health care professionals and parents cited financial concerns (reimbursement 
for providers and out-of-pocket cost to patients) as one of the barriers to provision 
and receipt of HPV vaccine for adolescents (Holman et al., 2014). Understanding 
what other factors affect low HPV vaccine coverage among VFC providers is 
important. Data regarding missed opportunities for vaccination (during which a teen 
received at least one vaccine but did not receive the HPV vaccine) showed that if the 
HPV vaccine was given every time a provider gave the Tdap or meningococcal 
vaccine, HPV vaccine coverage would be more than 80% (CDC, 2013b). Reasons 
cited by parents for not vaccinating or not planning to vaccinate their adolescent 
include lack of knowledge about the vaccine, a belief that the vaccine is not 
necessary, concerns about the safety of the vaccine and side effects, that it was not 
recommended to them by their provider, and that their adolescent is not sexually 
active (Stokley et al., 2014). Because providers are frontline personnel in 
recommending immunizations for their patient population, focusing on understanding 
reasons why vaccines were not recommended to their adolescent population seems 
to be important for improving HPV vaccine coverage.  
Barriers and Facilitators to HPV Vaccination  
Several provider barriers to adolescent HPV vaccination have been discussed 
and documented. Providers identified multiple factors that impeded HPV vaccination, 
including vaccine safety concerns, a low perceived severity of HPV disease, lack of 
school mandates, and policies against co-administration of HPV and meningococcal 




misconceptions may act as barriers, and include the belief that adolescents do not 
need vaccinations (only younger children do), and that programs such as Vaccines 
for Children are only available for younger children (Javanbakht et al., 2012). A 
different study that looked at providers’ attitudes towards immunizing males with the 
HPV vaccine found that providers who did not offer vaccination believed that parents 
would not be interested in vaccinating sons. Furthermore, they were largely unaware 
of serious HPV-related diseases in males (Perkins & Clark, 2012a).  
Additionally, some providers discussed financial concerns and insurance 
coverage and reimbursement issues as barriers to providing HPV vaccines (Luque, 
Raychowdhury, & Weaver, 2012; Malo et al., 2013). Malo and colleagues found that 
the VFC status of providers remained significantly associated with the barriers 
regarding lack of adequate reimbursement for vaccination (Malo et al., 2013). 
Another study looked at VFC provider challenges to providing vaccines in rural 
settings and found that there were cost issues related to stocking the vaccines and 
reaching a target community (Luque et al., 2012). The financial barriers to HPV 
provision among some providers, coupled with parental attitudes towards HPV 
vaccine, could create the perfect environment for lower HPV vaccine administration, 
especially in communities serving high-risk individuals. This combination of parental 
refusal, lack of knowledge about vaccine benefits for adolescents, as well as VFC 
provider-related reimbursement and stocking challenges in rural clinics, impact how 
and when providers offer the HPV vaccine to their adolescent population.     
In 2013, parents discussed the top five reasons for not vaccinating their 




included lack of knowledge (15.5%), not needed or necessary (14.7%), safety 
concern/side effects (14.2%), not recommended (13.0%), and not sexually active 
(11.3%). For their adolescent boys, the reasons included not recommended (22.8%), 
not needed or necessary (17.9%), lack of knowledge (15.5%), not sexually active 
(7.7%), and safety concern/side effects (6.9%) (Stokley et al., 2014). Additionally, a 
more recent study that looked at why adolescents do not complete their HPV 
vaccine series interviewed parents and providers and found that the failure to 
complete the HPV vaccine series occurred because providers expected parents to 
make appointments while parents expected to be reminded (Perkins et al., 2016). 
Poor communication about expectations created missed opportunities for HPV 
vaccination. This shows that among other reasons, providers have an enormous 
opportunity to recommend the HPV vaccine for both boys and girls, to remind 
parents, and to address some concerns these families might have with HPV vaccine 
during their visit. Addressing these interconnected barriers to HPV vaccine uptake is 
crucial to improve HPV vaccine rate among adolescents.  
Previous qualitative studies documented several facilitators to HPV 
vaccination, including certain processes and procedures in place at clinics such as 
the availability of an immunization registry system, provision of additional information 
regarding the HPV vaccine, verification of vaccines by non-physician staff, family 
history, especially of mothers’ abnormal Pap or cervical cancer, and supportive 
family and friends (Javanbakht et al., 2012). This study also discussed the need for 
tailored community support for different populations, such as using promotoras-peer 




The current vaccination rate with the recommended three-dose HPV vaccine 
is low in Colorado (NIS teen, 2014). In 2015, the three-dose HPV vaccine had been 
received by 46% of girls and 37% of boys in Colorado (CDPHE, 2017). VFC 
providers play a vital role in providing vaccines for adolescents who are high risk. 
Although there are some reimbursement issues cited by previous studies with VFC 
providers, there has not been a study that looked at VFC provider barriers to HPV 
vaccination in Colorado. This study will add to the literature by identifying VFC 
provider challenges, facilitators, and opportunities to HPV vaccination.   
Variation in HPV Vaccine Uptake 
 
Inequalities in the uptake of HPV vaccination exist among different races, 
geographic locations, rural/urban areas and genders. A systematic review and meta-
analysis conducted in 2013 looked at studies that compared HPV vaccination 
initiation and/or completion by at least one ethnicity or socioeconomic-related 
variable in adolescent young women. They found evidence of differences in HPV 
vaccination initiation by ethnicity and healthcare coverage (Fisher, Trotter, Audrey, 
MacDonald-Wallis, & Hickman, 2013). Receipt of a health professional's 
recommendation to vaccinate is strongly associated with vaccine uptake; however, 
the odds of receiving a recommendation are negatively associated with low socio-
economic status and Black racial/ethnic status (Polonijo & Carpiano, 2013). We 
expect to see a similar trend in our Colorado population. 
Perkins and colleagues looked at a comparison of factors associated with 
HPV and meningococcal vaccination among adolescent girls and found provider 




2014). This study further solidifies the need to understand what sources of variations 
in HPV vaccine receipt and recommendation exist, if any, in Colorado. Recent 
studies found that higher rates of HPV vaccine initiation are associated with urban 
residence and physician recommendation (Holman et al., 2014). Many Colorado 
counties are in mountain and rural regions, so understanding HPV vaccine receipt 
variations is essential to address vaccine coverage issues in these regions 
(Colorado Rural Health Center, 2016). 
Previous studies have used regression decomposition techniques to identify 
sources of variations among immunization recipients and the extent to which those 
sources contribute to the observed disparities. O’Malley and colleagues looked at 
immunization disparities in older Americans and found that despite similarities in 
insurance coverage and usual care by a physician, Black beneficiaries were 
significantly less likely than their white counterparts to receive influenza and 
pneumococcal vaccinations (O’Malley & Forrest, 2006). 
Gaps in the Literature 
 
Although there are some data indicating financial issues VFC providers face 
in stocking vaccines in other regions, there has not been a study that looked at VFC 
provider barriers to HPV vaccination in Colorado. Because of Colorado’s vast 
geographical variation, understanding rural, plains, and urban VFC provider barriers 
to ordering, recommending and administering HPV vaccine needs to be assessed to 
properly address challenges they face. This study will add to the literature by 
identifying VFC provider challenges, facilitators, and opportunities to HPV 




To our knowledge, there has not been a study that looked at provider HPV 
ordering data to understand variation and intention to vaccinate adolescents. This 
study uses a unique approach to understand HPV vaccine variation trends in 
Colorado. This variation data will inform the qualitative inquiry to explore in-depth the 
reasons behind provider and regional variations and the barriers they see that hinder 
HPV uptake. This approach is unique in that it fills the gap in the literature to 
understanding the Colorado HPV vaccination landscape. Understanding the reasons 
behind HPV vaccine ordering and receipt variations is key to identifying barriers and 
addressing them to improve low immunization rates. Furthermore, testing the 
different hypothesis that emerge from qualitative data using claims data is important 
for generalization in the larger population.  
Summary 
 
In summary, HPV-associated disease is deadly and costly to those affected. 
Because of its transmission through skin-to-skin contact, the burden of disease is 
high. Vaccines that protect against the most common strains of HPV infections exist 
and are available starting at adolescence. However, vast challenges exist in closing 
the coverage gap for the HPV vaccine. Some barriers to adequate immunization 
include provider factors (reimbursement, lack of recommendation, etc.) and parental 
factors (vaccine refusal). The VFC program aimed at removing cost as a barrier has 
been providing free vaccines for children via participating providers. However, 
vaccine coverage in this population is as inadequate for HPV as it is for the non-VFC 
eligible population. There is more work that needs to be done to understand practice 




understanding variations in provider barriers to recommending the HPV vaccine to 
their adolescent population, and disparities in HPV uptake and factors that contribute 








Colorado is one of the states that lags in achieving the needed vaccination 
rate for HPV prevention for their adolescents. The 2013 National Immunization 
Survey filed by the CDC found that the HPV rate lags behind the other two 
recommended adolescent vaccines, Tdap and MCV4. This project applies mixed 
methods to understand provider variations in HPV vaccine practices and identify the 
barriers and facilitators providers face in recommending and administering HPV 
vaccine to their adolescent population. We also examine patient factors that explain 
variation in uptake among groups.  
The purpose of Aim 1 is to identify geographic areas and VFC provider sites 
that are high and low performing in terms of HPV vaccine ordering relative to Tdap 
vaccine-ordering ratio. The practices identified in Aim 1 were used as the qualitative 
samples in Aim 2 to apply qualitative methods to gather in-depth information as to 
why variation in HPV vaccine-ordering rates exist.  This approach enabled us to 
understand providers’ experience and discuss their perspective about HPV 
immunization rates in their adolescent population. To date, there has not been a 
mixed methods study done in Colorado that looked at VFC providers’ HPV vaccine-
ordering ratio.  
The purpose of Aim 3 was to test the hypotheses that arose from Aim 2 and 
confirm or refute findings. We expected population, patient, and provider level 




Payer Claims Data (APCD), PCSA data, Association of Religion Data Archives 
(ARDA) data and VFC ordering data in Colorado to examine initiation and 
completion of the HPV vaccine series. We analyzed these outcomes using logistic 
regression and performed a regression decomposition to understand the main 
determinants of differences in HPV vaccination rates across different populations to 
inform future interventions and policies. 
In sum, this research study used mixed methods to uncover variations in HPV 
vaccine recommendations, initiation, and completion of the 3-dose HPV vaccine. 
Integrating mixed methods in health services research delivery is important and 
timely. When researchers gather data directly from system leaders and practitioners, 
it provides opportunities to better understand stakeholder perspectives. Mixed 
methods have the capacity to capture the experiences, emotions, and motivations of 
people delivering healthcare, as well as the objective conditions of healthcare 
delivery. Furthermore, mixed methods allow for full engagement of policy makers 
and practitioners in understanding current healthcare delivery for comprehensive 
policy implications of the findings (Miller, Crabtree, Harrison, & Fennell, 2013).  
Research Design and Methods 
 
Aim 1. Identify geographic areas and VFC provider sites that are high and 
low performing in terms of HPV vaccine relative to TDAP vaccine-ordering ratio.  
Previous studies have shown that there is a gap nationally in administering 
HPV vaccines compared to other adolescent vaccines. This aim explores to what 
extent the trend holds in Colorado, and if so, how prevalent the issue is among VFC 




compares with other adolescent vaccines such as Tdap. This information was then 
used to compare providers who order the HPV vaccine versus those who do not, 
and to infer Colorado HPV vaccine administration and provider recommendation 
based on statewide representative samples.  
Data source. VFC data from over 500 VFC providers with clinics ranging in 
size from 2-200 providers were analyzed from the period 2012-2015, consisting of 
adolescent vaccine (HPV, Tdap, and meningococcal vaccines) ordering information 
in Colorado. The data included provider name, vaccine type, ordering intention, 
quantity of vaccine ordered, unit price per vaccine type, and net value of the vaccine 
ordered.  
Primary Care Service Area. Practice location was used to identify the 
practice’s catchment area using the PCSAs defined by the Dartmouth Health Atlas 
(Dartmouth Institute for Health Policy and Clinical Practice, 2016). These data were 
used to meet Aim 1 and to determine Aim 2 qualitative interview participating 
providers. PCSA was used to identify areas with low supply of primary care and 
safety net providers, and populations with relatively high health risk. At the heart of 
the data are 6,542 areas defined by aggregating ZIP codes to reflect patient travel to 
primary care providers. These geographic markets of primary care are linked to 
hundreds of measures relevant to improving the availability of primary care 
services.  
 Data analysis. Using VFC data, we conducted descriptive analysis by 
examining provider-specific versus PCSA-specific factors that explain variations in 




analytic tools to identify primary care provider supply and needs in communities 
across the United States, with areas that reflect patients’ travel to primary care. Our 
primary outcome of interest in this aim is VFC providers’ intention to provide the 
HPV vaccine. Intention to provide the HPV vaccine was defined as a VFC 
participating provider ordering the HPV vaccine at the same rate as other adolescent 
vaccines. 
Benchmarking HPV ordering ratio patterns compared to other adolescent 
vaccines was performed using VFC ordering data. Providers from practices whose 
HPV vaccine-ordering ratio was low were sampled, as were PCSAs for the 
qualitative key informant interviews to understand current barriers and facilitators to 
recommending and administering the HPV vaccine. We calculated the percent of 
HPV vaccines ordered compared to the Tdap vaccine to determine the HPV ordering 
ratio for each provider and separately for PCSAs using the equation:        
%  = % ��� � �� � ���� � = ��� � �  ��� �� �  �� ��� � � �� � ���� � �  �  �� �  �� ��� �  � �� � � ∗ % 
The Tdap vaccine was used for benchmarking instead of meningococcal 
vaccine because Tdap is a school required vaccine that has reached many more 
adolescents than the meningococcal vaccine. It is a vaccine in the adolescent 
immunization platform that has been received relatively well and one that the HPV 
vaccine should aspire to reach or surpass.  
Total variance across all providers and PCSAs was calculated to determine 
within and across PCSA variations. We expected to see large variations in HPV 




HPV ordering ratio was then ranked and quartiles were computed and 
identified (Kohler, 2005). We categorized providers and their PCSAs as follows: high 
provider/high PCSA, low provider/high PCSA, high provider/low PCSA, low 
provider/low PCSA.  
This provider sample was used for the Aim 2 qualitative study key informant 
selection. Once we identified the potential sample for Aim 2, we contacted 
individuals to set up a one-on-one phone interview to understand the extent that 
variation in HPV recommendation and provision is explained by practice/provider 
and regional factors.  
Aim 2. Through key informant interviews, identify root causes of provider 
variations and barriers to recommending and administering the HPV vaccine to 
adolescents in Colorado. Awareness of vaccines and national vaccine 
recommendations precede the formulation of attitudes about HPV vaccination, which 
in turn influences actual vaccine recommendations. Several factors, including 
provider characteristics and communication about vaccines with patients and their 
families affect awareness (see figure 1). Factors that directly impact attitudes about 
HPV vaccine recommendation include provider characteristics, communication, 
perception of parental refusal/acceptance, vaccine policies and procedures, vaccine 
cost, and parental factors.  
Methods. Using an adopted grounded theory approach, key-informant 
interviews were conducted from October 2016 to March 2017 from providers in the 
three different categories: low practice-high PCSA, high practice-low PCSA, and low 




providers including those with backgrounds in public health nursing, as well as 
primary care providers, nurse practitioners, and physician assistants. The interviews 
lasted 30-60 minutes with each provider. These providers were identified in Aim 1, 
using their HPV vaccine-ordering ratio. The interviews were completed over the 
phone, were recorded and transcribed by a professional transcriptionist, and 
validated by the researcher to ensure data accuracy and agreement with the voice 
recording.  
The interview guide questions were designed to explore: 
1. Provider perceptions, barriers, and facilitators to HPV vaccine 
recommendation and uptake compared to other adolescent vaccines 
2. Provider understanding of parental decision-making, and to understand 
factors that influence parental willingness to vaccinate their adolescents  
3. Any emerging themes that depict the changing landscape of HPV 
vaccination in Colorado 
Data analysis. We followed the analysis strategy described by Miller and 
Crabtree (1999). This approach included five phases that are described below and 
outlined in Table 1. Data analysis and management was conducted using Nvivo 10. 
The grounded theory approach allowed us to explore existing areas of interest in 
HPV vaccination for adolescents in Colorado while allowing for participants to 
introduce new themes and factors they feel are important to HPV vaccination of 
adolescents. 
 After completing each interview, our initial phase involved reading all 




each provider. Our second phase involved the development of preliminary codes to 
identify and organize key themes and factors, and coding revisions to compare, 
reconcile, and validate codes and themes. The researcher and a colleague initially 
double-coded one transcript and then met to discuss and clarify meanings of codes 
and discuss themes and codes that emerged from the data. Inconsistencies and 
disagreements were resolved using a consensus-based process. Subsequent 
transcripts were coded using the initial codebook but emergent themes and codes 
were added as they emerged from the data. This iterative process continued until no 
additional themes emerged. The researcher and colleague then double-coded two 
additional transcripts to ensure coding consistency. Coding agreement between the 
researcher and colleague was assessed using percent agreement and kappa 
statistics (≥ 0.4).  
After each transcript was coded, our third phase involved discovery of themes 
and patterns, and making linkages between themes and categories. Codes were 
summarized and integrated to tie together different themes that emerged across 
different practices. Preliminary synthesis was shared with the research mentor and 
research committee members with HPV vaccine-related research expertise to further 
validate the codes developed and the themes identified. Connections within and 
between our qualitative findings and quantitative findings were hypothesized for 
further exploration.  
Our fourth phase was to generate findings and conclusions from the 
interpretation and synthesis of the qualitative findings. We compared our findings 




variations if any emerged. This process involved the researcher’s review and 
validation and expert review from this research study’s committee members. At this 
stage, the researcher identified ways in which generalizability of initial findings and 
additional insights into the themes and factors we identified relate to the Aim 3 
analysis.  
The final phase in our analysis involved identifying the most meaningful ways 
of disseminating the results of this research study, including this dissertation write-up.  
Aim 3. Understand the contribution of providers, patients, and PCSA factors 
to disparities in HPV vaccination rates and to test any hypothesis generated by the 
qualitative interviews. We expected to find disparities by race, ethnicity, provider 
type (i.e., primary care versus other types of providers), and PCSA. Hypotheses we 
expected to emerge from qualitative interviews included regional, patient-level and 
provider-level variation in HPV vaccine recommendations and receipt in Colorado.   
Research outcomes of interest for Aim 3 were: 
 Receipt of at least one dose of the HPV vaccine (HPV initiation)  
 Completion of 3 doses of the HPV vaccine (HPV completion)  
 Completion of 3 doses of the HPV vaccine (HPV completion), 
conditional on HPV initiation 
 HPV initiation and completion by Medicaid-insured Hispanic and non-
Hispanic adolescents (decomposition between the two groups) 
 HPV initiation and completion by publicly-insured and non-publicly 




Table 1: Five-Phase Data Analytical Process 
Phase                                 Analytical Process 
1. Describing  Read transcripts in detail and described factors 
related to the various phenomena seen. Involved 
memo writing using individual key informant interview 
to describe each participant’s perspective. 
 
2. Organizing  Involved the development of preliminary codes to 
identify and organize key themes and factors, and 
coding revisions to compare, reconcile, and validate 
codes and themes. Helped in the development and 
application of a static codebook.  
 
3. Connecting  Reviewed the coded text for discovery of themes and 
patterns, and making linkages between categories to 
draw on connections within and between our 
qualitative findings and quantitative findings or 
analysis plans. This process involved PI validation 
and colleague review.  
 
4. Determining validity  Generated findings and conclusions from the 
interpretation and synthesis of my qualitative findings. 
Compared findings with previous published research 
to validate, solidify my conclusions and explain 
variations if any emerged. 
  
5. Representing the 
account  
Identified ways of sharing understandings and 
interpretations, found ways to represent an account 
of what has been learned in the research in a 
meaningful way.  
Adapted from “Integrating Mixed Methods in Health Services and Delivery System 
Research,” by W. L. Miller, B. F. Crabtree, M. I. Harrison, & M. L. Fennell, 
2013, Health Services Research, 48, p. 53. Copyright 2013 by the Health Research 
and Educational Trust. 
 
Vaccine receipt was defined in the APCD data as a claim for HPV vaccination given 
to children aged 11-18. Completion of the full course of HPV vaccination only 
considered unique claims that did not occur on the same date.  
A logistic regression of the probability of a positive outcome as a function of 




estimate the relationships between the covariates and outcomes. The results were 
used to test whether the factors discussed by providers (e.g., Are Hispanics really 
initiating and completing HPV vaccine series more than non-Hispanics?) were 
represented in the data.  
The results of the logistic regression informed a regression decomposition 
that was estimated to understand the determinants of the variation in rates of HPV 
vaccination between groups (Hispanics vs. non-Hispanics and publicly-insured vs. 
non-publicly insured). Specifically, we performed an Oaxaca–Blinder decomposition 
to identify the reasons for disparities in the outcomes between the groups. The 
disparity in the outcome was decomposed into a part that is explained by group 
differences in the magnitude of the covariates and a part that was due to between 
group differences in the relationship between the covariates and the outcomes 
(Jones, 2012). The first part is commonly referred to as “explained” because it 
represents the portion in the disparity that is due to between group differences in the 
values of the covariates. The second part is the portion that is “unexplained” by the 
covariates because it is due to factors that are not included in the model. 
Unexplained factors could represent differences in culture, discrimination, or other 
elements of decision-making and behavior that are not possible to measure in the 
data.    
In our specific application, the decomposition reveals how much variation in 
HPV immunization rates is due to between group differences in the relationship 
between immunization and patient, provider, or PCSA characteristics and 




in the characteristics of each group. For example, a hypothesis that religious beliefs 
that are significantly more prevalent in one group is a major reason why the group’s 
vaccination rates were significantly lower can be tested using the decomposition by 
assessing the extent to which between group differences in vaccination rates are 
explained by differences in the prevalence of religious adherents in each group. 
Similarly, a hypothesis that group differences in mothers’ level of education 
contributes to disparities in HPV vaccine receipt can be assessed by examining the 
magnitude and significance of the disparity that is explained by parents’ level of 
education. In other words, if highly educated people were less likely to have their 
children vaccinated, and highly educated people were more prevalent in one group, 
then the decomposition enables us to measure the extent that the increased 
prevalence of highly educated mothers led to the group’s lower vaccination rates. On 
the other hand, if children of highly educated mothers in one group were more likely 
to be vaccinated whereas children of highly educated mothers in the one group were 
less likely the decomposition would define this component of the disparity as 
unexplained because there is some other difference between the groups that leads 
highly educated mothers to behave differently with respect to HPV vaccination. 
(Jann, 2008).  
Data. The dataset used in this analysis included claims data from the CO 
APCD merged with PCSA-level demographic info (Dartmouth Health Atlas, 2010) 
and county-level information on religion adherence (Religion Census, 2010).  
The sample population of interest is children aged 11-18 years of age who 




continuously in the sample for 365 days after receiving the Tdap vaccine. Tdap is a 
school-required vaccine in Colorado and one of three vaccines in the adolescent 
immunization platform. Tdap receipt by adolescents is high compared to HPV and 
meningococcal vaccine. We anchored the initial HPV vaccine uptake to Tdap 
vaccinations to hold constant general attitudes towards vaccines in order to better 
focus the analysis on the barriers an precursors that are specific to HPV vaccination. 
We used a 365-day follow-up period to assess whether required series of 
vaccinations was completed. Another reason for using TDAP vaccination as the 
index event is because vaccination guidelines suggest that HPV vaccinations should 
be performed at the same age as Tdap. Thus HPV vaccinations should be 
conducted within a year of Tdap receipt, which would leave more than enough time 
to complete the six-month series. It is possible that we excluded some children who 
received the HPV vaccine before TDAP but we expect this to be rare given that 
TDAP is required for school attendance and is much more common.   
We identified immunization administration using Current Procedural 
Terminology (CPT) codes for Tdap and HPV vaccines. CPT codes were also used to 
identify primary care utilization (preventive, vaccine only or sick visit; see Appendix 
C). These were selected to ensure all pertinent immunization CPT codes, primary 
care utilization, and dates and times of services were captured. For example, if our 
CPT codes were repeated for the same person twice on the same day, the data 
were cleaned to ensure zero duplications of services in the data. 
The models for Aim 3 were estimated using key covariates drawn from the 




privacy laws and in 2016 it contained more than 510 million health insurance claims 
from more than 21 commercial health insurance companies, Medicare, Medicare 
Advantage, and Health First Colorado (Colorado’s Medicaid Program). It is the only 
claims repository in the state that represents the majority of insured individuals in 
Colorado. It contains more than five years of data and thus offers a more 
comprehensive picture of Colorado’s health care system than other available 
sources of claims information from individual insurers.  
Covariates. The covariates included variables that measured patient, 
provider, and population characteristics. Patient characteristics were obtained from 
CO APCD data. Patient characteristics included: age in years, gender, race, 
ethnicity, insurance, rural/urban residence, CPT codes, and visit type. These were 
included because there is established evidence that showed that the HPV vaccine is 
most effective with younger patients before they are exposed to any HPV types. VFC 
eligible children, a large population of which are Medicaid-insured, receive vaccines 
free of cost, and it is important to understand their utilization by age. Furthermore, 
the adolescent vaccine platform that includes Tdap and HPV vaccine 
recommendations is age-specific, and controlling for age is important in controlling 
for age-related confounders. 
Trends in the HPV vaccination rate among men and women vary significantly, 
and men lag behind in initiation and completion of the HPV vaccine for several 
reasons, including that the HPV vaccine was indicated for women before men, and 
differences in the perceived higher severity of HPV-related diseases that impact 




research has demonstrated that parents and providers encourage more women to 
get the HPV vaccine than men. For these reasons we controlled for gender.  
Race and ethnicity are important factors because there are clear and 
established disparities in vaccination rates and in the severity of HPV-related 
diseases. For example, African-American women die of cervical cancer at higher 
rates than Hispanic women, even though Hispanic women have a higher rate of 
HPV infection (McCarthy, Dumanovsky, Visvanathan, Kahn, & Schymura, 2010). Because 
the infection rate and preventative healthcare access are not uniform among 
different racial and ethnic groups, it is crucial to understand the association of each 
racial and ethnic group with our outcomes of interest.  
Health insurance and the type of TDAP visit are included in the model to 
measure the role these factors play in HPV vaccinations. Furthermore, they provide 
an avenue for assessing and comparing between different insurance types and 
patient ability to access the HPV vaccine. We hypothesized that HPV vaccination 
rates would be influenced by insurance type, which is related to overall access to 
health care. We also hypothesized that HPV vaccination rates differ among 
adolescents who receive regular preventative services compared to those who do 
not. To test this, we included the index visit type: preventative, sick, and vaccine-
only visits in a year.  
The provider characteristics included provider type (primary care or other 
types) and gender (male or female). Primary care provider categories included 
family medicine physicians, internal medicine, nurse practitioner, pediatrics, 




and local FQHC clinics. Providers in the other category included midwife, obstetrics 
& gynecology, pharmacy, and other specialists. Children in our cohort were seen by 
variety of providers, ranging from pediatricians to obstetrics and gynecologists. 
However, how adolescent vaccine access interacts with the types of providers in 
care settings is unclear. For example, previous research shows better health 
communication among female providers compared to male providers in 
recommending preventative services. It was unclear if that same phenomena held 
true in our data. However, prior research has shown that provider gender influences 
the provision of preventive screening and counseling. (Henderson & Weiman, 2001) 
We merged in information about local populations measured at the PCSA 
level to control for population characteristics. In addition, we merged in county-level 
data on religion adherents from the U.S. Religion Census: Religious Congregations 
and Membership Study (2010). This study, designed and completed by the 
Association of Statisticians of American Religious Bodies (ASARB), represents 
statistics for 149 religious bodies on the number of congregations within each county 
of the United States. This included the number of members by religion, and total 
adherents. The data included 149 Christian denominations, associations, or 
communions (including the Latter-Day Saints and Unitarian/Universalist groups); two 
specially-defined groups of independent Christian churches; Jewish and Islamic 
totals; and counts of temples for six Eastern religions. While these data contain 
membership data for many religious groups in the United States, including most of 




Population characteristics included religion adherence per 1000 populations: 
evangelical rate, Catholic rate, mainline Protestant rate, black Protestant rate, 
Orthodox rate, and other religion rate (including Islam, Buddhist, etc) obtained from 
the religion census data. The role of religion in HPV vaccine uptake — especially 
among parents of adolescents — is an ongoing theme in which vaccinating their 
children against a sexually transmitted infection presents a moral dilemma for some 
parents. Parental religious beliefs and the education they receive from their faith 
communities about HPV and other vaccines may influence vaccine uptake. Several 
dimensions of religion such as behaviors, beliefs and attitudes could be linked to 
health seeking behavior (Koenig, Larson, & Larson, 2001; Cotton et al., 2007). 
Furthermore, studies have shown association between religion and sexual health 
behavior such as delayed sexual initiation and fewer sexual partners (Cotton & 
Berry, 2007). These are important factors to consider when studying adolescent 
health outcomes. Controlling for religious affiliations and adherence rates is 
essential to understanding the alignment between religious beliefs and HPV vaccine 
uptake. 
The role of education in health care utilization, understanding provider 
recommendations, and the ability to afford and access vaccine is important to control 
for in our analysis. However, there are also pockets of educated communities who 
are opposed to all or some types of vaccines and who refuse or hesitate to provide 
any vaccine to their adolescents. Controlling for parental and population level 
educational attainment is important to remove confounding due to education. For 




of HPV vaccine initiation (Feiring et al., 2015). However, a lack of parental education 
status in our individual level data necessitated the use of population-level education 
levels by PCSA. These educational variables included population under age 25 who 
received below a high school education, percent high school graduation, and college 
graduation rates in the population.  
PCSA-level variables also included the percent of residents who are white, 
black, and Hispanic. The percentage of other races was constructed by subtracting 
percent white and black from 100% (100 -%white - %black = % other race). Non-
Hispanic percentage was constructed by subtracting the Hispanic rate from 100 
percent (100 - %Hispanic = %non-Hispanic). Including both individual and population 
level race and ethnicity data was necessary because healthcare utilization could be 
impacted by different combinations of factors such as differences between diverse 
communities and communities where families feel like they are the only families of 
color. For example, health care utilization for black families living in white 
neighborhoods might be different than those living in diverse communities due to 
factors such as perceived or actual differences in treatment when visiting provider 
offices.  
Estimation approach. The outcomes were modeled as a function of the 
covariates using a logistic regression. This model provided us with estimates of the 
relationship between the probability of a positive outcome and the covariates. First, 
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Marginal effects were calculated to measure the change in the probability of 
initiating or completing the HPV vaccine given a one unit increase in each respective 
covariate, holding other covariates at their mean values.  For our binary outcomes, 
the change is from 0 (no initiation, no completion) to 1 (initiation, completion), or one 
“unit” as it is usually termed. The standard errors (SEs) reported are those of the 
average marginal effects. 
Next, we performed an Oaxaca-Blinder decomposition to assess whether the 
observed differences in outcomes were due to changes in explained or unexplained 
differences. This analysis also further helped test if results were aligned with the 
qualitative findings. The decomposition also sheds light on the underlying reasons 
behind disparities in HPV initiation and completion uncovered in the logit models. 
This method was used to decompose the disparity in each outcome variable.   
Motivation for regression-based decomposition. This method provides 
insight into the nature of the observed differences in outcomes whether due to the 
characteristics of the groups (i.e. Endowments) or unexplained factors such as 
cultural nuances. Oaxaca-Blinder (OB) decomposition methods have not been used 
widely in health services research. Decomposition analysis of differences is 
important for understanding the main determinants of differences and for policy 




decomposition is that the former model does not show the various covariates that 
impact HPV vaccination differently but only that they affect immunization rates, and it 
assumes that the impact of insurance is the same between the two groups. 
However, the OB method provides an avenue to indicate to what extent the variation 
is due to the covariates and the interactions with the groups being studied (Yoo, 
2015). OB decomposition explains the gap in the means of an outcome variable 
between two groups. The gap is decomposed into the part that is due to group 
differences in the magnitudes of the determinants of the outcomes in question as 
well as the group differences in the effects of these differences on the outcome. 
(O’Donnell, 2008; Jann, 2008). 
We explained the distribution of the outcome variables in question through a 
set of factors that vary systematically with HPV immunization. We used OB 
decomposition on CO APCD claims data to look at patient, provider, and health care 
access characteristics that facilitate or hinder patient propensity to receive the HPV 
vaccination. The decomposition method is used because it reveals how far 
immunization variation with HPV can be explained by differences among groups of 
patient, provider, or health care access characteristics. The decomposition method 
outlined below will explain the gaps in the means of an outcome variable between 
two groups (i.e., vaccinated or unvaccinated with at least one dose of the HPV 
vaccine). The gap is decomposed into two parts: group differences in the effects of 
the determinants, and group differences in the determinants of the outcome in 




An example based on a Hispanic/non-Hispanic decomposition is useful to 
understanding how the decomposition works in practice. The decomposition is 
performed using several steps: 
1. Calculate the means of all covariates for the pooled, Hispanic and non-Hispanic 
samples, denoted for males  ���̅̅ ̅̅ ̅̅ ̅��� , ���̅̅ ̅̅ ̅̅ ̅�, and ���̅̅ ̅̅ ̅̅ ̅ �, respectively. 
 
The difference between the Hispanic and non-Hispanic means reflects the 
different sample endowments. In my sample: ∆���̅̅ ̅̅ ̅̅ ̅ = ���̅̅ ̅̅ ̅̅ ̅� − ���̅̅ ̅̅ ̅̅ ̅ � = –0.06 
The negative sign implies that there are more Males in the non-Hispanic 
sample than Hispanic sample. 
2. Estimate a linear probability model using the pooled sample: � � ��� = ��� + � ���� ��� + ��′ ��� + ��  to yield:    ,̂ ̂ � ���� , and ̂���  ̂���  measures the difference in the probability of vaccine initiation of males 
versus females. In this example, the probability of males receiving HPV is 
0.0624 points lower than females: ̂ � ���� = –0.0624 
3. Re-estimate the model using only the Hispanic sample: � � ��� = � + � �� ��� + ��′ � + ��   to yield:    ̂� , ̂ � �� , and ̂� ̂ � ��  measures the difference in the probability of Any HPV vaccine of 
Hispanic males versus Hispanic females: ̂ � �� = -0.04 
4. Re-estimate the model using the Non-Hispanic sample: � � ��� = � + � ��� + ��′ � + ��  to yield:    ̂ � , ̂ � , and ̂ � ̂ � ��  measures the difference in the probability of Any HPV vaccine of Non-
Hispanic males versus females. In my sample: ̂ � �� = –0.8 
5. The portion of the Hispanic – Non-Hispanic differential that is explained by 
differences in the number of males in the respective groups is measured by 
multiplying the pooled Male coefficient by the difference in mean Males in the 
respective samples: 




In other words, 0.0037 of the differential is explained by the different number of 
males in the respective samples.  
6. The portion of the Hispanic – Non-Hispanic differential that is unexplained, i.e. 
related to differences in the probability that Hispanic and non-Hispanic males get 
HPV is:  
 
Unexplained:  ( ̂ � �� − ̂ � �� ) ∗ ���̅̅ ̅̅ ̅̅ ̅��� =(–0.04) – (–0.08) * (0.36) = 0.0144 
In other words, 0.0144 of the differential is due to unexplained difference the 
likelihood Hispanic males and non-Hispanic males receive HPV vaccinations. 
This is interpreted as differences in the general cultural approach to medical 
care, and other factors that are not in the model: 
7. Steps 3-6 are repeated for each covariate. The sum over all covariates 
represents an estimate of the entire portion of the HPV vaccine differential that is 




Ethical approval was obtained from the Colorado Multiple Institutional Review 
Board (COMIRB) on March 16, 2016. Providers were consented prior to participation 
in the key informant interviews. Qualitative data that was collected and recorded was 
stored in a safe, locked cabinet to which the researcher has access. Quantitative 
data was only be accessed through secure computer access that the researcher 
has. The needs assessment report was de-identified and aggregated before 












Results are presented by research aim. This research was conducted 
between October 2016 and August 2017. 
Aim 1 
The objective of Aim 1 was to identify geographic areas and VFC provider 
sites that are high and low performing in terms of HPV relative to Tdap vaccine 
ordering ratio. Additionally, this aim was used to identify sites for Aim 2 qualitative 
interviews.  
Using VFC ordering data from 2015, we examined variations among practices 
in ordering HPV vaccines versus Tdap vaccines. We set the minimum quantity of 
Tdap ordered at 24 doses per year (at least 2 doses of Tdap per month for 1 year) to 
ensure that we captured practices with experience in Tdap vaccine ordering and 
administration. The HPV vaccine-ordering ratio was calculated using the formula: 
 % ��� � �� � ���� � = tal r r  HPV Va i  at Cli i r PC A �tal r r  a  Va i  at Cli i  r PC A � ∗ % 
Detailed summary statistics for the percent of HPV vaccines ordered were 
obtained and low and high provider as well as PCSA cut off points were determined. 
We used the 25th top and 25th bottom percentile of the cut-off points to identify low 
and high ordering practices. Means of percent of HPV vaccine ordered were 
obtained for each of the four groups of interest: low practice-low PCSA, high 




To obtain the PCSA cut offs, we used PCSAs with more than one practice to ensure 
that we would be able to compare at least two practices in the same PCSA. Stata/IC 
version 13 was used for analysis.  
Based on this characterization, we identified practices in each of the four 
categories. The largest number of practices were in the high practice-high PCSA (n 
= 92) category followed by practices in the low practice-low PCSA (n = 40). The 
smallest number of practices were found in the high practice-low PCSA category (n 
= 12), as shown in Table 2. 
 
Table 2: Category of Practices Based on Vaccine for Children HPV Vaccine 
Ordering Ratio 
 
      PCSA 
   High 
(% HPV > 0.67) 
Low 














(%HPV > 0.79) 
N = 93 
Mean % HPV = 1.30   
N = 12 
Mean % HPV = 1.22   
Low 
(%HPV < 0.34) 
N = 32 
Mean % HPV = 0.23   
N = 40 
Mean % HPV = 0.19 
 
Based on identifying high and low HPV vaccine ordering sites in Colorado (Aim 1), 
we chose three main categories for Aim 2 qualitative sampling.  
HPV Ordering Ratio is the ratio of HPV to Tdap orders by VFC clinics. After 
identifying high and low HPV VFC vaccine ordering sites in Colorado (Aim 1), we 




1) Low practice-high PCSA: clinics with low HPV ordering ratios located in 
PCSAs with aggregate HPV ordering ratios in the top 25th percentile.  
2) Low practice-low PCSA: clinics with low HPV ordering ratios located in 
PCSAs with aggregate HPV ordering ratios in the bottom 25th percentile.  
3) High practice-low PCSA: clinics with high HPV ordering ratios located in 
PCSAs with aggregate HPV ordering ratios in the bottom 25th percentile.  
Providers and PCSAs in these top 25th and bottom 25th percentile were considered 
for the qualitative sample. This measure was used to stratify the sample up to 30 
providers or until we reached information saturation.  
Aim 2 
The objective of Aim 2 was to identify root causes of provider variations and 
barriers to recommending and administering the HPV vaccine to adolescents in 
Colorado using key informant interviews. This was done using an interview 
questions designed to understand: 
 provider perceptions, barriers, and facilitators to HPV vaccine 
recommendation and uptake compared to other adolescent vaccines 
 provider understanding of parental decision-making and to understand 
factors that influence parental willingness to vaccinate their adolescents   
 Any emerging themes that may show the changing landscape of the HPV 
vaccine in Colorado 
Key Informant Interviews 
We interviewed a total of 26 participants: seven from the high provider-low 
PCSA category, 12 from the low provider-low PCSA category, and seven from the 




providers from the different categories, the low provider-low PCSA category 
responders were largely public health nurses from local public health departments. 
There were no interviews conducted from the high-practice, high-PCSA sites. With 
limited capacity to do interviews with all the categories, the researchers determined 
that barriers to HPV vaccine uptake and variation would emerge mostly from the 
three categories that were chosen for qualitative interviews. We reached saturation 
at the 23rd interview but added three more interviews to ensure no more themes 
were arising from our interviews. This method of checking for new themes once the 
analyst feels saturation has been reached has been used in prior studies and is 
considered methodologically rigorous (Francis et al., 2010).  
Barriers and Facilitators Identified by Providers 
Key consistent themes regarding barriers were fundamentally present across 
the three (high-provider, low-PCSA category; low-provider, low-PCSA; and low-
provider, high-PCSA) categories. These categories describe the same underlying 
dynamic; however, the magnitude of how and when providers experience these 
barriers may partially have driven the differences in the categories. Furthermore, 
participant discussion of facilitators explained how providers addressed these 
similarly-experienced barriers and showed differences across the three categories. 
Many participants across categories identified parental, provider, and policy-related 
barriers to recommending and delivering the HPV vaccine to adolescents. 
Participants from all three categories identified knowledge and attitude and 
perception of parental interest as factors in engagement in HPV and other vaccine 




 Like barriers to HPV vaccine uptake, participants from all sites discussed 
some facilitators to the HPV vaccine in their sites. These facilitators were factors that 
enabled them to provide or recommend the HPV vaccine to their adolescent 
population. Even though all the categories expressed experiencing similar barriers, 
there was variation in how participants from these sites addressed these barriers 
(see Table 3). Participants from all three categories discussed several facilitators to 
HPV vaccine uptake in their practices. Some of these facilitators were efforts they 
made to ensure vaccine uptake by adolescents, whereas other facilitators included 
what providers perceived as supportive parental behaviors towards the HPV 
vaccine. Provider factors discussed varied greatly across the three categories and 
might have been drivers of differences among categories (Table 3). Some of these 
patient and provider level facilitators discussed by participants included: receptive 
segments of the population, moving away from a focus on sexually transmitted 
infection prevention to a focus on cancer prevention and new billing methods that 
improved their billing process for vaccines. Providers in the key informant interviews 
were unaware of their performance categories during their interview with the 
researcher. All barriers and facilitators discussed to improve HPV vaccine uptake in 
their practice were not influenced by the researcher-determined performance 
category. The following section details barriers and facilitators to HPV vaccine 
uptake of adolescents as discussed by participants.  
Parental factors. Participants across categories elaborated on the role of 
parental factors in determining HPV vaccine uptake by adolescents. They discussed 




knowledge about vaccines, and varying perceptions when they arrive at the clinic. 
Most barriers to HPV vaccine uptake were attributed to parental factors, and 
participants across all three categories discussed vaccine hesitancy and refusal. 
Reasons for vaccine hesitancy and refusal included parental fear of inadvertently 
promoting an early sexual debut, religious conservatism, and a lack of regular well 
child visits for adolescents that created less opportunity for providers to interact with 
parents and their adolescents. Additionally, providers from low practice-low PCSA 
and low practice-high PCSA categories mentioned parental barriers to immunizing 
adolescent boys with the HPV vaccine. Furthermore, high practice-low PCSA 
category participants identified the need for written parental consent for vaccines for 
institutionalized adolescents as another barrier to HPV vaccine uptake.  
Even though the majority of the barriers related to parental factors were 
similarly discussed across categories, facilitators to HPV vaccine uptake discussed 
were mainly different with some overlap between categories. Participants from the 
three different categories discussed parental factors that enabled them to provide 
the HPV vaccine to adolescents they serve. The role of certain vaccine-receptive 
populations in the community was consistently discussed by all three categories. 
These receptive populations were described as trusting provider recommendations 
more and were publicly-insured individuals and/or minority/Hispanic populations. 
Parental factors discussed in the low-practice high-PCSA also included parental 
prior experience with HPV or other cancers and the role the Tdap school 




facilitating other vaccine recommendation and discussion was also discussed by 
providers from low-practice, low-PCSA sites.  
Participants from low-practice, low-PCSA sites also discussed how parents 
generally trusted local public health departments, especially in rural settings. The 
parental factor facilitators were not strong in driving differences between categories. 
However, they provide a further understanding of facilitators. These facilitators are 
described in more detail below, and are supported by illustrative quotes.   
 Because barriers were discussed similarly between the three categories, it 
was at times unclear how these barriers were driving the differences in practice 
categories to high or low HPV vaccine-ordering ratio. However, the discussion of 
facilitators provides an insight into drivers of the variation between categories and a 
glimpse at efforts made by different practices to address these barriers. For 
example, participants from low practice-low PCSA and low practice-high PCSA 
categories mentioned parental barriers to immunizing adolescent boys with the HPV 
vaccine. However, neither discussed specific efforts to improve HPV uptake among 
boys. This might explain why these two sites have low practice-level HPV vaccine 
ordering ratios. However the discussion of creative communication as a facilitator by 
high-practice, low-PCSA sites might have helped them reach more parents of boys 
and girls. The following section details each of these parental barriers and facilitators 
to HPV vaccine uptake among adolescents with selected illustrative quotes from 
participants to support the synthesis. 
Vaccine hesitancy and refusal. Participants across the three categories 




participants discussed experiencing some type of vaccine hesitancy and/or complete 
refusal of all vaccines from parents of adolescent patients. Some of the reasons 
included religious conservatism, alternative vaccine schedules, fear of inadvertent 
promotion of early sexual debut, fear of vaccine side effects, and lack of trust in 
provider recommendations. 
 Many participants stated that some parents had already decided to refuse the 
HPV vaccine for their adolescent before coming to the clinic. Participants described 
these parents as stern in their stance against the HPV vaccine but vague about their 
reasons, thus creating no room for an open communication with providers. Some 
participants explained that they didn’t push the vaccine discussion further to avoid 
tarnishing their existing relationship with the parent and to not jeopardize future 
vaccine-related discussions.  
. . . for HPV, occasionally somebody will say well, I just don’t want it.  I’ve 
read a bunch of stuff about it, and they’re pretty vague, but you know, I’ve 
read the things on the internet. I know what they’re reading, they’re reading 
about brain damage and things that are not valid, but they don’t want to go 
into it, they’ll just say, ah I just don’t think we’re gonna get that one [HPV 
vaccine].  Low-practice, low-PCSA provider 
 
Almost all families are willing to get that 11 year Tdap for their budding 
adolescent and some, most of them are OK with the Meningococcal which is 
also due at that age, but they are very hesitant to get the HPV or Gardasil. 
High-practice, low-PCSA provider 
 
Participants from all three categories discussed segments of the population who are 
anti-vaxxers but some participants from all three categories discussed the role of 
vaccine-receptive segments of the population. Participants said that low-income 
families are generally receptive to HPV and other vaccines recommended by 




more receptive of provider recommendations to vaccinate their adolescents with the 
HPV vaccine as opposed to private-pay patients. Participants felt that the reason for 
the public-insured population’s vaccine acceptance was less about lack of significant 
out-of-pocket cost and more about trusting providers. Similarly, participants 
mentioned that the Latino community and the underserved population are the most 
receptive to HPV and other vaccines. They discussed how this population generally 
trusts provider recommendations, and that they perceive the vaccine to be safe and 
important.  
The patients who have, you know, Medicaid and access to VFC vaccines, I 
don’t think it’s a cost thing, it’s more of a mindset when they seem to be more 
you know, acceptable of the HPV vaccine or they accept it more frequently. . . 
.  it seems like I don’t have to have as long of a discussion with my Medicaid 
patients as I do with the private pay. Low-practice, high-PCSA provider 
 
. . . it seems like maybe VFC [recipient population] is a little bit more 
accepting to them all I think, cause you know they’re like well yeah, let’s get 
everything that I need. I think they’re just more likely to accept 
recommendations by a health care provider. Low-practice, low-PCSA provider 
 
I think our population is at least 50 percent Hispanic and a decent amount 
that are Spanish speaking . . . I think there’s also just a culture of vaccines 
are safe and important, you know, in that subset of our population, too, so it 
makes it a pretty easy sell. High-practice, low-PCSA provider 
 
This also aligns with the overall HPV vaccine recipient characteristics of certain 
populations who trust and use certain avenues such as the public health department 
for vaccines—who tend to be publicly insured individuals. Participants from low-
practice, low-PCSA sites mentioned that there is some level of trust in public health 
departments that helps facilitate parental acceptability of immunizations. Providers 




because they are not a for-profit organization, but because their goal is to prevent 
disease.  
I think there’s a lot of trust in public health. I think the general public, one they 
trust nurses a lot and they trust public health. They don’t want everything we 
have to offer, but I think they feel like we’re not in the money-making 
business. We’re just here to try to make everybody healthier and decrease 
disease, and I think people realize that, so I think that’s, you know, whether 
they take it or not, I believe they put some trust into we say, at least think 
about it. Low-practice, low-PCSA provider 
 
Religious conservatism. Religion was discussed as an underlying reason 
some parents refused the HPV vaccine for their adolescents. These parents usually 
hoped for monogamous relationship for their adolescents and believed that the HPV 
vaccine might promote early sexual activity, which goes against their beliefs. 
However, a few participants mentioned increasing numbers of anti-vaccinators in 
their community who believed in faith healing and oppose medical intervention. 
Some participants stated that it was difficult to change the attitudes of such parents 
regarding the HPV vaccine. All participants talked about pockets of conservative 
religious groups present in their communities who are strictly opposed to the HPV 
vaccine. However, some participants from low practice-low PCSA sites discussed a 
unique trend in which their community composition changed notably in the past few 
years after several people moved in who believed strongly in faith healing and 
absolutely refused vaccines. Although religious conservatism was discussed across 
the different categories, it was unclear if this perspective alone was the driver in the 
differences between categories.  
. . . most of it is religiously oriented.  Like I said, they don’t want to trigger 
sexual activity, and they feel like if they get this shot, I have to giggle cause I 
mean it’s just so ridiculous, if they get the shot then they’re basically saying 




These kids don’t even know what we’re doing, you know, what kind of shots 
we’re giving. Low-practice, low-PCSA provider 
 
I mean on the HPV, the sexual connotation of exposure is a barrier to some, 
especially in this little population, we have a Bible church college that just 
moved in our community, and so we’re getting a lot of pushback from that 
population. We’re getting some pushback even on the Tdap though and all 
vaccines. Low-practice, low-PCSA provider 
 
 Alternative vaccine schedules. Participants discussed having difficulty 
addressing vaccine hesitancy and refusal when parents bring their own vaccine 
schedules and refuse provider recommendations that follow evidence-based 
guidelines. Some participants mentioned how parents wanted one vaccine at a time 
for their children, making it difficult to provide all the vaccines in the adolescent 
platform in one visit. Most of the time parents did not discuss reasons behind their 
alternative schedules. But some other parents based their decision on “research” 
they had done that supported their stance against the HPV vaccination. Participants 
did not know the source or the type of research done by parents, but suspected the 
research was not from an evidence-based source because it went against standard 
vaccine practice.  
. . . we do have what we worry is a growing number of “anti-vaxxers” in our 
community, despite all our efforts, and of interest, it’s not the low socio-
economic level. It’s the well-educated yuppies, and so we have found that if 
we try to argue or twist their arm to aggressively, it backfires and we lose 
them forever, so we go along with the parent that says they only want their 
child to have one vaccination per visit, you know, it’s driving us crazy inside, 
we like to get this kid vaccinated. High-practice low-PCSA provider 
 
Fear of inadvertent promotion of early sexual debut. Most participants 
stated that providing a vaccine that protects against a sexually transmitted disease 
was the main cause of vaccine hesitancy and refusal among many parents. Many 




about the HPV vaccine because they hope that their children will not have sex 
before marriage or will remain monogamous throughout their life.  Although not 
always discussed as intertwined and connected to religious conservatism, 
participants also noted that parents were hesitant to give HPV vaccines to their 
adolescents because they believe that their adolescents are currently not sexually 
active and do not need the vaccine now.  
I have a few religious people who truly believe their child is only going to have 
sex with one person in their lifetime, and that person will have been a virgin 
and, therefore, they don’t need it.  So, some people are certain that they’re 
going to have a monogamous relationship forever and, therefore, they don’t 
need it.  That’s a small number, but some. Low-practice, low-PCSA provider 
 
Furthermore, many participants discussed parental perceptions that providing the 
HPV vaccine would mean giving license to their adolescents to be sexually active; 
as a result, some parents hesitated or refused to vaccinate their adolescents. One 
participant from a high practice-low PCSA site specifically mentioned a 
misconception about the HPV vaccine among the Latino population in which parents 
did not understand that the HPV vaccine would not change an adolescent’s desire to 
be sexually active, nor did they understand that their children need to be protected 
before sexual debut for full protection. Although this misconception was discussed 
as a unique phenomenon, it was illustrative of the larger concern among parents to 
not promote early sexual activity among their adolescent children. Some participants 
felt that these perceptions by parents were shortsighted because parents were 
focusing on the short-term age of adolescence and not seeing the life-course need 
for protection against HPV infection. 
I think what people typically do not understand is that you know it doesn’t 




fear that somehow that is gonna make a child want to have sexual 
intercourse, so. High-practice, low-PCSA provider 
 
 . . . the main one I am hearing is that they don’t want their child feeling like 
they have a license to be promiscuous. Low-practice, high-PCSA provider 
 
. . . that’s so engrained that some parents don’t see the value, you know, their 
kids aren’t ever gonna have sex in their mind. Low-practice, low-PCSA 
provider 
 
Many participants framed parental refusal or hesitation to vaccinate their 
young adolescents as their lack of seeing the big picture. Participants felt that some 
parents are less focused on protecting their children throughout their lives from the 
HPV infection, instead seeing their children as little kids that are not going to grow 
up. Participants believed it prevented parents from understanding and discussing the 
importance of vaccinating their children before sexual debut. Furthermore, a few 
participants talked about the challenges of discussing the HPV vaccine with parents 
because parents are not yet ready to face the possibility of their adolescent children 
having sexual activity. Parental focus on fear of inadvertent promotion of early 
sexual debut and protecting their children from sexual activity itself was more 
important than protecting them from HPV infection, making this one of the central 
concerns for hesitant or refusing parents. 
I know they start having sex younger these days than it seems like 20 years 
ago or 30 or 40 years ago, so we’ll see that more with the little bit, the teens, 
13s, 14s if they have not had it you know, we’ll see and the parents are really 
getting into it then, we’ll see it more a little bit older, but a lot of the parents 
are still you know, some parents don’t want a written thing when their 11 year 
old is just 11, oh they’re not gonna have sex for a while, that is way, this child 
is way too young for that. High-practice, low-PCSA provider 
 
Yes, I can remember one more recently than others and it was just 
specifically about the HPV vaccine and that’s frequently the vaccine I have 
the most trouble with and trying to explain the new recommendations for HPV 




and throat cancer in men, and trying to get the parents to more or less see 
the big picture and not just see their children as little kids that aren’t gonna 
grow up and that’s often times hard to do. Low-practice, high-PCSA provider 
 
This resistance from parents to immunize their adolescents presented 
significant challenges to parents but participants also discussed the role of willing 
parents, especially those with prior parental experience with HPV. Few participants 
from low-practice, high-PCSA sites discussed the role of a parent’s prior experience 
with cancer or HPV infection in helping vaccinate their adolescents with the HPV 
vaccine. They said most parents want cancer prevention, which mothers of 
daughters were interested in protecting their children from HPV infection, and that 
parents were very receptive to education provided by participants. This interest from 
parents in HPV vaccine prevention of cancer aligns with some provider efforts to 
move away HPV vaccine STI prevention to cancer prevention.  
Most of the parents want cancer prevention. Some of the parents, the 
mothers, especially, some of the mothers have had experience with having 
HPV infection and they want their daughters protected and most of them are 
very receptive once you educate and explain to them why this vaccine is 
being recommended and what the benefits are and you know, once you do 
that, it’s mainly there are a few dads that you know are understanding 
because we also have dads bring their children in. Low-practice, high-PCSA 
provider 
 
One participant from a high practice-low PCSA site observed that some 
parents do not want to give the HPV vaccine to their adolescents with a disability or 
other condition because they assume those children will not need the HPV vaccine. 
The underlying assumption was that these adolescents will not be sexually active 
anytime soon, adding to the parental perception that those who are currently 




because they never know if or when their adolescents will become sexually active, 
protecting them early is the best option.  
We have a few parents that don’t want to give it if their child has autism or 
some, mentally delayed, down syndrome that kind of thing, that no, they don’t 
need it but you just never know. High-practice, low-PCSA provider 
 
Fear of early sexual activity promotion was also a repeated theme, with parents sure 
their children were not sexually active, and hoping that when they become sexually 
active that they will remain monogamous. However, this illustrated parental lack of 
knowledge regarding when the vaccine is most effective —before sexual debut —
and that adolescents might not always communicate with their parents when and if 
they are sexually active. Furthermore, fear that the vaccine would give license to 
sexual activity hindered parents from seeing the big picture of long-term protection 
from infection.  
Fear of vaccine side effects and ineffectiveness. Fear of vaccine side 
effects were discussed by many participants from the three categories. Several 
participants discussed concerns parents have because the HPV vaccine is relatively 
new. Many participants stated that some parents didn’t believe the vaccine had been 
on the market long enough to convince them it was safe. A few participants 
mentioned that parents stated they didn’t want their children to be “guinea pigs” for 
new vaccines. Some participants also discussed that parents would conduct internet 
searches and bring up unproven negative allegations about the HPV vaccine, while 
others questioned the provider about chemicals in the vaccine and hesitated or 




made it difficult for providers to address if the topic was layered with other concerns 
parents have, such as sexual activity debut.  
I will say that there is some concern about vaccine safety just because it, you 
know, hasn’t been on the market for eternity like polio has, you know. Low-
practice, high-PCSA provider 
 
. . . how long has it been around, you know, I don’t want my kid to be the 
guinea pig, that kind of hesitation. High-practice, low-PCSA provider 
 
Another big one is because it’s so new. They feel that it’s, you know, there’s 
not good statistics about it and yet they’ll get the Meningitis, and the 
Meningitis is actually newer than the HPV, so it’s, it’s just interesting how they 
rationalize it in their brain. Low-practice, low-PCSA provider 
 Furthermore, a few participants also mentioned that some parents expressed 
concern about how long the HPV vaccine would be effective if provided to their kids 
at an early age. Because parents want their children to be protected during the years 
they really would need such vaccine-when they are sexually active, participants 
noted that some parents delayed vaccination date so that their adolescents are 
covered longer. 
I think some people are worried about the length of the effectiveness, you 
know, is it gonna be good in 30 years, you know, we’re looking, talk about 
their 11-year-old who is likely still gonna be sexually active in 30 years and 
we don’t have data for 30 years.  We’ve got some long-standing data, but I 
think that’s a concern that I don’t want to start it too late cause it’s gonna wear 
off. Low-practice, low-PCSA provider 
 
A few participants from low practice-high PCSA and high practice-low PCSA 
sites mentioned examples of concerns parents have with the HPV vaccine and its 
impact on female reproductive organs and fertility. Those parents were concerned 
that the HPV vaccine would diminish fertility and result in ovaries that do not grow 
properly.  Because of these perceived side effects and adverse outcomes, the HPV 




I mean, it’s still fairly new in so many of their minds, that they are like we don’t 
know the long term effects and there are some, . . . fertility concerns are all 
over the board . . . that have struggled to conceive, their parents say that it 
had something to do with the HPV vaccine. It’s because of that shot; it’s 
making people infertile to control our population. Low-practice, high-PCSA 
provider 
 
. . . she read something about ovaries and they’re not growing right or 
something of that nature, and I said I’ve never seen that study. I said please 
note that we would be the first front lines to know of any studies saying that. 
And the pediatrician did speak with the mom and still, she didn’t do it [receive 
the HPV vaccine]. High-practice, low-PCSA provider 
 
Parental concerns about unknown vaccine side effects because the HPV vaccine is 
relatively new and concerns about long-term coverage from HPV infection were 
discussed by all participants as a barrier. Although unsubstantiated, parents felt that 
they were protecting their children from HPV vaccine-related side effects or felt that 
they were giving them an advantage by delaying the vaccination date to protect 
them when they need it most. This created clear obstacles to participants who 
wanted to provide all needed vaccines for their adolescent population earlier rather 
than later.  
 Lack of trust in provider recommendations. Participants in all three 
categories discussed seeing different levels of trust and reliance on provider vaccine 
recommendations from different segments of the population. A few participants from 
the different categories discussed differences in parental education and 
socioeconomic status levels that affected their receptiveness to provider 
recommendations. Several participants noted that some upper middle class parents 
with private insurance have no issues with access to care but ask a lot more 
questions about the vaccines, do their own research, and pick and choose their own 




three categories discussed lack of parental trust in provider vaccine 
recommendations, how providers addressed and communicated to parents 
regarding these barriers aligned with the differences seen in the three categories. 
This phenomenon is discussed in-depth in the facilitators section below.  
. . . upper middle class, you know, educated, are much more skeptical about 
vaccines and ask a lot more questions, they have no problems with access, 
but they’re the ones that are picking and choosing schedules, picking and 
choosing shots, choosing to do nothing at all. Low-practice, low-PCSA 
provider 
 
However, many participants also noted the contrast with low-income families who 
are mainly publicly insured and trust provider recommendations, but have 
challenges accessing care. These challenges included not being able to take time 
off from work to bring their adolescents to the clinic for vaccines or well child visits. 
Some participants mentioned how trusting Hispanics and other minority groups are 
regarding provider recommendations for the HPV vaccine. Perceived willingness for 
immunization by certain community members might have played a role in provider 
recommendation trends for HPV vaccines.  
. . . the lower class it has a lot more to do with access, you know, parents 
have to take time off of work to take their kid in and the parent can’t get time 
off, so it’s not that they are not available, it’s just they don’t have that easy 
access to them. Low-practice, low-PCSA provider 
 
I think Hispanics and well even, we’ve had like Jamaican and things like that, 
I think they’re much more accepting and trusting and, for the 
recommendation, so they tend to be more apt to get them. . . I think it’s 
private insurance people that you know, are sometimes a little bit more 
resistant. Low-practice, low-PCSA provider 
 
Yeah, it seems like they [public insurance parents] do seem to trust my 
recommendation more so than a private pay patient, and I don’t really know 
the reason behind that, I think some of the more well-to-do parents of patients 




somewhat, somewhat against it, at least the HPV vaccine. Low-practice, high-
PCSA provider 
 
Lack of regular visits for adolescents. Participants described reduced or 
zero regular adolescent well child visits as a barrier to providing HPV and other 
vaccines. On top of the previously discussed barriers by participants, they explained 
that because the adolescent population is generally healthy, parents don’t bring 
them in for well-child checks unless they are involved in sports or need the school-
required Tdap vaccine. This prevented providers from seeing these patients 
regularly and reduced opportunities to catch them in the office for vaccine 
recommendations. Many participants described how difficult it is for some parents to 
take time off from work and pull adolescents out of school to bring in their children to 
the clinic. Participants observed that this trend resulted in lower HPV and other 
vaccination rates.   
. . . when you have teenagers that are busy with after school activities all the 
time and parents that work until 5:00, trying to take them out of school or take 
an hour and a half off work to come down here on a Tuesday, we only do 
shots once a week, is a burden, so a lot of times, . . . You know, I wouldn’t 
say it’s a huge burden, but it’s a little bit of a burden, and we try to address 
that by going up there. Low-practice, low-PCSA provider 
 
. . . that just makes it hard for them to justify, you know, with limited 
resources, coming, taking time off work to come into clinic or concerns about 
cost. High-practice, low-PCSA provider 
 
They’re below the Healthy People 2020 and they are below the state average 
or the state immunization rate and it’s hard to determine what that reason 
might be, but what we think it is that when you have a healthy adolescent or 
teenager but you don’t, they don’t necessarily go in for an annual exam and 
so their immunizations get missed at their PCP office. Low-practice, high-
PCSA provider 
 
However, a few participants from low-practice high-PCSA sites discussed calls they 




out reminder notices. They explained how this informed parents of certain needs for 
their children, and participants said they receive better responses from parents when 
they call them directly instead of using a letter-only approach. 
so after we give the first initial HPV shot, then two months later, we will send 
out a reminder notice for the second shot, and then on the day of the clinic, 
we will call parents and what we have found is that by calling, we get better 
response than if we send out notices. Low-practice, high-PCSA provider 
 
. . . we pulled up ops with the CIIS operating system teenagers that were due 
for immunizations, and we called all these parents and told them that you 
know, what their teenagers needed, and we had quite a huge turnout. Low-
practice, high-PCSA provider 
 
Additionally, many participants from low-practice high-PCSA and low-practice 
low-PCSA categories talked about the role of the Tdap vaccine school requirement 
in bringing parents and their adolescents to the clinic. They said that parents are told 
by the school that if their children do not receive Tdap vaccine, they are not allowed 
in the school. This pushes parents and their adolescents to come to the clinic, which 
in turn provides opportunities for providers to educate parents about HPV and other 
vaccines. Although this was discussed by participants from these two categories as 
facilitators, the Tdap a state-wide school requirement and thus provides an avenue 
for all providers to interact with adolescents and their parents. Tdap vaccine school 
requirement alone won’t drive differences between the three categories, unless 
some providers have more parents signing the vaccine exemption form for the 
school rather than coming to the clinic for the required vaccines. In current practice, 
parents only need to sign the exemption form, which they can get from the school 
nurse or clinic aide. A lot of parents do not mind getting the Tdap vaccine for their 




come in more likely because the school requirement provides them a more 
motivating deadline.  
. . . once they come in to the office for a vaccination [Tdap], then you talk to 
them about the others, and we tell them they’re recommended. This is the 
recommendation. It’s, while they’re here, why don’t we go ahead and do this. 
Low-practice, high-PCSA provider 
 
. . . the only way we can really get kids in here is when the schools buckle 
down on the required immunizations. Low-practice, high-PCSA provider 
 
. . . a lot of them come over here originally just cause they need the Tdap 
before they get kicked out of school, so that’s the time when we usually, when 
they’re coming for the Tdap as well talk to them about Meningitis and then the 
HPV as well. Low-practice, low-PCSA provider 
 
HPV vaccine for boys. Participants from low practice-high PCSA and low 
practice-low PCSA sites described challenges in providing the HPV vaccine to 
adolescent boys. Most participants noted that they observe additional vaccine 
hesitancy among parents of adolescent boys about vaccinating them with the HPV 
vaccine. Participants said most parents assumed the HPV vaccination is for girls 
because it protects against cervical cancer; parents were not knowledgeable about 
how the vaccine protects adolescent boys. A few participants specifically discussed 
how HPV vaccine advertisements that excluded adolescent boys may play a role in 
this perception by giving parents the impression that adolescent boys do not need 
the vaccine. Even though this theme was explicitly discussed in the low practice-high 
PCSA and low practice-low PCSA sites, the focus of the HPV vaccine to prevent 
cervical cancer is a larger phenomenon that might have impacted the high practice-
low PCSA category as well and beyond. This theme ties in with the overall 




HPV vaccine — showing a need for increased and consistent messaging on the 
needs and benefits of the vaccine.  
I think that the parents are more aware and have heard more about the HPV 
for the girls and so it’s kind of got a little bit of background and they are, 
usually have kind of already made up their minds, but the boys’ parents, it 
seems like they’re a little bit more like, oh I didn’t know that was 
recommended, you know, like it’s kind of a new thing for them, and then of 
course, I also add the decreases of the testicular cancer and oral cancer and 
things like that with the males and the parents as well. Low-practice, low-
PCSA provider 
 
. . . a lot of moms of boys don’t think that they need the HPV vaccine, so 
explaining that to moms, letting them know that yes, the HPV is for boys as 
well as girls. Low-practice, low-PCSA provider 
 
. . . the mother was aware that he had not had the HPV series and she was 
quite resistant to considering it. Low-practice, high-PCSA provider 
 
 Parental consent for vaccines. One unique clinic from a high practice-low 
PCSA site discussed barriers to providing HPV and other vaccines to adolescents 
housed in their local youth detention center. This facility served adolescents who 
were there for behavioral treatment. The participant stated that it was difficult to 
receive consent to vaccinate forms from parents via mail because parents and their 
detained adolescents do not co-reside. Even when providers receive consent, 
participants stated that it could be difficult to convince needle-shy adolescent 
residents to receive vaccines. Although adolescents being afraid of needles is hardly 
a unique phenomenon, parents are not there to encourage their children to receive 
the vaccine. This created some discordance between parental wishes and 
adolescents disinterested in receiving the HPV or other vaccines. In addition, 




their home or to other facilities for care, leaving the provider minimal opportunity to 
vaccinate.  
I mean, on the consent form, if they’re under 18, we have to have, you know, 
we also have to have the parents’ consent as well, however, when they come 
in, the parents and the paperwork that they fill out, there is a consent for 
medical treatment and I believe immunizations is in there, however, we still 
have them sign and notify them when we are giving them any type of 
immunizations. Low-practice, low-PCSA provider 
 
Yes. There are times where if the child will refuse and we call the parents, 
then the parents says that’s fine because ultimately, even if the child refuses 
and the parent wants them to get it, we still can’t force that child to take it, you 
see what I’m saying. Low-practice, low-PCSA provider 
 
I guess sometimes a lot of it is we are a correctional/treatment facility, but 
we’re also, we deal with committed youth and we deal with detained youth, so 
with the detained youth, sometimes they’re not here to receive the full course 
of the shots or of the vaccines, and sometimes like they’re not even here long 
enough for me to give them to them, like they’re here and two days later 
they’re gone. Low-practice, low-PCSA provider 
 
Although this barrier was discussed uniquely in this institution in high-practice low-
PCSA sites, other participants from high-practice low-PCSA sites in a different 
practice arena discussed how they removed barriers to parental consent after 
adolescents’ first visit to the clinic for HPV vaccine. Participants from these sites 
discussed not expecting parents to remember future schedules to immunize 
children. Consequently, they suggested receiving parental permissions for future 
booster shots at the school-based clinic when parents are in the clinic to ensure that 
adolescents are immunized. Although, participants noted that the school-based clinic 
removes some of the barriers that pediatric clinics might face, receiving consent for 
the series at the time of initial visit provides less barriers to HPV vaccine uptake by 
allowing providers to not need additional parental permission every time an 




We tell their parent right in the room, right with them there so that that barrier 
is taken away and then if they’re due for a booster, such as the HPV, we don’t 
expect anybody to remember when to come.  We automatically put them in 
their schedule, in our schedule so they’re called down during school and then 
we already have the parental permission for it. High-practice, low-PCSA 
provider 
 
 I think as a school-based clinic, I think we can cut down the barriers of a 
pediatric clinic and so we give a lot of immunizations. High-practice, low-
PCSA provider 
 
This special case from local youth detention center in the high-practice, low-
PCSA site was illustrative of an underlying dynamic where adolescent healthcare is 
reliant on parental willingness to allow uptake of HPV or other vaccines. Although 
the mailing of consents was unique in this instance, the underlying method by which 
parents are gatekeepers of care and recommendations by providers remains the 
same. Asking parents for future consent as done by the school based clinic in the 
same category facilitates HPV vaccine uptake by removing the need to request 
consent from parents each time.  
Non-inclusive vaccine marketing. A couple of participants from low 
practice-high PCSA sites discussed the importance of vaccine marketing in 
informing parents about new and existing vaccines. However, they felt that the 
marketing was not inclusive of individuals who were uninsured, underinsured, or 
undocumented and thus these individuals have no exposure or knowledge to these 
vaccines. This relates to how and where parents receive information regarding HPV 
and other vaccines. It seems to tie-in with the lack of knowledge parents showed in 
deciding whether the HPV vaccine is necessary for their adolescent boys as well.   
My current practice is not a private practice. This is a public, this is a 
federally qualified clinic, so most of my patients are uninsured, underinsured 




techniques are missed and they are not exposed to that. Low-practice, high-
PCSA provider 
 
Vaccine related decision-making. All of the parental factors in barriers to 
adolescent HPV vaccine uptake were experienced and framed by different types of 
decision-making processes. Several participants discussed how the context of 
parental decision-making impacted and colored adolescent’s HPV vaccine uptake in 
the clinic. On top of parental vaccine hesitation and refusal, participants perceived 
that some parents were persuaded more by outside factors and less by medical 
professionals. Most participants stated that a parent’s attitude and decision towards 
vaccines depended on what they have been reading or whom they have spoken to 
recently regarding vaccines. Some participants talked about parents who discuss 
and learn about vaccines while in the office but leave without the vaccine to further 
think about it. Several participants identified these situations as a missed opportunity 
because they do not know for sure whether the parent and adolescent would return 
to the clinic for vaccines or not. Other providers discussed how there is no new 
decision-making process while parents are in the clinic because they have already 
made up their mind about vaccines in general or about a certain vaccine and the 
parents do not want their adolescents to be vaccinated.  
But, I don’t see a lot of decision-making process in the office.  I don’t think 
we’ve ever had anyone really change their mind in the office.  We get phone 
calls later about, this one’s recommended but it’s not required, so what can 
you tell me, you know, what’s the difference, why do I need to do it, so you 
know, they seek more information, but they’ve already done lots of other 
information seeking online and from questionable sources. Low-practice, low- 
PCSA provider 
 
The people who don’t want to even have a discussion about it are the ones 
that already have their mind made up and they’re like nope, I don’t want it. 





It’s usual, I mean, sometimes when like the 17 and 18-year-old come in alone 
for like kind of their final visit before going off to college, like the more mature 
students that you know are like going to college and seem to have been 
pretty self-sufficient are usually pretty open to vaccinations. Low-practice, 
high-PCSA provider 
 
 In most cases, participants discussed parents as the decision makers for their 
adolescent vaccine needs. However, some participants discussed the role 
adolescents played in the HPV vaccine decision. In some cases, adolescents did not 
want a shot and refused the vaccine while in the clinic even though their parents 
were open to them receiving it. This refusal was more due to adolescents being 
needle-shy. This disagreement between parents and adolescents made it harder for 
providers to provide the vaccine. In contrast, a few participants mentioned situations 
where parents were hesitant but adolescents were receptive to the HPV vaccine. 
This was elicited when participants followed a standard practice in which they asked 
parents to step out of the room to speak with adolescents alone about risky 
behaviors such as alcohol and drug consumption and sexual activity. During this 
time, these participants explained what the HPV vaccine does and noted interest in 
receiving it from the adolescents. However, because there was no parental consent, 
participants were unable to vaccinate those willing adolescents.  
… the kids never want a shot. High-practice, low PCSA provider 
 
I do periodically ask the parents to step out of the room so I can talk to the 
adolescent about certain health care topics such as STDs and drug, alcohol 
and tobacco use and often times the adolescent thinks they should probably 
get the vaccine, but the parents are a little resistant. Low-practice, high-PCSA 
provider 
 
Although there are adolescents who actively refuse or are willing to receive the HPV 




Participants explained that most adolescents do not participate in the decision-
making process while in the office unless they are at the clinic on their own to get 
pre-college related vaccines. However, one health clinic physician stated that some 
adolescents come to their clinic alone, learn about the different vaccines, and go 
home to think about these vaccines more. They may or may not return to the clinic 
for HPV and other vaccines but most adolescents do not share their reasons for the 
HPV vaccine refusal.  
. . . the child, the 16-year-old was just completely withdrawn, you know, he 
wasn’t interested, didn’t want to have the conversation, really you could tell 
that the decision was being guided by the parent. Low-practice, high-PCSA 
provider 
 
In summary, the parental barriers discussed by providers show interrelated 
themes that influence parental decision-making about the HPV vaccine. All 
categories discussed similar barriers they faced in interactions with parents and how 
parents were gatekeepers to their adolescent’s health and well-being. In that role, 
parents were pushing to ensure safety and innocence of their children by refusing or 
hesitating HPV vaccine, a vaccine they assumed would have an adverse health 
impact or one that will give their adolescent permission for an early sexual debut. 
How providers addressed these barriers and differences in approach between 
categories are discussed in the facilitators section of this dissertation.  
Provider Factors. Almost all participants from the different categories 
discussed several provider factors that hindered and facilitated HPV vaccine uptake 
for their adolescent patients. Participants noted four main barriers across categories: 
limited provider persuasiveness, clinic location and vaccines offered, challenges in 




efforts. Barriers to funding for the cost of vaccines and vaccination efforts were 
mentioned by participants from high practice-low PCSA and low practice-high PCSA 
sites only. Only participants from the low practice-low PCSA category discussed 
challenges to vaccine ordering and billing in their clinics. However, participants also 
discussed facilitators to HPV vaccine that were different between the performance 
categories. Providers from low-practice high-PCSA sites discussed new billing 
methods that improved their billing process for vaccines, and using reminder recalls 
to remind parents to return to the clinic for vaccines. However, there was a drastic 
difference in the discussion of facilitators by high-practice, low-PCSA sites where 
provider factors included providers who communicate up-to-date immunization 
information with parents, increased accessibility to clinics and reminders, and 
moving away from a focus on sexually transmitted infection (STI) prevention to a 
focus on cancer prevention. Additionally, low-practice, low-PCSA sites discussed 
several provider factors including increasing the number of vaccine providers, 
collaboration with other organizations, and moving from discussing the HPV vaccine 
as a STI prevention vaccine to a cancer prevention vaccine. Although there was 
some similarities in the facilitators discussed, there was a clear difference in efforts 
made among providers from the different categories to facilitate increased HPV 
vaccine uptake.  
It is not clear how the barriers discussed could have resulted in those 
practices in the different categories, but the facilitators discussed highlight potential 
mechanisms why some practices were in those categories. For example, some 




explain more their intention to improve practice. Some barriers that are unique to 
some categories further explained reasons why a given practice was in that 
performance category. For example, low practice-low PCSA challenges in vaccine 
ordering and billing might have resulted in their facilities’ low HPV vaccine-ordering 
ratio. Participants from this site did not discuss facilitators to improve billing method, 
however participants from low-practice high-PCSA sites discussed billing-related 
improvements due to using a new system. This could have explained their PCSA 
level high HPV vaccine-ordering ratio. The following section provides in-depth 
discussion of each of these barriers and facilitators with illustrative direct quotes 
from participants to explain and support the synthesis of barriers and facilitators 
discussed.  
Limited provider persuasiveness. There was a central communication of 
HPV related information to parents that providers navigated carefully as they 
discussed their approach to parents who are hesitant about the HPV vaccine or 
vaccines in general. Although most participants tried to determine the reasons for 
vaccine hesitancy or refusal by asking direct questions of parents, other participants 
stated that they do not probe further in anticipation of negative responses from 
parents. Some participants said they expect to be stonewalled and do not have 
effective persuasive tactics to move the discussion forward, while other participants 
assumed parents would not listen to their vaccine-related information, so they found 
it difficult to even start the conversation.  
Most are so adamant with their ‘no’ that we don’t even ask them why because 






. . . you can just tell that no matter what you say they’re not gonna hear you 
so at that point it’s just hard to even start the conversation. Low-practice, low-
PCSA provider 
 
While many participants cross categories struggled to balance vaccine related 
communication and persuading parents, some participants from high-practice, low-
PCSA category sites discussed communicating up-to-date immunization information 
with parents by staying up to date on immunization information. They discussed 
attending conferences, and reading and sharing materials from the CDC and state 
health departments with parents on HPV and other vaccine-related information. 
They also mentioned receiving journal articles and other print materials that kept 
them informed about current opportunities for vaccine uptake improvement and how 
to improve communication with patients’ parents. These participants also discussed 
creating an avenue for adolescents and their parents to learn about HPV vaccine 
directly from providers in schools and the community by using grant money for 
movie screenings and other activities. They said that being intentional about 
balancing vaccine information and fun activities might facilitate a better learning 
environment about HPV vaccine and increased vaccine uptake.  
. . . people do look to us for their vaccination services and they look to us for 
their answers to their vaccinations questions, so we tend to use all of the 
materials that are made available to us through the state department of health 
and also through ACIP, and we try to stay right on, in line with those 
recommendations.  We also, about every, we can’t justify it financially every 
year, but about every three or four years we try to attend the vaccine 
preventable disease conference that is sponsored by the Centers for Disease 
Control and then we just try to always do reading you know, there’s several 
periodicals that we get via email, things like vaccinate today and 
immunization express and there’s a lot of things like that.  We just always try 
to make sure we read those and stay up to date on our vaccinations and then 






 . . . so we’ve tried to dispel that myth in many ways.  We purchased, with a 
little bit of grant money that we had cause we do work on a shoestring here, 
we purchased the movie Someone You, what was that, Someone You Love?  
Isn’t that crazy, I know that movie well. We purchased that movie and had a 
special evening for high school students and their parents to come.  We had a 
nice supper for them and then we prepared a little PowerPoint presentation 
talking about vaccines, all the vaccines, I gave them some statistics on the 
improvement in mortality since vaccines have been introduced in our country 
and told them all about the safety process it goes through in having these 
vaccines developed and put onto the market and just went over each vaccine.  
We also shared with them the new rules with regard to school and reporting. 
High-practice, low-PCSA provider 
 
 In addition, participants wrote articles on HPV and other vaccines for the local 
newspaper, and provided pamphlets and books for parents to do further reading in 
hopes of encouraging vaccinations and dispelling any vaccine related myths. This 
effort by some participants from high-practice, low-PCSA category sites showed 
their general investment in the effort to improve HPV and other vaccine uptake, 
which illustrates motivated providers in the practice.  
. . . we are such a small community and we’ve put articles in the paper and 
they know us personally when they come in and they hear our little mantra, 
but on the other hand, we also don’t want to turn them off. We have two 
copies of Dr. Paul Offit’s book, which has really been, well I shouldn’t say 
really been successful, but it has been successful in changing one young 
mother’s view of vaccinations. We just checked it out to her and said take it 
and read it, keep it as long as you want. High-practice, low-PCSA provider 
 
I would, you know, what is your concern, find out what their concern is and 
then you know, well, let me give you a handout on it and see if this can help 
alleviate your fears, or let me give you this little booklet on it. High-practice, 
low-PCSA provider 
 
While such efforts to communicate and further improve HPV vaccine uptake was 
discussed by participants from high-practice, low-PCSA category sites, lack of effort 
to persuade and communicate HPV vaccine-related information was discussed by a 




provider-low PCSA sites discussed using value/observational judgment of 
adolescents in their community and encouraging the HPV vaccine for those who 
they assumed were sexually active or would be soon. This perception was then 
followed by a push to recommend the HPV vaccine to some adolescents but not all 
adolescents who are eligible for the HPV vaccine. For example, one participant from 
a low provider-low PCSA site specifically discussed the lack of dating in their 
community among adolescents because the kids have directly told the providers that 
they are not dating anyone. This approach to HPV provision and recommendation is 
clearly one that prevents some practices from performing well in HPV vaccine 
provision. Because lack of persuasiveness was discussed across categories and 
parental barriers were similar across categories, it is difficult to say whether this is 
the sole driver for the different categories. However, it is one of the potential 
mechanisms by which participants in these areas are not receiving HPV vaccine. 
We don’t ask them why you are not wanting this vaccine.  We see that as an 
opportunity to educate about the importance rather than, so we don’t come 
across as putting someone on the defensive, so we took that opportunity to 
discuss HPV vaccine and give them both, you know, education by discussion 
and education by some printed materials to preserve the relationship and not 
you know make the family defensive because they chose not to immunize for 
that particular one. Low-practice, high-PCSA provider 
 
They get almost defensive in their, no, we’re not doing any vaccines.  Do you 
mind me asking you what your concerns are?  No, I don’t want to talk about it.  
Like, they’re pretty defensive. So, then the door closes and I just keep it 
closed.  Now, the doctor will then in turn, do their thing, but as a nurse, you 
know, I’m like OK I gotta go.” High-practice, low-PCSA provider 
 
. . . there is not a lot of dating that goes on because a lot of them have grown 
up together, so I think that is part of the opinion that, you know what, look 
around, who would they be sleeping with, you know? I think this [HPV 
vaccine] can wait, a lot of parents I think have a really, the reality is that the 
kids are probably going to start being sexually active you know, later on 





While lack of persuasiveness and communication was discussed by several 
participants, some participants from high-practice, low-PCSA and low-practice, low-
PCSA categories discussed how they changed their approach the HPV vaccine 
discussion by moving away from emphasizing STI prevention to emphasizing cancer 
prevention to ease parental and adolescent discomfort. Moreover, participants talked 
about how parents were persuaded by the HPV television commercial, one that 
focused on cancer prevention and not STI prevention, and came to the clinic with 
their adolescents to receive the vaccine or called the clinic to request about the 
vaccine. Some participants discussed providing other parallels for parents to think 
about by saying Hepatitis B is also a cancer prevention vaccine and that their 
adolescents have been immunized with it, making a logical argument for HPV 
vaccine harmlessness.  
. . . talk about it [HPV vaccine] as a vaccine that prevents cervical cancer in 
women and several types of cancer in men and then just leave it at that 
initially. And then if they have more questions, then I go into the details, but I 
think, and I haven’t really had anyone getting upset about the talking about 
sex part since I sort of switched to that spiel. High-practice, low-PCSA 
provider 
 
I think the commercial that HPV has put out is, has been amazing. I’ve 
actually had many parents with teens come to me and say we want to start 
this now . . . they shifted the focus from sexually transmitted to the cancer 
portion of it, and I think that commercial has done a lot of good. Low-practice, 
low-PCSA provider 
 
I think one of the things specific with HPV was getting away from the sex talk 
with parents and discussing it from a standpoint of cancer prevention, and 
even to the point of saying like you gave your child Hepatitis B vaccine and 
that is also a cancer prevention and helps prevent liver cancer and that’s 
sexually transmitted as well, and people have no idea when you tell that to 





Even though there is a drastic difference in the HPV vaccine-ordering ratio among 
the practices in the high-practice, low-PCSA and low-practice, low-PCSA categories, 
the change in communication might be to focus a wider effort to change community-
level HPV vaccine interest, perception, values and societal context. Participants 
identified concerns about early sexual debut as a major reason for parental 
hesitancy or refusal throughout the three categories. Providing facts about the 
vaccine as cancer prevention through innovative communication seems to remove 
some of the hesitation and concerns about the HPV vaccine. 
 Additionally, some professional confidence and authority in recommending 
and vaccinating adolescents played a role in provider’s limited effort to persuade 
parents to vaccinate their children. Some immunization nurses from public health 
departments mentioned feeling like parents listen to and trust physician 
recommendations more than their recommendations, and because of that they 
would try recommending vaccines but not be persistent if they believe the “door is 
shut” for further discussion with parents. In these instances, they allow the patient to 
communicate with the physician further. However, participants from low-practice, 
low-PCSA sites mentioned that there is some level of trust in public health 
departments—usually led by nurses-- that helps facilitate parental acceptability of 
immunizations. Providers from rural public health departments especially felt that 
parents trusted them more because they are not a for-profit organization, but 
because their goal is to prevent disease. This professional level feeling of 
inadequacy to recommend and persuade patients to vaccinate their adolescents with 




opportunity for some providers. It also shows a lack of confidence in future 
interactions where physicians might not always be present to drive the vaccination 
agenda further.  
It’s definitely a time thing because I look at it as the patient came for the 
doctor’s advice, not the nurse’s advice. That patient population trusts doctors 
more than nurses, so I’m gonna give my spiel, it’s gonna be quick, it’s gonna 
be precise, and if they shut me down, I’m gonna leave. I’m not gonna try. If 
there’s a sliver of a, the door open, then I’d be like OK, what is your concern, 
how can I help you, you know, that kind of thing, but if they’re gonna shut me 
down, then no. High-practice, low-PCSA provider 
 
. . . I can’t sit in here for 20 minutes and try to convince you to get this 
vaccine. Like, they’re pretty defensive. So, then the door closes and I just 
keep it closed. Now, the doctor will then in turn, do their thing, but as a 
nurse, you know, I’m like OK I gotta go. High-practice, low-PCSA provider 
 
I think there’s a lot of trust in public health. I think the general public, one they 
trust nurses a lot and they trust public health. Low-practice, low-PCSA 
provider 
 
While some participants discussed a lack of professional confidence in persuading 
parents to vaccinate, others reflected on the process and practice of discussing 
vaccines and felt that they might be missing an opportunity by currently only 
discussing about vaccines on well-child visits and not on sick visits. They talked 
about how they are programmed to think about vaccines on well-child visits only, but 
felt that they should check vaccine status every visit to ensure communication about 
up-to-date status with parents and their children. This reflection from providers on 
their own practice during the interview process showed the motivational aspect of 
asking individuals regarding their practice.   
. . . right now the way that our system is set up, we only really do a good job 
of thinking about vaccines on well type visits, like at 14 for an annual check 
or something and we don’t do it a good job if they’re there for other reasons, 
like if they have a cold or something, which I’m trying to change a little bit of 




opportunities like if we, we should be checking vaccine status every time, 
regardless of what a kid’s there for and hopefully reduce some missed 
opportunities that way. High-practice, low-PCSA provider 
 
Clinic location and vaccines offered. Participants also discussed major 
barriers in reaching certain populations for vaccines due to geographic and weather 
conditions. For example, participants from low practice-low PCSA sites discussed 
the role of geographical distance between clinics and some residents as a barrier to 
receiving timely well-child and preventive services, making vaccine recommendation 
and provision that much harder. In some rural areas, other participants noted, 
parents must take a whole day off from work — especially in the winter — and pull 
their adolescents out of schools to get to a clinic. This is often extremely difficult for 
families and it creates missed opportunities for vaccinations when they miss or 
cancel an appointment. Participants from high practice-low PCSA sites, however, 
discussed efforts they made to increase access to HPV vaccine uptake by having 
off-business hour clinics to increase access to adolescents and their families. This 
entailed staying open in evenings and even on weekends if needed. Participants 
also mentioned holding back-to-school immunization clinics in the evenings to 
provide additional access to adolescents and their parents and make sure 
adolescents are up-to-date on vaccines. They said they usually pre-reviewed 
patients’ previous vaccination status using electronic medical records to ensure 
patients are told about vaccines they need before arriving to the clinic. Participants 
also discussed sending letters to parents to inform them of upcoming back-to-school 
immunization events, and making phone calls to remind them if they do not hear 




We are open 8:00 to 4:30 Monday through Friday, but we are willing to stay 
open evenings.  In fact, we do evening clinics from time to time as needed.  
We will even schedule to come in on a weekend. If it’s, say, a college kid 
that’s gone away to college, but they’re still under age 18 and they didn’t 
finish their HPV series. If that child is home to visit his parents over a college 
weekend, we’ll meet them up here at our office on a Saturday morning, so 
the, one thing that could be a barrier would be hours of service, is never a 
barrier here. High-practice, low-PCSA provider 
 
Because you know, school nursing, now you have to report, you have to look 
at the students and if they’re up to date. If they’re not, they get a letter from 
us. We also are the school nurse in one of the schools, the very small school, 
but we work closely with the school nurse in the little bit bigger school, and so 
that’s one of the first things you do in the fall when the new school year 
begins. We have a back to school vaccination evening and then we, those 
who didn’t get their, are lagging behind, their parents get a letter and then if 
we don’t hear from them in two weeks, we start making phone calls. Phone 
calls are probably something that wouldn’t be logical or realistic in a big 
metropolitan area, but it is here. High-practice, low-PCSA provider 
 
These efforts by high-practice, low-PCSA category participants to educate parents 
and their adolescents about the HPV vaccine, provide resources for parents, and to 
be more accessible to those who cannot schedule an appointment during normal 
business hours were discussed only by participants from the high-practice sites. It 
possibly explains why these practices are in the high practice category even though 
they were in low HPV-ordering PCSAs. This level of accessibility and communication 
of information by participants is vital in addressing concerns expressed by vaccine-
hesitant or refusing parents.   
Another community factor discussed by low practice-low PCSA participants 
was the difficulty of reaching homeschooled children for vaccinations because many 
of them do not come to the clinic for vaccines unless they are about to go to college. 
Inability to reach the homeschooled population made it difficult for participants to 




discussed by low-practice, low-PCSA sites might explain in part why their PCSA 
level HPV vaccine-ordering ratio is low. However, it does not explain why these 
populations are receiving the Tdap but not the HPV vaccine. Although this 
phenomenon was only discussed by participants from low practice-low PCSA 
categories, the challenge of reaching home-schooled children is illustrative of 
common barriers to reaching these children across all regions.  
Weather, we get snow a lot, we’re in between two mountain passes to the 
nearest town and so I, the, a lot of the kids do not have regular well child 
visits.  I would imagine as much as other places ‘cause again, they have to 
take, either they need to go in the summer or they have to take a day off from 
school and work and take the whole day to go and do their errands in [town 
name] and I think that there’s a lot of missed opportunity for vaccinations 
because of that.  I do think it’s more challenging in rural communities that do 
not have a regular doctor or pediatrician and so these communities I feel like 
are a bit more difficult and then like I said before, you know, we, even with my 
little kids, we would have where oh well shoot, we didn’t make their well child 
check but we’ll go next month, well actually we’re taking the kiddo in because 
they’re sick and we’re not gonna get vaccinations on the day they’re sick and 
so it’s just. Low-practice, low-PCSA provider 
 
You don’t [reach homeschooled children for immunizations] and the reason 
we know about it is that we have had homeschool, you know, 18-year-olds 
come to us for vaccines because they’re going to college, and they want to 
get vaccinated. And so, so we know they’re out there, but we don’t know how 
to get to them. Low-practice, low-PCSA provider 
 
 Additional barriers discussed by participants included physician’s offices not 
providing vaccines for various reasons, even though adolescents went to the clinics 
for numerous reasons.  A few participants from high practice-low PCSA and low-
practice high-PCSA health departments discussed fragmented care because the 
local physician’s office did not provide vaccines to their patients, instead 
recommending that patients go to the local public health department for vaccines. 




not come back or make another appointment at the local public health department 
just for a vaccine. Participants said that this also happened in their neighboring local 
health departments, and that the issue is bigger than their county only. Some 
participants, especially in rural public health departments, stated that the lack of 
physicians who offer immunizations in their community left the health department as 
the only option for vaccine-related conversation and delivery. Although it was a 
phenomenon described by only two of the three categories, referral to local public 
health departments for vaccines is a common trend that creates fragmentation of 
care. Participants said that physicians pointed to the cost of vaccines or lack of 
appropriate reimbursement as the main reason they did not provide them in their 
patients.  
We’re as far out east as you can get.  We border the [name of state] state 
line, so the next county to the north of us is [name of county], and they’re like 
us, their physician’s offices also want the public health nurses to do the 
vaccinations and then the county south of us is [name of county] and they’re 
in the same situation as us.  They don’t even have many immunization 
services through their public health agency. High-practice, low-PCSA provider 
 
Another barrier we have in our area is that our lack of physicians in a rural 
area.  A lot of physicians are not giving immunizations. Low-practice, high-
PCSA provider 
 
One doctor’s office has just stopped offering private stock immunizations due 
to the cost, so he refers his patients down here.  Other offices, they just aren’t 
doing that.  It would make sense to do it with well child checks, but they’re just 
not providing them. When people go, yeah, when people go see their doctor, 
they should be able to receive their immunizations during that visit. Low-
practice, high-PCSA provider 
 
Participants not only discussed fragmentation of care for adolescents when 
they are referred to local health departments for vaccines but also the challenge of 




offices are referring patients to the local health department for vaccines, some 
participants discussed difficulties creating contractual agreements with insurance 
companies, some who refuse to sign a contract with the local public health 
department. This made vaccine provision extremely difficult and costly. As the sole 
provider of vaccines for that region, some health departments faced barriers without 
a contract with private insurance companies, where vaccines are not covered by 
insurance. Thus, parents must drive hundreds of miles to get to the nearest 
physician’s office that takes their private insurance and provides vaccines to cover 
the cost of immunization. Participants said that even with the Affordable Care Act in 
place, there are still patients who are underinsured, and that not all of their 
vaccination needs were covered. This issue is further complicated when patients 
receive the vaccine at the health department but insurance companies refuse to 
reimburse the local health department, leaving them stuck with a vaccine bill.  
There is a hospital that has physicians but they do not provide vaccines other 
than Tdap in case of emergencies; we’re the only provider of infant as well as 
adolescent vaccinations in our county. High-practice, low-PCSA provider 
 
There’s some companies that won’t even sign an agreement with us. They 
won’t consider us to be a preferred because we are a department of health.  
We don’t have physicians here. We’re nurses, and they want to work with 
physician’s offices. Well there’s not a physician’s office in our county that is 
willing to do it. There’s only one physician’s office in our county and they’ve 
said we’re not interested in getting into the immunization business, so that 
means that family that has insurance. Maybe it’s even insurance that will pay, 
but it’s insurance that will not sign an agreement with [name of county] 
County Public Health, so those families then need to drive to a neighboring 
county, which may be 3 or 4 counties away as in the Front Range, Colorado 
Springs or Denver and go to a family practice office that has a vaccine. Well, 
maybe it’s not convenient to drive 180 miles into the city. So it really has 
become a barrier for some. High-practice, low-PCSA provider 
 
Because they’re saying that according to the Affordable Care Act, there 




but the plain and simple truth is all don’t. Insurance companies refuse 
payment and usually we get stuck with the bill because we agreed to bill the 
insurance and so the patient is able to leave. High-practice, low-PCSA 
provider 
 
Participants discussed challenges to HPV and other vaccine provision where not all 
the physician offices in their area provided vaccines for various reasons, such as low 
reimbursement rates. However, physician’s offices referred parents and their 
adolescents to the local health department regularly. But local health departments 
are unsure if all of the referred families are coming to their clinic because it is difficult 
to make more opportunities once the primary provider misses the opportunity to 
administer vaccines during the initial visit. The lack of a contractual agreement 
between insurance agencies and health departments is another diminished 
opportunity for families to receive the HPV vaccine in a place accessible to them. 
Even though challenges exist, performance categories for the HPV vaccine were 
anchored to the Tdap ordering trend.  
 Furthermore, the role of winter and driving distance due to lack of 
immunization providers who accept certain insurances was another barrier to HPV 
vaccine uptake. These insurance and geographic factors experienced by low PCSA 
categories further explain the challenges experienced by providers and the patients 
they serve in providing the HPV vaccine to the adolescent population. These 
phenomena in low-PCSA category might explain the overall challenge faced by low 
PCSA category sites in providing HPV vaccine to adolescents; however, it might not 
explain the performance categories that are anchored to the Tdap-ordering trend. If 
the practices were ordering Tdap, then they should also be ordering the HPV 




to adolescents. In that case, the low PCSA category of these sites explains the 
regional level low performance.  
Challenges in vaccine ordering and billing. Several participants from low-
practice, low-PCSA sites discussed barriers related to billing and ordering HPV and 
other vaccines. They are familiar with billing for VFC/publicly-insured vaccines but 
discussed challenges they faced with private insurance. Many participants from 
public health departments across categories noted challenges in billing for private 
vaccines because they have to learn about insurance companies and negotiate 
individual contracts with them for payment or reimbursement. They added that some 
billing programs did not work well in their facility, leaving them with added challenges 
when billing private insurance for vaccine reimbursement. Some participants noted 
an additional challenge in which some private insurers assumed that local health 
departments get vaccines for lower price or for free, and as a result, reimburse them 
at lower amounts than the actual cost of vaccines. Because of this incorrect 
assumption, covering vaccine costs became more difficult for local health 
departments. This ties in with challenges local health departments face in some 
areas where they are receiving referrals from physician offices with privately-insured 
adolescents but do not have the means to bill for the service.  
Private is a little difficult because we now are required to bill for private 
insurance and so that requires getting contracts with insurance companies 
and so that’s been very difficult because public health until about four years 
ago did not have to do that at all. Low-practice, low-PCSA provider 
 
I think that they’ve got a good mechanism if they can get it working efficiently 
because I mean, it sounded great, but and some of the people that were in 
the pilot loved it and some people were like oh I would never ever, ever, ever 





Another barrier for us is with private insurance and getting more contracts 
that, we’ve come across that insurance companies feel that we’re, we get 
vaccine for a lower price, but at the private level we really don’t and so what 
they want to reimburse us doesn’t even cover our costs, and so we’ve had to 
turn away many private clients because we don’t have a contract with their 
company. Low-practice, low-PCSA provider 
 
Even though, participants from low-practice, low-PCSA sites discussed 
challenges in billing different insurers for HPV vaccine, several participants from low-
practice high-PCSA sites discussed the role of a new and recently implemented 
billing system that helps them bill private as well as public-insured patients. Because 
of this new system, called Vaxcare, participants were able to accept more types of 
insurers and allow more people to have access to vaccines. Furthermore, this new 
system reduced vaccine waste and cost to the clinic because VaxCare absorbs the 
cost of any vaccine not administered. Although this was a new billing method, it was 
addressing challenges these clinics faced that might have initially put them in the low 
practice category.  
. . . they [VaxCare] contract with all of these insurance agencies, so insurance 
agencies that we were not able to contract before, that has allowed us to offer 
vaccinations to more people because we’re accepting more insurance 
companies. Low-practice, high-PCSA provider 
 
. . . it reduces the risk that the public health agencies have in purchasing 
vaccine, so if you, under, if a public health agency purchases private stock 
and we’re not able to get that administered, then they could incur the loss of 
that vaccine if it expires. So that eliminates that risk because the company 
purchases the vaccine and then they do the billing for the insurance agencies 
and all we do is enter the information in and administer it. Low-practice, high-
PCSA provider 
 
Because VaxCare is working well to address challenges discussed in vaccine billing 
by low-practice, low PCSA sites, finding best practices from other regions — in this 
case from low-practice, high-PCSA sites — is important to transfer best practices for 




PCSA specifically discussed challenges in billing for private vaccines due to lack of 
contractual agreement with private insurers. If using systems like VaxCare would 
benefit the low-practice, low-PCSA challenges, solutions like this should be shared. 
 Even though providers from some sites discussed challenges in billing for 
private vaccines, other participants discussed barriers to becoming VFC providers. 
Many participants discussed how VFC vaccine ordering is difficult because of the 
federal guidelines required to be a VFC provider to order vaccines. Some 
participants stated that VFC vaccine-related ordering and requirements are 
burdensome to private clinics without much experience with the program. This 
deters them from being a VFC provider who could offer more opportunities for 
adolescents to receive the vaccine in an affordable way. Furthermore, many 
providers felt like the VFC rules were constraining in rural communities where there 
are not a lot of vaccine providers. These challenges in vaccine ordering and billing 
experienced and shared by participants from low-practice, low-PCSA sites helps 
explain to some extent why sites in these categories are in the lower HPV vaccine-
ordering ratio category. While there is a clear lack of immunization providers in this 
PCSA, one provider from a low-practice, low-PCSA site indicated that more provider 
offices are starting to provide both private and public vaccines (VFC vaccines) 
because the public health department helped the private offices with the paperwork 
and refrigerator purchase needed to stock VFC vaccines using grant money. This 
new phenomenon might help overcome barriers discussed by participants from this 




that having more VFC vaccine providers in the area will provide more opportunities 
for HPV vaccine uptake among adolescents. 
I guess VFC sometimes is a little more difficult just ‘cause of all the ordering 
guidelines. Low-practice, low-PCSA provider 
 
It’s really frustrating that with VFCs [because providers can’t give vaccines for 
children with insurance] if their insurance doesn’t cover it [the vaccine], then 
one time I remember the family of twins who were due for all three vaccines, 
their closest in-network person was an hour and a half away, so it’s really 
hard for them to get the series of three and so, so you know I kind of, I 
understand the VFC and I know why they need to do that, but we miss out on 
some vaccines because of, of vaccinating kids because of those rules. Low-
practice, low-PCSA provider 
 
[Name of clinics] has since gotten a provider that got VFC. We were able with 
a grant to help him get a pharmaceutical grade refrigerator, that was always a 
big barrier to, you know, to the private doctors because the, you know, the 
paperwork to do the government-funded vaccine and all of that, so and as 
they became stricter with the VFC, it became evident to us that we needed to 
carry two separate sets of vaccine. We needed to carry private fund vaccine 
and start billing insurance, and we needed to continue to offer VFC because 
of the Medicaid population and no insurance. So we’ve done that for probably 
five years maybe, I don’t know, and we’ve had really good success in billing 
for private insurance, so it’s been, it’s been a good deal for everybody. Low-
practice, low-PCSA provider 
 
 Funding for vaccination efforts/cost of vaccines. Some participants from 
high practice-low PCSA and low practice-high PCSA sites discussed the cost of the 
HPV vaccine as a barrier for those who are underinsured. Participants wished they 
could give the VFC vaccine to underinsured patients as well as uninsured, but 
because of changes in healthcare policy, those opportunities are no longer available.  
 Participants also noted sporadic vaccine supply shortages due to VFC 
vaccine backorders, resulting in an inability to provide vaccines when adolescents 
come to the clinic. Some participants also expressed an interest in improving HPV 




funding to help support their efforts. They believe that having more funding would 
help improve vaccine uptake. This showed some participants are interested in 
improving HPV vaccine uptake but do not have the means to do so due to lack of 
resources. However, it does not explain their HPV vaccine-ordering ratio categories 
but rather an overall challenge faced by participants when they want to improve 
vaccine uptake.  
. . . there’s the folks that do have insurance but they’re maybe underinsured, 
and for some reason or other, the vaccine doesn’t get paid for after all. That’s 
a problem. That’s why I wish we could just give the darn VFC vaccine to 
everyone and we’ll bill for those who are able to pay and those who aren’t, 
we’ll let them have it, but that’s just not gonna happen anymore. We enjoyed 
that, we enjoyed that for 15 years, but it’s ancient history now. High-practice, 
low-PCSA provider 
 
. . . for Medicaid that we order once a month and occasionally, we will get a 
notice that it’s on backorder or there’s a shortage, oh, maybe a year ago the 
HPV was, we had a little shortage and didn’t get quite as much as we had 
hoped. High-practice, low-PCSA provider 
 
Other issues are, you know, finding funding for, you know, vaccinations and 
things like that.  So there is a difference between here and when I was in 
private practice in Indiana for the number of patients that I see and counsel 
for this versus the number that are accepting it, but once again, I think you 
know having availability and you know grants for that will increase compliance 
with that if we’re able to offer it to patients they, you know, it helps. Low-
practice, high-PCSA provider 
 
Collaboration with other organizations. A few participants from low-
practice, low-PCSA sites discussed collaborating closely with school nurses and 
community health centers to facilitate adolescent immunization. Participants 
discussed being co-located with a community health center so they could be alerted 
when someone needs a certain vaccine. This collaboration is starting to help them 
capture adolescents who are not up-to-date with HPV and other vaccines. Some 




adolescents to receive the HPV and other vaccines. In these cases, participants 
discussed sending consent forms to parents ahead of their visit to these schools to 
request permission to immunize their children. These efforts might explain this 
category’s efforts to improve immunizations as they were in the low-practice, low 
PCSA HPV vaccine-ordering ratio. 
We, because we are a rural county, we are able to, every spring I work in 
conjunction with the school nurse, and we actually go into the schools, we 
send home like consent forms with children that are needing to be up-to-date 
on their vaccines for school. We get a list of those and we send home like an 
information sheet and consent form with those children, and then we actually 
have an agency go into the schools and get everybody caught up on what 
they’re needing for the following school year. . . . 
Low-practice, low-PCSA provider 
 
. . . . so we have a community health center and we actually screen every 
child that they see for immunizations and then recommend what they need. 
Low-practice, low-PCSA provider 
 
We work very closely with all the schools in our community. We always hold 
spring immunization clinics and fall immunization clinics at the schools, that 
way parents have a chance to get TDAPs and then we offer them Meningitis 
and HPV and information. Low-practice, low-PCSA provider 
 
Policy Factors: Changes due to the Affordable Care Act. A couple of 
participants from different practices in the low practice-high PCSA category 
discussed the Affordable Care Act’s (ACA) rule change regarding the appropriate 
use of federally-funded vaccines. Although the rule change they discussed was not 
due to ACA, the change they discussed removed the ability for providers to give 
VFC and other federally-funded vaccines to anyone without checking a patient’s 
eligibility. Participants said this new policy made it harder for public health 
departments to offer vaccines in the clinics if parents did not bring documentation for 




the misinterpretation of the changes to the eligibility rule demonstrates a lack of 
knowledge among some providers about the policies that govern their immunization 
practice.    
Prior to the Affordable Care Act, when the federally-funded vaccine laws 
changed, or the rules around the appropriate use of federally-funded 
vaccines, we were able to immunize at schools and we did not have to 
determine eligibility, and our immunization rates were much better, but we 
were not able to do that, we were not able to use the vaccines, the federally-
funded vaccine for you know all those individuals once those rules changed 
and our rates have been down. Low-practice, high-PCSA provider 
 
I think it has to do with immunization opportunities, so our community was, we 
had many insured individuals who came to public health because we’re easy 
to access and we’re, you know, we’re not a provider office where you have to 
pay for an office visit, make an appointment and things like that, so it was the 
ease of obtaining immunizations at public health that was a big factor. Low-
practice, high-PCSA provider 
 
 Opportunity for improved HPV vaccine uptake: Change in the HPV 
vaccine dosage. Participants from all categories discussed the new change in the 
number of HPV vaccine doses as an opportunity to improve HPV vaccine uptake 
among their adolescent population. Although most learned about the change at 
different times — some learned about the new vaccine guideline from the researcher 
during the interview, while others knew but had not implemented the new guidelines 
at the time of the interview — they discussed opportunities that will come with the 
new guideline and shared their optimism that the change will increase vaccine 
uptake.  
Several participants discussed how moving from the three-dose requirement 
to the two-dose requirement will reduce the HPV vaccine cost burden on families. 
Furthermore, providers discussed how one of their biggest issues is getting 




times would improve vaccination rates. A few participants also mentioned that 
adolescents will be happy with less visits since some are needle-shy. 
In addition, participants said they plan to communicate with families about the 
new vaccine guidelines via a letter. Messaging strategies included writing the letter 
in layman’s terms and keeping it positive to capture a parent’s attention.  
So I think that’s gonna be real good because number one, it’s gonna save the 
family money, number two only two trips in instead of three, so I think it’s 
going to help with our vaccine series completion rate. I have high hopes that it 
will. High hopes. High-practice, low-PCSA provider 
 
I think the kids will be excited because it . . . it is a painful vaccine for 
whatever reason, it is more painful than other vaccines, and so I think if 
they’ve talked to any of their friends or relatives or they’ve already had one 
dose, knowing that they only have to have one more will make them happy, 
and I think for parents, only having to remember one more visit versus two 
more visits will make them happy. Low-practice, high-PCSA provider 
 
Yeah, I think it’ll probably help people be a little bit more apt to come back if 
they only have to come back one more time on the HPV. Low-practice, low-
PCSA provider 
 
In conclusion, these findings enhance our understanding of the current 
barriers to HPV vaccination of adolescents. Participants from the three categories 
who participated in key informant interviews described parental, provider, and policy 
factors that hinder HPV vaccine uptake in Colorado. There were fundamental 
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Parental factor barriers to the HPV vaccine combined with provider factors 
provided a clear picture of the challenges present today in HPV vaccine 
recommendation and provision. Although progress has been made in improving 
HPV vaccine provision rates, this qualitative research highlights the effects of 
parental refusal and hesitancy to vaccinate their adolescents, and the effects of 
providers who do not recommend the vaccine, who are not sufficiently persuasive, or 
who do not always have opportune environments to provide the HPV vaccine. For 




data and provider communication. Furthermore, provider assumption that certain 
adolescents need the HPV vaccine more than others, and thus recommending the 
vaccine for some but not others by observational judgment, is sure to create missed 
opportunity to vaccinate.  
The findings of this research compliment prior studies that looked at barriers 
to HPV vaccine uptake nationally. Furthermore, the empirical findings in this 
research have several practical implications for improving HPV and other adolescent 
vaccines in Colorado. The variations in HPV ordering ratio showed differences in 
practice and PCSA level HPV vaccine trends. However, the barriers discussed 
primarily showed similarities in terms of barriers and very subtle differences in 
provider practice behaviors. Such information can be used to develop targeted 
interventions aimed at improving HPV vaccination rates. Further exploration of these 
qualitative findings will be carried out to test and solidify the generalizability of some 
themes that were persistent throughout the qualitative exploration.  
In summary, participants from the three categories who participated in key 
informant interviews described several barriers to HPV vaccine uptake in Colorado. 
These ranged from barriers due to conservative parental outlooks and concerns 
about their adolescents’ untimely sexual debut to provider barriers in believing that 
certain parents and their children do not need the HPV vaccine. These variations in 
HPV ordering ratio that showed variations in vaccine ordering also unveiled 
variations in enabling and hindering factors to adolescent HPV vaccination, such as 
practice, perceptions of their community, and lack of resources. There were also 




For example, vaccine ordering and billing was a barrier discussed only by providers 
from low-practice, low-PCSA categories. Although there was not a clear difference in 
all the themes of barriers in driving the three categories apart, how they dealt with 
these barriers provides a better understanding of differences between categories.  
In summary, all three categories discussed facilitators to HPV vaccine 
provision and recommendation in their sites. Some facilitators included what clinics 
did to improve HPV vaccine uptake by increasing availability and talking to the 
parents and adolescents directly about HPV vaccine. Other sites discussed the Tdap 
vaccine school requirement as a facilitator that motivates parents to come into the 
clinic so that providers can have the opportunity to speak to them about HPV and 
other adolescent vaccines. The most striking facilitator was how high-practice, low-
PCSA sites discussed their efforts to collaborate with and share HPV vaccine-
related information to adolescents directly. They also discussed staying up-to-date 
on immunization information by attending meetings and receiving journal articles for 
readings.  
 The key themes obtained from Aim 2 qualitative research are that there are 
similar existing barriers faced by all categories. The extent to which these barriers 
were addressed by the different categories to some extent explained differences in 
the categories. Because the categories were determined by using VFC ordering data 
from 2015, it is important to make the distinction that the HPV vaccine-ordering ratio 
might not equate to HPV vaccine receipt.  However, because the ratio was anchored 
to the Tdap vaccine-ordering ratio, it does provide practice-level initial plans to 




 Several factors influence HPV vaccine provision. Provider, parental and 
adolescent discussions about HPV vaccine do not occur in vacuum. They are 
influenced by population level context: culture, norms and values as well as 
perceived and actual disease risk and system and structural level context: 
geography, payment systems, insurance, office hours of clinics, etc. Figure 2 was 
created to depict contextual factors that influence HPV vaccine uptake. Providers, 
adolescents and their parents are influenced by the population context where they 
live in that includes values, morality, and messaging about prevention and 
perceptions and actual risk of HPV-related disease. This population context is 
influenced by: 
• Vaccine messaging and communication via providers and general 
advertisement 
• Religiosity of parents and their influence on adolescents 
• Population level perceptions of adolescent health and what is deemed 
appropriate prevention for their age 
• Parental experience with HPV infection-actual risk 
There are also system and structural contexts that enable or hinder their 
willingness to vaccinate. These included current vaccine policy, payment methods at 
the clinic, availability of immunization providers, office hours and ability to schedule 






Figure 2: Contextual factors that influence HPV vaccine uptake 
 
 
• Communication change in vaccine policy from top down 
• Availability of immunization providers who provide off-hour services 
• Ability for practices who accept different types of insurance to increase 
access 
 The barriers and facilitators discussed by participants revealed interrelated 
population level as well as system and structural level contextual factors that 
informed adolescent HPV vaccine uptake. Parents were influenced by cultures, 




from vaccine side effects as well as early sexual debut, and their perceived risk of 
disease due to their prior experience with cancer or HPV infection. Providers in the 
meantime interacted with different adolescents and their parents while trying to 
communicate HPV vaccine need. This was clearly influenced by professional 
confidence (types of providers). Adolescents, however, were less engaged in their 
care, were needle-shy and had sometimes a say in what their parents decided. This 
also was dependent on whether the adolescent had come to the clinic to receive 
HPV vaccine, emphasizing why the role of preventative visits in HPV vaccine 
initiation and completion is important.  
These structural and population level factors can be tested using quantitative 
data for generalizability and further validity. These possible testable points include:  
 Hispanics are open to all vaccines, including the HPV vaccine, for their 
adolescents 
 Parents with public insurance are more likely to accept provider 
recommendations 
 Differences in male and female adolescent HPV rate 
 Differences in rural and urban setting with focus on seasonal differences in 
immunization uptake 
 HPV vaccine difference among adolescents in different religious groups 
 Obtaining information from parents of adolescents regarding their perception 
and attitudes towards HPV vaccine 
These notions obtained from the qualitative data can be tested for further 




testable hypothesis that were tested are below. Testing Hispanic/non-Hispanic HPV 
vaccine uptake tests the underlying mechanism by which culture, value, attitudes and 
behaviors influence HPV vaccine uptake in different populations. The insurance status 
hypothesis however looks at the larger system and structural factors that influence 
HPV vaccine uptake. Testing these two hypothesis provides insight into the larger 
contextual factors that hinder or facilitate HPV vaccine uptake. 
 Hispanics are open to all vaccines, including the HPV vaccine, for their 
adolescents. This notion gets at the role of culture and population level norm 
and value in HPV vaccine uptake and how it contributes to differences in 
outcomes.  
 Parents with public insurance are more likely to accept provider 
recommendations than privately insured individuals. This notion discusses 
the role of system and structural factors such as insurance in enabling HPV 
vaccine uptake.  
Understanding nuances by testing these two hypotheses can provide insight into 
facilitating factors to improve HPV vaccination. Furthermore, decomposition analysis 
will further help identify explained and unexplained factors contributing to these 
factors.  
Aim 3 
The objective of Aim 3 was to understand the contribution of providers, 
patients, and PCSA factors to disparities in HPV vaccination rates and to test 






Using APCD data from 2011-2014, children aged 11-18 years of age in 
Colorado were used for this analysis. There were 345,985 claims in the APCD data 
from 2011-2015. Among those, 183,743 claims had Tdap vaccine and 54,146 claims 
were in the data for 365 days after index Tdap visit. Finally, 26,654 children met the 
365-day follow-up window requirement after the index event. The reasons someone 
would not have a full 365 post-Tdap index date include: loss of health insurance 
during the time following Tdap vaccine, moving to a different state, etc.     
Explanatory Analysis 
A total of 26,654 patients between ages 11-18 were included in the APCD 
data between 2011 and 2014. Unadjusted patient level demographic and other 
characteristics of interest are reported in Table 4. These characteristics included age 
in years, gender, race, ethnicity, urban/rural residence, insurance status, and visit 
type (preventative, sick, or vaccine-only visits).  
Population level characteristics of the above patients are described in Table 
5. These characteristics included religion adherence per 1000 population, percent of 
racial/ethnic residents in the population, population level educational characteristics, 
percent linguistically isolated households, percent income below poverty and 
institutionalized population. 
Logit Analysis Results  
The marginal effects from the logistic regressions are reported in Table 6. Although 
race and ethnicity data were available, due to unreliable racial groups labeling in 




Column 1 of Table 6 includes the estimates of the probability of the HPV vaccine 
initiation.  After controlling for several covariates, we found that males compared to 
females were significantly less likely to initiate HPV vaccine. In addition, individuals 
who had male providers compared to females and those who saw other types of 
providers compared to primary care providers were significantly less likely to initiate 
the HPV vaccine. Individuals living in high mainline Protestant adherence counties 
as well as in counties with higher black Protestant adherence rates were significantly 
less likely to initiate the HPV vaccine. Furthermore, adolescents living in areas with 
higher percentage Hispanic population compared to non-Hispanics, those living in 
areas with higher percentages of individuals with income below the poverty level, 
and those living in areas with a higher institutionalized population were significantly 





Table 4: Study Population Characteristics by Receipt of at Least One Dose of HPV 
Vaccine  




Did not receive 
any HPV (%) 
  N = 12,533 N = 12,481 
Age in years 11 56.62 41.97 
12 16.7 18.03 
13 6.62 6.85 
14 4.94 5.54 
15 4.35 5.27 
16 4.02 5.84 
17 3.38 7.4 
18 3.36 9.08 
Gender Male (Ref) 48.52 54.52 
Female 51.37 45.24 
Unknown 0.11 0.24 
Race Race 1 5.86 5.38 
Race 2 4.68 6 
Race 3 2.75 2.17 
Race 4 0.47 0.45 
Race 5 (Ref) 3.38 3.91 
Race 6 8.03 7.43 
Unknown race 74.83 74.67 
Ethnicity Non-Hispanic (Ref) 25.26 17.75 
Hispanic 74.74 82.25 
Insurance Private 39.66 41.18 
Other 3.37 97.29 
Public (Ref) 51.33 48.16 
Rural/Urban Urban (Ref) 90.12 85.65 
Rural 9.07 13.7 
TDAP Visit Type  Vaccine only (Ref) 64.58 41.31 
Preventive 88.23 76.13 
Sick 89.54 88.56 
Provider type Primary care (Ref) 41.16 46.15 
 Other providers 58.84 53.85 
Provider gender Male 40.04 51.07 
 Female (Ref) 59.85 48.77 
 Unknown 0.11 0.16 





Table 5: Characteristics of Study Population’s Residence  
Characteristics  Received HPV Did not receive 
HPV 
Religion adherence 





















































Population under age 25 below 




































Note. Unadjusted County and PCSA level data. Standard deviations are in parentheses 
 
 We also found that Hispanics compared to non-Hispanics, those who live in 
urban settings compared to rural areas, and those who had more preventative visits 




Table 6: Logistic Regression Results (Marginal Effects) 
Variables HPV initiation HPV completion 
Observations n=24,553 n=24,553 
Patient characteristics 
Male (ref. female) -0.0600*** -0.0498*** 
 (0.0061) (0.0047) 
Urban (ref. rural) 0.0791*** 0.0426*** 
 (0.0151) (0.0123) 
Unknown Hispanic ethnicity -0.0005 0.0266** 
 (0.0153) (0.0116) 
Hispanic ethnicity (ref. non-Hispanic) 0.1340*** 0.0557*** 
 (0.0163) (0.0130) 
Private insurance (ref. public insurance) 0.0086 0.0371*** 
 (0.0081) (0.0062) 
Other insurance 0.0553*** 0.0309** 
 (0.0195) (0.0138) 
Provider and visit type characteristics 
Preventative visit 0.0720*** 0.0595*** 
 (0.0024) (0.0018) 
Sick visit (ref. vaccine-only visit) 0.0002 0.0016*** 
 (0.0004) (0.0003) 
Male provider (ref. female providers) -0.0760*** -0.0240*** 
 (0.0065) (0.0050) 
Other providers (ref. Primary care providers  -0.0555*** -0.0311*** 
 (0.0067) (0.0051) 
Population level characteristics 
Evangelical rate -0.0002* -0.0001 
 (0.0001) (0.0001) 
Catholic rate 0.0001* 0.0001 
 (0.0001) (0.0000) 
Mainline protestant rate -0.0010*** -0.0002 
 (0.0003) (0.0002) 
Black protestant rate -0.0130*** -0.0073*** 
 (0.0018) (0.0014) 
Orthodox rate 0.0225*** 0.0105*** 
 (0.0031) (0.0025) 
Other religion rate -0.0010*** -0.0008*** 
 (0.0002) (0.0002) 
Pct. Black (ref. pct. white) 0.0822 0.0641 
 (0.1209) (0.0890) 
Pct. other race 0.5990*** 0.5544*** 
 (0.1957) (0.1450) 
Pct. Hispanic (ref. non-Hispanic) -0.2774** -0.1302 
 (0.1351) (0.1005) 
Pct. ling isolated house 0.3039 0.1540 
 (0.1861) (0.1520) 
Pct. income below poverty -0.3541*** -0.2383*** 
 (0.0930) (0.0730) 
Pct. institutionalized pop -0.4768** 0.1519 




Table 6 cont’d 
Variables HPV initiation HPV completion 
 
Pct. below High school pop under age 25 0.7604** -0.1042 
 (0.3131) (0.2533) 
Pct. high school graduates 0.4169** 0.5286*** 
 (0.1702) (0.1330) 
Pct. college graduate 0.5406*** 0.4180*** 
 (0.1441) (0.1163) 
Notes. Standard errors in parentheses.  *** p < 0.01, ** p < 0.05, *p < 0.1. 
 
Furthermore, individuals who lived in areas with increased number of other races 
(non-black, non-Hispanic) compared to whites, those living in communities with 
higher linguistically-isolated households and with a higher percentage of individuals 
under age 25 who have not completed high school were significantly more likely to 
initiate the HPV vaccine. Furthermore, individuals living in areas with higher 
percentages of high school and college graduates were more likely to receive at 
least one dose of the HPV vaccine (Table 6). 
Column 2 reports the estimates related to the HPV vaccine completion.  
When we look at individuals who completed the three-dose HPV vaccine series, we 
find that males compared to females were significantly less likely to complete the full 
dose of the HPV vaccine. Furthermore, adolescents who received care by male 
providers compared to female providers and those who received care by other types 
of providers compared to primary care providers were less likely to complete the full 
dose. Additionally, individuals living in high mainline Protestant, black Protestant and 
other religion adherence counties, and those who resided in areas where a higher 
percent of the population lives below the poverty level were less likely to complete 




Individuals who live in urban settings compared to rural areas, and those who 
had more preventative and sick visits compared to vaccine-only visits were 
significantly more likely to complete the full dose. Furthermore, adolescents living in 
areas with higher Orthodox religion adherence, those with Hispanic ethnicity 
compared to non-Hispanics, and those with private as well as other insurance types 
compared to public insurance were more likely to complete the full dose of the HPV 
vaccine. Additionally, adolescents living in areas with increased number of other 
races (non-black, non-Hispanic) compared to whites and with more high school and 
college graduates in the population were significantly more likely to complete the full 
dose (Table 6). 
 Furthermore, we graphed the marginal effect of each index age on the 
adjusted probability of HPV vaccine initiation in Figure 3. The probability of receiving 
any HPV vaccine declines from about 0.7 at age 11 to about 0.35 at age 18. In 
Figure 4 we similarly graph the estimates related to the probability of completing the 
three doses of the HPV vaccine series by age of Tdap receipt, the probability starts 
low at about 0.3 at age 11 and drops to less than 0.1 for 18-year-olds, indicating a 
lower probability of completing the HPV vaccine series over the years.  
The logit model of HPV vaccine initiation showed increased HPV vaccine 
initiation by Hispanics compared to non-Hispanics. This finding is in line with our 
qualitative findings that providers shared indicating vaccine acceptability among 
Hispanics compared to non-Hispanics. Furthermore, our results show that publicly-






























Note: This analysis is adjusted for gender, urban/rural residency, ethnicity, insurance 
type, trend year, visit type, provider gender, and population level characteristics 
listed in Table 6. 95% confidence intervals are shown.  
 
The logit model of HPV vaccine completion also showed increased Hispanic HPV 
vaccine completion compared to non-Hispanics, but indicated the opposite effect of 
public insurance in HPV vaccine completion. In this model, non-publicly insured 
individuals were more likely to complete the three-dose series of the HPV vaccine 
compared to publicly-insured individuals. Because of this, decomposing Hispanic 
ethnicity and insurance status (public vs. non-public) is important to further 
understand the contribution of endowments (explainable factors) and coefficients 
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Figure 4. Adjusted probability of completion of the HPV vaccine series by age of 























Note: This analysis is adjusted for gender, urban/rural residency, ethnicity, insurance 
type, trend year, visit type, provider gender, and population level characteristics 
listed in table 6. 95% confidence intervals are shown. 
 
Decomposition on Hispanic ethnicity. Due to the reliability of ethnic group 
labeling among individuals with Medicaid insurance, the Hispanic decomposition 
analysis was limited to individuals who had Medicaid insurance only. This allowed 
for a better comparison of outcomes between Medicaid-insured Hispanics and 
Medicaid-insured non-Hispanics. Even though the labeling was incorrect, race was 
still controlled for in the analysis. For example, African Americans in the dataset 
were incorrectly labeled as American Indian/Alaska natives and we were able to 
include that data in the analysis but withheld from displaying due to incorrect 
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Hispanic individuals, their HPV vaccine status outcome-initiation, and completion of 
the HPV vaccine series. 
When we looked at the decomposition results for those who initiated the HPV 
vaccine, we saw that Medicaid-insured Hispanics were more likely to receive at least 
one dose of the HPV vaccine compared to Medicaid-insured non-Hispanics. The gap 
in HPV vaccine initiation between the two groups is 0.121. Adjusting non-Hispanic 
endowments levels to the levels of Hispanics would increase their probability by 23% 
(0.0283/ 0.1214). A statistically significant gap of 77% (0.0931/0.1214) remains 
unexplained (see Table 7).  
Table 7: Pooled Regression Decomposition Results on Hispanic Ethnicity of 
Adolescents who Initiated the HPV Vaccine 
 HPV initiation 
Variables Differential Decomposition 
Prediction_2 (Hispanic) 0.5977***  
 (0.0070)  
Prediction_1 (non-Hispanic) 0.4762***  
 (0.0086)  
Difference 0.1214***  
 (0.0111)  
Explained  0.0283 
  (0.0175) 
Unexplained  0.0931*** 
  (0.0201) 
Observations 8,338  
Note. Robust standard errors in parentheses. *** P < 0.01, ** p < 0.05, * p < 0.1 
 
Examination of the decomposition results for those who completed the HPV 
vaccine series, we notice a significant difference between the two groups, in which 
Hispanics are more likely than non-Hispanics to complete the three-dose HPV 
vaccine series. The gap in completing the HPV vaccine series between the two 




Hispanics increased their probability of completing the HPV vaccine series by about 
-39% (-0.0114/0.0296). However, 139 % (0.0411/0.0296) of the gap remains 
significantly unexplained (see Table 8). The unexplained gap in differences 
overcomes the deficit of the explained factors.  
Table 8: Pooled Regression Decomposition Results on Hispanic Ethnicity of 
Adolescents who completed the HPV Vaccine 
 HPV Completion 
Variables Differential Decomposition 
   
Prediction_2 (Hispanic) 0.167***  
 (0.00529)  
Prediction_1 (non-Hispanic) 0.137***  
 (0.00592)  
Difference 0.0296***  
 (0.00794)  
Explained  -0.0114 
  (0.0118) 
Unexplained  0.0411*** 
  (0.0138) 
   
Observations 8,338 8,338 
Note. Robust standard errors in parentheses. *** P < 0.01, ** p < 0.05, * p < 0.1 
 
We also estimated a detailed decomposition to understand the role of 
individual covariates in determining the explained and unexplained contributions to 
the difference in HPV vaccine initiation and completion. Tables 9 and 10 report the 
results of the detailed decomposition between Hispanic and non-Hispanic individuals 
and HPV vaccination status. Due to a lack of data among individuals with non-
Medicaid insurance, the Hispanic decomposition analysis is limited to individuals 
who had Medicaid insurance only. This allowed for a better comparison of outcomes 







Table 9: Detailed Regression Decomposition Results on Hispanic Ethnicity Among 
Individuals who Initiated the HPV Vaccine 
 (1) (2) (3) 
 Differential Explained Unexplained 
Patient characteristics 
Male  0.0001 0.0088 
  (0.0008) (0.0103) 
Age 12 (ref. age 11)  0.0010* -0.0008 
  (0.0006) (0.0061) 
Age 13  0.0010* -0.0004 
  (0.0005) (0.0038) 
Age 14  0.0016** -0.0002 
  (0.0007) (0.0032) 
Age 15  0.0036*** -0.0092*** 
  (0.0010) (0.0030) 
Age 16  0.0045*** -0.0068** 
  (0.0011) (0.0030) 
Age 17  0.0052*** -0.0064** 
  (0.0016) (0.0028) 
Age 18  0.0055*** -0.0035 
  (0.0021) (0.0025) 
Urban (ref. rural)  -0.0011 0.0003 
  (0.0008) (0.0074) 
Provider and visit type characteristics 
Preventative visit  0.0068*** -0.0126 
  (0.0021) (0.0135) 
Sick visit (ref. vaccine-only visit)  0.0024** -0.0094 
  (0.0010) (0.0096) 
Male provider (ref. female providers)  0.0064*** -0.0040 
  (0.0012) (0.0083) 
Other providers (ref. Primary care providers   0.0022*** 
(0.0008) 
0.0189 
  (0.0231) 
Population characteristics 
Evangelical rate  -0.0026 
(0.0029) 
-0.1179*** 
  (0.0454) 
Catholic rate  -0.0043 0.0115 
  (0.0032) (0.0329) 
Mainline Protestant rate  0.0037* 0.0713* 
  (0.0021) (0.0404) 
Black Protestant rate  0.0007 -0.0170 
  (0.0010) (0.0175) 
Orthodox rate  -0.0005 -0.0173 
  (0.0011) (0.0247) 
Other religion rate  -0.0021** 0.0007 
  (0.0009) (0.0294) 
Pct. Black (ref. pct. White)  0.0024 0.0094 
  (0.0017) (0.0201) 








Table 9, cont’d 
 (1) (2) (3) 
 Differential Explained Unexplained 
                         Population characteristics 
  (0.0116) (0.1216) 
Pct. Hispanic (ref. non-Hispanic)  -0.0080 -0.0777 
  (0.0219) (0.1325) 
Pct. Ling isolated house  0.0170 -0.0281 
  (0.0104) (0.1216) 
Pct. Income below poverty  -0.0061* -0.0078 
  (0.0032) (0.0479) 
Pct. Institutionalized pop  0.0009 -0.0017 
  (0.0008) (0.0074) 
Pct. Below High school pop under age 25  -0.0011 -0.0056 
  (0.0081) (0.0536) 
Pct. High school graduates  0.0005 -0.0433 
  (0.0021) (0.1027) 
Pct. College graduate  -0.0025 0.0554 
  (0.0038) (0.0645) 
Total  0.0283 0.0931*** 
  (0.0175) (0.0201) 
Prediction_1(Hispanic) 0.5977***   
 (0.0070)   
Prediction_2 (non-Hispanic) 0.4762***   
 (0.00860)   
Difference 0.1214***   
 (0.0111)   
Constant   -0.0849 
   (0.2429) 
    
Observations 8,338 8,338 8,338 
Note. Robust standard errors in parentheses. *** p < 0.01, ** p < 0.05, * p < 0.1 
 
Decomposing Hispanic ethnicity on HPV vaccine initiation. Factors that 
significantly explained and drove the gap in initiation of the HPV vaccine among 
Medicaid-insured Hispanics and non-Hispanics included having preventative or sick 
visits compared to vaccine-only visits, having male providers compared to female  
providers, being seen by other types of providers compared to primary care 
providers, and living in higher mainline Protestant adherence areas.  
However, explained factors that closed the gap in any HPV vaccine receipt 




adherence to other religions and living in areas with a higher percentage of the 
population living below the poverty level (see Table 9). 
The predicted probability of HPV vaccine initiation was 0.5977 for Hispanic 
and 0.4762 for non-Hispanic adolescents. Therefore, a difference of 0.1214 or 12.14 
percentage points existed between the two groups. The decomposition estimated a 
positive coefficient 0.0283 for explained disparity in HPV vaccine initiation between 
the two groups. Thus only 23% (0.0283/0.1214) of the total difference was explained 
by observed characteristics. The remaining 77% (0.0931/0.1214) of the difference 
was due to unexplained factors. Increasing age, visit type, provider gender and 
provider type, having primary care provider visit and living in communities with 
higher percentage of mainline Protestant religion adherence were significant factors 
in the decomposition. The contribution of observed characteristics in explained 
factors of HPV vaccine initiation decomposition between Medicaid-insured Hispanics 
and non-Hispanics is presented in table 9. The percent contribution of each 
covariate is calculated by dividing the individual coefficient estimate from the 
explained decomposition by the total explained by measurable characteristics and 
multiplying by 100. The results including the percent contribution are presented in 
Table 10.  
If a higher number of non-Hispanic adolescents had more preventive visits 
compared to vaccine-only visits, then the likelihood of initiating HPV vaccine would 
have increased by 24.03%, which would have reduced the observed gap. If a higher 
number of non-Hispanic adolescents had vaccine-only visits instead of sick visits, 




would have reduced the observed disparity. If a higher number of non-Hispanic 
adolescents had visits with female providers instead of male providers, then the 
likelihood of initiating the HPV vaccine would have increased by 22.61%, which 
would have reduced the observed gap. If a higher number of non-Hispanic 
adolescents visited primary care providers instead of other types of providers then 
the likelihood of initiating HPV vaccine would have increased by 7.77%, which would 
have reduced the observed gap.  
Additionally, if a higher number of non-Hispanic adolescents lived in 
communities with higher mainline Protestant religion adherence, then the likelihood 
of initiating HPV vaccine would have increased by 13.07%, which would have 
reduced the observed gap. However, living in communities with higher adherence to 
other religions and living in areas with a higher percentage of the population living 
below the poverty level had an opposite effect in explaining the observed gap in 
HPV vaccine initiation. If a higher number of non-Hispanic adolescents lived in 
communities with higher adherence to other religions, then the likelihood of initiating 
HPV vaccine would have decreased by 7.42%, which would have increased the 
observed gap.  
Similarly, if a higher number of non-Hispanic adolescents lived in 
communities with a higher percentage of the population living below the poverty 
level, then the likelihood of initiating HPV vaccine would have decreased by 21.55%, 
which would have increased the observed gap between Hispanics and non-Hispanic 




The results of the decomposition show the contribution of observed factors, 
especially the role of provider and visit type characteristics in HPV vaccine initiation 
gap between the two groups. The following section discusses the role of observed 
factors in HPV vaccine completion among Medicaid-insured Hispanic and non-
Hispanic groups.  
Table 10: Explained Percent Contribution of Observed Factors in Hispanic Ethnicity Decomposition 
Results of HPV Vaccine Initiation 
Probability of initiating any HPV vaccine for Hispanics                                                  0.5977*** 
Probability of initiating any HPV vaccine for non-Hispanics                                           0.4762*** 
Difference in HPV vaccine initiation                                                                                0.1214*** 
        Total unexplained by measurable characteristics                                                       0.0931***  
   Total explained by measurable characteristics                                                            0.0283 










Male (ref. female) 0.0001 0.0008 0. 35 
Age 12 (ref. age 11) 0.0010* 0.0006 3.53 
Age 13 0.0010* 0.0005 3.53 
Age 14 0.0016** 0.0007 5.65 
Age 15 0.0036*** 0.0010 12.72 
Age 16 0.0045*** 0.0011 15.90 
Age 17 0.0052*** 0.0016 18.37 
Age 18 0.0055*** 0.0021 19.43 
Urban (ref. rural) -0.0011 0.0008 -3.89 
Provider and visit type characteristics 
Preventative visit 0.0068*** 0.0021 24.03 
Sick visit (ref. vaccine-only visit) 0.0024** 0.0010 8.48 
Male provider (ref. female providers) 0.0064*** 0.0012 22.61 
Other providers (ref. Primary care providers)  0.0022*** 0.0008 7.77 
Population characteristics 
Evangelical rate -0.0026 0.0029 -9.19 
Catholic rate -0.0043 0.0032 -15.19 
Mainline Protestant rate 0.0037* 0.0021 13.07 
Black Protestant rate 0.0007 0.0010 2.47 
Orthodox rate -0.0005 0.0011 -1.77 
Other religion rate -0.0021** 0.0009 -7.42 
Pct. Black (ref. pct. White) 0.0024 0.0017 8.48 
Pct. Other race 0.0133 0.0116 47.00 
Pct. Hispanic (ref. non-Hispanic) -0.0080 0.0219 -28.27 
Pct. Ling isolated house 0.0170 0.0104 60.07 
Pct. Income below poverty -0.0061* 0.0032 -21.55 
Pct. Institutionalized pop 0.0009 0.0008 3.28 
Pct. Below High school pop under age 25 -0.0011 0.0081 -3.89 
Pct. High school graduates 0.0005 0.0021 1.77 
Pct. College graduate -0.0025 0.0038 -8.83 




Decomposing Hispanic ethnicity on completion of the HPV vaccine. 
Factors that significantly explained and drove the gap in completion of three doses 
of the HPV vaccine among Medicaid-insured Hispanics and non-Hispanics included 
having preventative visits compared to vaccine-only visits and living in areas where 
an increased percent of the population is composed of other races (non-black, non-
Hispanic).  
However, explained factors that closed the gap in completing the three-dose 
HPV vaccine among Medicaid-insured Hispanics and non-Hispanics was having 
more sick visits compared to vaccine-only visits, living in areas with high evangelical 
Christian and other religion adherence, and living in areas with an increased 




Table 11. Detailed Regression Decomposition Results on Hispanic Ethnicity among 
Individuals who Completed the Full Dose of the HPV Vaccine 
 (4) (5) (6) 
Variables Differential Explained Unexplained 
Patient characteristics 





Age 12 (ref. age11)  0.0008 -0.0015 
 (0.0005) (0.0046) 
Age 13 0.0015*** -0.0016 
 (0.0006) (0.0027) 
Age 14 0.0020*** -0.0016 
 (0.0006) (0.0022) 
Age 15 0.0030*** -0.0015 
 (0.0007) (0.0019) 
Age 16 0.0029*** -0.0012 
 (0.0007) (0.0018) 
Age 17 0.0020*** 0.0004 
 (0.0006) (0.0016) 
Age 18 0.0018** 0.0004 
  (0.0007) (0.0013) 
urban  0.0003 -0.0024 
  (0.0005) (0.0394) 
Provider and visit type characteristics 
Preventative visit  0.0053*** 0.0015 
  (0.0016) (0.0112) 
Sick visit (ref. vaccine-only visit)  -0.0025*** -0.0130* 
  (0.0008) (0.0076) 
Male provider (ref. female providers)  -0.0002 0.0070 
  (0.0007) (0.0061) 
Other providers (ref. Primary care 
providers  
 0.0002 -0.0067 
  (0.0005) (0.0168) 
Population characteristics 
Evangelical rate  -0.0045* -0.0713** 
  (0.0026) (0.0279) 
Catholic rate  -0.0009 0.0397* 
  (0.0022) (0.0227) 
Mainline Protestant rate  0.0004 0.0160 
  (0.0016) (0.0294) 
Black Protestant rate  0.0004 -0.0033 
  (0.0005) (0.0136) 
Orthodox rate  -0.0003 -0.0210 
  (0.0007) (0.0195) 
Other religion rate  -0.0012** 0.0046 
  (0.0005) (0.0179) 
Pct. Black (ref. pct. white)  0.0007 0.0168 
  (0.0011) (0.0147) 





Table 11, cont’d 
 (4) (5) (6) 
Variables Differential Explained Unexplained 
  (0.0075) (0.0844) 
Pct. Hispanic (ref. non-Hispanic)  -0.0022 -0.1049 
  (0.0141) (0.0919) 
Pct. ling isolated house  0.0082 -0.0827 
  (0.0071) (0.0833) 
Pct. income below poverty  -0.0100*** -0.0726** 
  (0.0025) (0.0353) 
Pct. institutionalized pop  -0.0011* 0.0003 
  (0.0006) (0.0058) 
Pct. below High school pop under age 25  -0.0087 0.0579 
  (0.0059) (0.0391) 
Pct. high school graduates  0.0005 -0.0494 
  (0.0015) (0.0739) 
Pct. college graduate  0.0010 0.0166 
  (0.0029) (0.0479) 
Total  -0.0112 0.0410*** 
  (0.0118) (0.0138) 
Prediction_1 (Hispanic) 0.1667***   
 (0.0053)   
Prediction_2 (non-Hispanic) 0.1369***   
 (0.0059)   
Difference 0.0299***   
 (0.0079)   
Constant   0.0744 
   (0.1943) 
    
Observations 8,338 8,338 8,338 
Note. Robust standard errors in parentheses. *** p < 0.01, ** p < 0.05, * p < 0.1 
 
The predicted probability of HPV vaccine completion was 0.1667 for Hispanic 
and 0.1369 for non-Hispanic adolescents. Therefore a difference of 0.0299 or 2.99 
percentage points existed between the two groups. The decomposition estimated a 
negative total explained coefficient (-0.112) for gap in HPV completion between the 
two groups. This indicates that observed characteristics did not successfully explain 
the difference in HPV vaccine completion of 0.0299 between the two groups. In 
other words, had non-Hispanic adolescents had similar distribution of observed 




completion (0.0299 or 2.99 percentage points) would be 37.5% higher 
(0.0112/0.0299). Significant unexplained factors related to HPV vaccine completion 
remain between the two groups.   
Having sick visits compared to vaccine-only visits, male providers compared 
to females, living in communities with a higher percentage of evangelical and other 
religion adherence as well as in communities with higher percentage of people with 
income below poverty level and institutionalized population were significant factors in 
the explained decomposition. The percent contribution of covariates in explained 
HPV vaccine completion can be seen in Table 12. The percent contribution of each 
covariate is calculated by dividing the individual coefficient results from explained 
decomposition by the total explained by measurable characteristics and multiplying 
by 100.  
If a higher number of non-Hispanic adolescents had vaccine-only visits 
instead of sick visits, then the likelihood of completing the HPV vaccine would have 
increased by 22.32%, which would have reduced the observed gap between 
Hispanics and non-Hispanics. If a higher number of non-Hispanic adolescents had 
visits with female providers instead of male providers, then the likelihood of 
completing the HPV vaccine would have increased by 1.79%, which would have 
reduced the observed gap.  
Additionally, if a higher number of non-Hispanic adolescents lived in 
communities with higher evangelical Christian religion adherence, then the likelihood 
of completing the HPV vaccine would have increased by 40.18%, which would have 




Table 12: Explained Percent Contribution of Observed Factors in Hispanic Ethnicity 
Decomposition Results of HPV Vaccine Completion among Adolescents 
Probability of completing HPV vaccine series for Hispanics                                 0.1667***        
Probability of completing HPV vaccine series for non-Hispanics                          0.1369***    
Difference in HPV vaccine completion                                                                  0.0299***        
        Total unexplained by measurable characteristics                                                       0.0411*** 
   Total explained by measurable characteristics                                                         -0.0114 
 









Male (ref. female) 0.0001 0.0005 -0.89 
Age 12 (ref. age 11) 0.0008 0.0005 -0.14 
Age 13 0.0015*** 0.0006 -13.39 
Age 14 0.0020*** 0.0006 -17.86 
Age 15 0.0030*** 0.0007 -26.79 
Age 16 0.0029*** 0.0007 -25.89 
Age 17 0.0020*** 0.0006 -17.86 
Age 18 0.0018** 0.0007 -16.07 
Urban (ref. rural) 0.0003 0.0005 -2.68 
Provider and visit type characteristics 
Preventative visit 0.0053*** 0.0016 -47.32 
Sick visit (ref. vaccine-only visit) -0.0025*** 0.0008 22.32 
Male provider (ref. female providers) -0.0002 0.0007 1.79 
Other providers (ref. Primary care providers  0.0002 0.0005 -1.79 
Population characteristics 
Evangelical rate -0.0045* 0.0026 40.18 
Catholic rate -0.0009 0.002 8.04 
Mainline Protestant rate 0.0004 0.0016 -3.57 
Black Protestant rate 0.0004 0.0005 -3.57 
Orthodox rate -0.0003 0.0007 2.68 
Other religion rate -0.0012** 0.0005 10.71 
Pct. Black (ref. pct. White) 0.0007 0.0011 -6.25 
Pct. Other race 0.0132* 0.0075 -1.18 
Pct. Hispanic  
(ref. non-Hispanic) 
-0.0022 0.0141 19.64 
Pct. Ling isolated house 0.0082 0.0071 -73.21 
Pct. Income below poverty -0.0100*** 0.0025 89.29 
Pct. Institutionalized pop -0.0011* 0.0006 9.82 
Pct. Below High school pop under age 25 -0.0087 0.0059 77.68 
Pct. High school graduates 0.0005 0.0015 -4.46 
Pct. College graduate 0.0010 0.0029 -8.93 
Total explained by measurable 
characteristics 
-0.0114  -37.5 







Similarly, if a higher number of non-Hispanics lived in communities with higher 
adherence to other religions then the likelihood of non-Hispanics completing the 
HPV vaccine series would have increased by 10.71%.  
If a higher number of non-Hispanic adolescents lived in communities with a 
higher percentage of the population living below the poverty level, then the likelihood 
of completing the HPV vaccine series would have increased by 89.29%, which 
would have reduced the observed gap. Similarly, if a higher number of non-Hispanic 
adolescents lived in communities with a higher percentage of the population is 
institutionalized, then the likelihood of completing the HPV vaccine series would 
have increased by 9.82%. 
However, preventative visits and living in areas with higher percentage of 
other races had an opposite effect in explaining the observed gap in HPV vaccine 
completion between the two groups. In other words, if more non-Hispanic 
adolescents received vaccine-only visits compared to preventative visits, the 
observed gap in HPV series completion would have increased by 47.32%. Similarly, 
if more non-Hispanic adolescents lived in communities with a higher percentage of 
other races compared to communities with whites, the observed gap in HPV series 
completion would have increased by 1.18%.  
These decomposition results showed several explained and unexplained 
factors that significantly contributed to the gap in vaccine receipt among Medicaid 
insured Hispanics and non-Hispanics. Factors such as having male providers 
compared to female providers seemed to explain and drive the gap in vaccine 




could be due to cultural influences on the covariates such as religion. Understanding 
known factors to these differences in HPV vaccine uptake provides a significant 
opportunity to further explore and address reasons behind the HPV vaccine lag in 
Colorado and nationwide. 
Decomposition on insurance (public vs. non-public) status. The following 
section reports the decomposition results between publicly-insured and non-publicly 
insured (private and other types of insurance such as self-pay) individuals and HPV 
vaccine initiation and completion of the three-dose HPV vaccine.  
Race and age variables were controlled for in this model. However, due to the 
inconsistent labeling of race data described previously, the race coefficients are not 
reported here. Although the overall ethnicity data has a high number of unknowns 
(63 % unknown ethnicity, 15.39% non-Hispanic and 21.61% Hispanic), the unknown 
variables are distributed across the two groups (publicly insured and non-publicly 
insured) evenly and thus ethnicity is included in this decomposition analysis. 
Unknown Hispanic ethnicity was created as its own dummy variable and added in 
the decomposition model along with Hispanic and non-Hispanic groups.     
When we look at decomposition results for those who initiated the HPV 
vaccine, we see that publicly-insured individuals were more likely to receive at least 
one dose of HPV vaccine compared to non-publicly insured individuals. The gap in 
any HPV uptake between the two groups is -0.0399. Adjusting publicly-insured 
individual endowment levels to the levels of non-publicly insured would increase 
their probability of initiating HPV vaccine by 44% (-0.0176/-0.0399). A significant gap 




Table 13. Pooled Regression Decomposition Results on Insurance (Public vs. Non-
Public) of Adolescents who Initiated the HPV Vaccine 
 HPV vaccine initiation  
VARIABLES Differential Decomposition 
Prediction_1(non-public) 0.4866***  
 (0.0045)  
Prediction_2 (public) 0.5265***  
 (0.0046)  
Difference -0.0399***  
 (0.0064)  
Explained  -0.0176** 
  (0.0072) 
Unexplained  -0.0223** 
  (0.0091) 
Observations 24,553 24,553 
Note. Robust standard errors in parentheses. *** p < 0.01, ** p < 0.05, * p < 0.1 
 
When we look at the decomposition results for the HPV vaccine completion, 
we notice a significant difference between the two groups where publicly-insured 
individuals were less likely to complete the three-dose series compared to non-
publicly insured individuals. The gap in completing the HPV vaccine series between 
the two groups is 0.0537. Adjusting non-publicly insured individual endowment levels 
to the levels of publicly insured would significantly increase their probability of 
completing HPV vaccine series by about 37% (0.0200/0.0537). However, 63% 





Table 14. Pooled Regression Decomposition Results on Insurance (Public vs. Non-
Public) Status of Adolescents who Completed the HPV Vaccine 
 HPV vaccine completion  
VARIABLES Differential Decomposition 
   
Prediction_1(non-public) 0.2075***  
 (0.0036)  
Prediction_2 (public) 0.1537***  
 (0.0033)  
Difference 0.0537***  
 (0.0049)  
Explained  0.0200*** 
  (0.0054) 
Unexplained  0.0338*** 
  (0.0070) 
   
Observations 24,553 24,553 
Note. Robust standard errors in parentheses. *** p < 0.01, ** p < 0.05, * p < 0.1 
 
Decomposing insurance status on initiation of HPV vaccine. Factors that 
significantly explained and drove the gap in initiation of the HPV vaccine among 
publicly-insured versus non-publicly insured individuals included: females compared 
to males, having male providers compared to female providers, having other types of 
providers compared to primary care providers, living in areas with higher percentage 
mainline Protestant adhering populations, areas with higher percentage of other 
races (non-black, non-white), areas with a higher percentage of linguistically isolated 
households, those with a higher percentage of high school graduates and those with 
population below high school under age 25.  
However, the explained factor that closed the gap in initiation of the HPV 
vaccine among publicly-insured versus non-publicly insured individuals included 
having preventative visits compared to vaccine-only visits, being an urban resident 




Protestant, more Hispanic residents and other religion adhering populations (Table 
15).  
Table 16 further details the explained portion of the decomposition results. 
Predicted probability of HPV vaccine initiation was 0.5265 for publicly-insured 
adolescents and 0.4866 for non-publicly insured adolescents. Therefore, a difference 
of -0.0399 or 3.99 percentage points exists between the two groups. The 
decomposition estimated a negative total explained coefficient (-0.0176) for gap in 
HPV completion between the two groups. This indicates that observed 
characteristics did successfully explain the difference in HPV vaccine initiation of      
-0.0399 between the two groups. In other words, had non-publicly insured 
adolescents had similar distribution of observed characteristics as publicly-insured 
adolescents, the probability of non-publicly insured individuals receiving the HPV 
vaccine would have increased 44% higher (-0.0176/-0.0399). Significant 
unexplained factors (56%) remain regarding HPV vaccine initiation between the two 
groups.   
If a higher number of non-publicly insured adolescents were female, then the 
likelihood of initiating the HPV vaccine would have increased by 11%, which would 
have reduced the observed gap between publicly-insured and non-publicly insured 
individuals. If a higher number of non-publicly insured adolescents were Hispanics, 
then the likelihood of initiating the HPV vaccine would have increased by 2.88%, 
which would have reduced the observed gap between publicly-insured and non-




Table 15: Detailed Regression Decomposition Results on Insurance (Public vs. Non-Public) 
Status among Adolescents who Initiated the HPV Vaccine 
 (1) (2) (3) 
Variables Differential Explained Unexplained 
Patient characteristics 
Female (Ref. Male)  -0.0019*** -0.0139** 
  (0.0004) (0.0059) 
Hispanic ethnicity (ref. non-Hispanic)  -0.0507*** 0.0091* 
  (0.0065) (0.0048) 
Unknown Hispanic ethnicity  0.0083 0.0363 
  (0.0100) (0.0259) 
Urban (ref. rural)  0.0056*** 0.0146 
  (0.0011) (0.0275) 
Age 12  0.0031*** -0.0041 
 (0.0005) (0.0029) 
Age 13 0.0021*** 0.0002 
 (0.0005) (0.0017) 
Age 14 0.0022*** -0.0017 
 (0.0005) (0.0014) 
Age 15 0.0017*** 0.0004 
 (0.0004) (0.0014) 
Age 16 0.0019*** 0.0029** 
 (0.0004) (0.0014) 
Age 17 0.0004 0.0066*** 
 (0.0005) (0.0014) 
Age 18 -0.0037*** 0.0129*** 
 (0.0007) (0.0015) 
Provider and visit type characteristics 
Preventative visit  0.0187*** 0.0228** 
  (0.0014) (0.0090) 
Sick visit (ref. vaccine-only visit)  -0.00001 0.0280*** 
  (0.0007) (0.0056) 
Male provider (ref. female providers)  -0.0048*** 0.0145*** 
  (0.0006) (0.0053) 
Other providers (ref. primary care 
providers   
 -0.0222*** 0.0695*** 
  (0.0033) (0.0088) 
Population characteristics 
Evangelical rate  -0.0012 -0.0603* 
  (0.0008) (0.0310) 
Catholic rate  -0.0020* 0.0541*** 
  (0.0011) (0.0188) 
Mainline protestant rate  -0.0007** -0.0017 
  (0.0003) (0.0242) 
Black protestant rate  0.0058*** -0.0136* 
  (0.0010) (0.0078) 
Orthodox rate  0.0002 0.0088 
  (0.0008) (0.0125) 
Other religion rate  0.0011*** 0.0471** 
  (0.0003) (0.0194) 
Pct. Black (ref. pct. white)  -0.0004 0.0113 
  (0.0010) (0.0103) 
Pct. other race  -0.0171*** 0.1877*** 





Table 15, cont’d 
 (1) (2) (3) 
Variables Differential Explained Unexplained 
Patient characteristics    
Pct. Hispanic (ref. non-Hispanic)  0.0181* -0.1465*** 
  (0.0098) (0.0564) 
Pct. ling isolated house  -0.0089* -0.1000 
  (0.0052) (0.0667) 
Pct. income below poverty  0.0113*** 0.0130 
  (0.0027) (0.0224) 
Pct. institutionalized pop  0.0013** 0.0002 
  (0.0005) (0.0033) 
Pct. below High school pop under age 25  -0.0136** 0.0740*** 
  (0.0054) (0.0257) 
Pct. high school graduates  -0.0089*** 0.1352*** 
  (0.0035) (0.0515) 
Pct. college graduate  0.0193*** 0.1201*** 
  (0.0048) (0.0428) 
Total  -0.0176** -0.0223** 
  (0.0072) (0.0091) 
Prediction_1 (non-public insurance) 0.4866***   
 (0.0045)   
Prediction_2 (public insurance) 0.5265***   
 (0.0046)   
Difference -0.0399***   
 (0.0064)   
Constant   -0.5665*** 
   (0.1458) 
    
Observations 24,553 24,553 24,553 
Note. Robust standard errors in parentheses. *** p < 0.01, ** p < 0.05, * p < 0.1 
 
 
 were age 18, then the likelihood of initiating the HPV vaccine would have increased 
by 21%, which would have reduced the observed gap between publicly-insured and 
non-publicly insured individuals.  
If a higher number of non-publicly insured adolescents were seen by female 
providers, then the likelihood of initiating the HPV vaccine would have increased by 
27.7%, which would have reduced the observed gap between publicly-insured and 
non-publicly insured individuals. If a higher number of non-publicly insured 
adolescents lived in communities with higher Catholic religion adherence, then the 




would have reduced the observed gap. Similarly, if a higher number of non-publicly 
insured adolescents lived in communities with higher mainline Protestant religion 
adherence, then the likelihood of initiating the HPV vaccine would have increased by 
4% and by 33% if they lived in communities with higher black Protestant adherence.  
If a higher number of non-publicly insured adolescents lived in communities 
where a higher percentage of the population is linguistically isolated, then the 
likelihood of initiating the HPV vaccine would have increased by 51%, which would 
have reduced the observed gap. If a higher number of non-publicly insured 
adolescents lived in communities with a higher percentage of the population in a 
linguistically isolated house, then the likelihood of initiating the HPV vaccine would 
have increased by 51%, which would have reduced the observed gap. 
If a higher number of non-publicly insured adolescents lived in communities 
where a higher percentage of the population has below high school population under 
age 25, then the likelihood of initiating the HPV vaccine would have increased by 
77%, which would have reduced the observed gap. Additionally, if a higher number 
of non-publicly insured adolescents lived in communities where a higher percentage 
of the population were high school graduates, then the likelihood of initiating the 










Table 16: Decomposition Results of HPV Vaccine Initiation between Public and Non-Public 
Insured Adolescents 
Probability of initiating any HPV vaccine for non-public insured                            0.4866*** 
Probability of initiating any HPV vaccine for public insured                                   0.5265*** 
Difference in HPV vaccine initiation                                                                     -0.0399*** 
        Total unexplained by measurable characteristics                                                      0.0223***  
   Total explained by measurable characteristics                                                         -0.0176*** 
 





% contribution of 
explained factors 
Patient characteristics 
Female (ref. male) -0.0019*** 0.0004 11.00 
Hispanic (ref. non-Hispanic) -0.0507*** 0.0065 2.88 
Unknown Hispanic ethnicity 0.0083 0.0100 -47.2 
Urban (ref. rural) 0.0056*** 0.0011 -38.82 
Age 12 (ref. age 11) 0.0031*** 0.0005 -17.6 
Age 13 0.0021*** 0.0005 -11.9 
Age 14 0.0022*** 0.0005 -12.5 
Age 15 0.0017*** 0.0004 -9.7 
Age 16 0.0019*** 0.0004 -10.8 
Age 17 0.0004 0.0005 -2.3 
Age 18 -0.0037*** 0.0007 21.00 
Provider and visit type characteristics 
Preventative visit 0.0187*** 0.0014 -6.25 
Sick visit (ref. vaccine-only visit) -0.00001 0.0007 0.06 
Male provider (ref. female providers) -0.0048*** 0.0006 27.3 
Other providers (ref. Primary care providers  -0.0222*** 0.0033 126 
Population characteristics 
Evangelical rate -0.0012 0.0008 6.8 
Catholic rate -0.0020* 0.0011 11.4 
Mainline Protestant rate -0.0007** 0.0003 4.0 
Black Protestant rate 0.0058*** 0.0010 33.0 
Orthodox rate 0.0002 0.0008 -1.14 
Other religion rate 0.0011*** 0.0003 -6.25 
Pct. Black (ref. pct. White) -0.0004 0.0010 2.27 
Pct. Other race -0.0171*** 0.0061 97.2 
Pct. Hispanic  
(ref. non-Hispanic) 
0.0181* 0.0098 -10.28 
Pct. Ling isolated house -0.0089* 0.0052 51.00 
Pct. Income below poverty 0.0113*** 0.0027 -64.2 
Pct. Institutionalized pop 0.0013** 0.0005 -7.4 
Pct. Below High school pop under age 25 -0.0136** 0.0054 77.3 
Pct. High school graduates -0.0089*** 0.0035 47.85 
Pct. College graduate 0.0193*** 0.0048 -109.7 
Total explained by measurable 
characteristics 
-0.0176**   







The results showed several predictors and their contribution in HPV vaccine initiation 
among publicly-insured and non-publicly insured adolescents. It specifically 
demonstrated the role of adolescent gender, Hispanic ethnicity and provider gender 
in contributing to HPV vaccine initiation. Furthermore, it shed light on certain 
community characteristics that are more likely to be conducive to HPV vaccine 
initiation, including living communities where there are linguistically isolated 
households, younger people under age 25 with below a high school education, and 
some religions. The following section details OB decomposition results on HPV 
vaccine completion between the two groups.  
Decomposing insurance status on completion of HPV vaccine. We saw 
in Table 14 that non-publicly insured patients were more likely to complete the three-
dose HPV vaccine series compared to publicly-insured individuals. Explained factors 
that increased the gap in receipt of the three-dose HPV vaccine among publicly-
insured versus non-publicly insured individuals included having preventative visits 
compared to vaccine-only visits, and being an urban resident compared to a rural 
resident.  In addition, living in areas with a higher percentage of black Protestant and 
other religion adhering populations, with higher percentage of Hispanics compared 
to non-Hispanics, and in areas with a higher percentage of individuals with income 
below the poverty line and a higher percentage of college graduates also increased 








Table 17: Detailed Regression Decomposition Results on Insurance (Public vs. Non-Public) 
Status among Individuals who Completed the Full Dose of the HPV Vaccine 
 (1) (2) (3) 
Variables Differential Explained Unexplained 
Patient characteristics 
 
Female (ref. Male)  -0.0016*** 0.0061 
  (0.0004) (0.0046) 
Urban  0.0023*** 0.0505** 
  (0.0007) (0.0196) 
Hispanic ethnicity (ref. non-Hispanic)  -0.0199*** 0.0041 
  (0.0046) (0.0035) 
Unknown Hispanic ethnicity  0.0172** 0.0488*** 
  (0.0069) (0.0184) 
Age 12  0.0024*** -0.0020 
 (0.0004) (0.0023) 
Age 13 0.0019*** 0.0011 
 (0.0004) (0.0012) 
Age 14 0.0022*** 0.0001 
 (0.0004) (0.0010) 
Age 15 0.0014*** -0.0010 
 (0.0003) (0.0009) 
Age 16 0.0013*** 0.0004 
 (0.0003) (0.0009) 
Age 17 0.0002 0.0011 
 (0.0002) (0.0009) 
Age 18 -0.0018*** -0.0004 
  (0.0003) (0.0008) 
Provider and visit type characteristics 
Male provider (ref. female providers)  -0.0018*** 0.0032 
  (0.0004) (0.0042) 
Other providers (ref. Primary care 
providers)  
 -0.0174*** 0.0372*** 
  (0.0026) (0.0069) 
Preventative visit  0.0166*** 0.0425*** 
  (0.0012) (0.0076) 
Sick visit (ref. vaccine-only visit)  -0.0028*** 0.0104** 
  (0.0006) (0.0045) 
Population characteristics 
Evangelical rate  -0.0003 -0.0611*** 
  (0.0006) (0.0217) 
Catholic rate  -0.0017** 0.0240* 
  (0.0008) (0.0131) 
Mainline Protestant rate  -0.0001 -0.0152 
  (0.0001) (0.0184) 
Black Protestant rate  0.0031*** -0.0128** 
  (0.0007) (0.0061) 
Orthodox rate  0.0001 -0.0006 
  (0.0003) (0.0093) 
Other religion rate  0.0007*** 0.0292** 
  (0.0002) (0.0135) 
Pct. Black (ref. pct. white)  -0.0009 0.0207** 
  (0.0007) (0.0081) 
    




Table 15, cont’d 
 (1) (2) (3) 
Variables Differential Explained Unexplained 
 Patient characteristics   
    
Pct. other race  -0.0145*** 0.1218*** 
  (0.0040) (0.0469) 
Pct. Hispanic (ref. non-Hispanic)  0.0110* -0.0588 
  (0.0066) (0.0420) 
Pct. ling isolated house  -0.0040 -0.1381*** 
  (0.0036) (0.0471) 
Pct. income below poverty  0.0076*** 0.0224 
  (0.0021) (0.0173) 
Pct. institutionalized pop  -0.0003 -0.0018 
  (0.0004) (0.0024) 
Pct. below High school pop under 
age 25 
 -0.0003 0.0594*** 
  (0.0040) (0.0193) 
Pct. high school graduates  -0.0108*** 0.0538 
  (0.0025) (0.0378) 
Pct. college graduate  0.0116*** 0.0852*** 
  (0.0036) (0.0325) 
Total  0.0200*** 0.0338*** 
  (0.0054) (0.0070) 
Prediction_1(non-public insurance) 0.2075***   
 (0.0036)   
Prediction_2 (public insurance) 0.1537***   
 (0.0033)   
Difference 0.0537***   
 (0.0049)   
Constant   -0.3026*** 
   (0.1072) 
    
Observations 24,553 24,553 24,553 
    
Note. Robust standard errors in parentheses. *** p < 0.01, ** p < 0.05, * p < 0.1 
 
However, factors that significantly closed the gap in receipt of the three-dose 
HPV vaccine among publicly-insured compared to non-publicly insured individuals 
included being female compared to male, being of Hispanic ethnicity compared to 
non-Hispanics, having male providers compared to female providers, having primary 
care providers compared to other types of providers, having sick visits compared to 




religion adhering populations, areas with higher percentage of other races (non-
black, non-white), and those living in areas with a higher percentage of high school 
graduates (see Table 17). 
In summary, these results show consistent trends in observed factors that 
contribute to differences between publicly-insured and non-publicly insured 
adolescent HPV vaccination uptake. It reinforces the value of having private 
insurance in HPV vaccine series completion, although publicly-insured individuals 
are more likely to initiate the HPV vaccine series.  
Table 18 further details the percent contribution of the covariates in HPV 
vaccine completion between the two groups: publicly-insured and non-publicly 
insured adolescents. The predicted probability of HPV vaccine completion was 
0.1537 for publicly-insured adolescents and 0.2075 for non-publicly insured 
adolescents. Therefore a difference of -0.0537, or 5.37 percentage points, exists 
between the two groups. Observed characteristics successfully explained the 
difference in HPV vaccine completion of 0.0537 between the two groups. In other 
words, had publicly-insured adolescents had similar distribution of observed 
characteristics as non-publicly insured adolescents, the probability of publicly-
insured individuals initiating HPV vaccine would have increased by 37% 
(0.0200/0.0537). Significant unexplained factors (63%) to HPV vaccine initiation 
remain between the two groups.   
If a higher number of publicly-insured adolescents were living in urban 
settings, then the likelihood of completing the HPV vaccine series would have 




between publicly-insured and non-publicly insured individuals. If a higher number of 
publicly-insured adolescents received preventative visits, then the likelihood of 
completing the HPV vaccine series would have increased by 83%, which would have 
reduced the observed explained gap between publicly-insured and non-publicly 
insured individuals. If a higher number of publicly-insured adolescents were older, 
then the likelihood of initiating the HPV vaccine would have increased in decreasing 
order from age 12 to 17.  
If a higher number of non-publicly insured adolescents lived in communities 
with higher black Protestant religion adherence, then the likelihood of completing the 
HPV vaccine would have increased by 15.5%, which would have reduced the 
observed explained gap. Similarly, if a higher number of publicly-insured 
adolescents lived in communities with higher other religion adherence, then the 
likelihood of completing the HPV vaccine would have increased by 3.5%.  
If a higher number of publicly-insured adolescents lived in communities where 
a higher percentage of the population is Hispanic, then the likelihood of completing 
the HPV vaccine series would have increased by 55%, which would have reduced 
the observed explained gap. Similarly, if more publicly-insured individuals lived in 
communities with higher percent of the population with income below the poverty 
line, then the likelihood of completing the HPV vaccine series would have increased 
by 38%. If they lived in areas with more college graduates, the HPV vaccine series 






Table 18: Decomposition Results of HPV Vaccine Completion between Publicly-Insured and 
Non-Publicly Insured Adolescents 
Probability of completing HPV vaccine for non-public insured                            0.2075*** 
Probability of completing HPV vaccine for public insured                                   0.1537*** 
Difference in HPV vaccine completion                                                                0.0537*** 
        Total unexplained by measurable characteristics                                                     0.0338***  
   Total explained by measurable characteristics                                                         0.0200*** 
 
 









Female (ref. male) -0.0016*** 0.0004 -8.00 
Hispanic (ref. non-Hispanic) -0.0199*** 0.0046 -99.5 
Unknown Hispanic ethnicity 0.0172** 0.0069 86.00 
Urban (ref. rural) 0.0023*** 0.0007 11.5 
Age 12 (ref. age 11) 0.0024*** 0.0004 12.00 
Age 13 0.0019*** 0.0004 9.5 
Age 14 0.0022*** 0.0004 11.0 
Age 15 0.0014*** 0.0003 7.00 
Age 16 0.0013*** 0.0003 6.5 
Age 17 0.0002 0.0002 1.00 
Age 18 -0.0018*** 0.0003 -9.0 
Provider and visit type characteristics 
Preventative visit 0.0166*** 0.0012 83.0 
Sick visit (ref. vaccine-only visit) -0.0028*** 0.0006 -14.0 
Male provider (ref. female providers) -0.0018*** 0.0004 -9.00 
Other providers (ref. Primary care providers  -0.0174*** 0.0026 -87.0 
Population characteristics 
Evangelical rate -0.0003 0.0006 -1.5 
Catholic rate -0.0017** 0.0008 -8.5 
Mainline Protestant rate -0.0001 0.0001 -0.5 
Black Protestant rate 0.0031*** 0.0007 15.5 
Orthodox rate 0.0001 0.0003 0.5 
Other religion rate 0.0007*** 0.0002 3.5 
Pct. Black (ref. pct. White) -0.0009 0.0007 -4.5 
Pct. Other race -0.0145*** 0.0040 -72.5 
Pct. Hispanic  
(ref. non-Hispanic) 
0.0110* 0.0066 55.00 
Pct. Ling isolated house -0.0040 0.0036 -20.00 
Pct. Income below poverty 0.0076*** 0.0021 38.00 
Pct. Institutionalized pop -0.0003 0.0004 -1.50 
Pct. Below High school pop under age 25 -0.0003 0.0040 -1.50 
Pct. High school graduates -0.0108*** 0.0025 -54.00 
Pct. College graduate 0.0116*** 0.0036 58.00 
Total explained by measurable 
characteristics 
0.0200***  37.00 






However, being female, Hispanic, age 18, having sick visits, visiting male and 
other providers, living in areas with more Catholic religion adherence, living in 
communities where higher percentage of community includes other races, and 
higher percentage of high school education had an opposite effect in explaining the 
observed gap in HPV vaccine completion between publicly-insured and non-publicly 
insured adolescents.  
In other words, patient characteristics indicate that if more publicly-insured 
adolescents were female, the observed explained gap in HPV series completion 
would have increased by 8%. If more publicly-insured adolescents were Hispanic, 
the observed explained gap in HPV series completion would have increased by 
99.5%. If more publicly-insured adolescents were age 18, the observed explained 
gap in HPV series completion would have increased by 9%.  
When we look at provider and visit type characteristics that had the opposite 
effect: if more publicly-insured adolescents received sick visits compared to vaccine-
only visits, the observed explained gap in HPV series completion would have 
increased by 14%. Similarly, if more publicly-insured adolescents received care by 
male providers, the observed explained gap in HPV series completion would have 
increased by 9% and by 87% if they visited providers other than primary care 
providers.  
When we look at population characteristics that had the opposite effect: if 
more publicly-insured adolescents lived in communities with more Catholic religion 
adherence, the observed explained gap in HPV series completion would have 




communities with a higher percentage of other races compared to whites, the 
observed explained gap in HPV series completion would have increased by 72.5% 
and by 54% if there were more high school graduates in the population.  
These results show several factors that influence HPV vaccine initiation and 
completion between publicly- and non-publicly-insured adolescents. When we look 
at patient characteristics, urban residence and receiving preventative visits 
significantly explained the lower predictive probability of HPV vaccine initiation 
among non-publicly insured adolescents. In HPV vaccine completion, however, 
where non-publicly insured adolescents had higher probability, urban residence and 
receiving preventative visits explained a portion of lower predictive probability of 
completing the HPV vaccine series among publicly-insured adolescents.  
When it comes to provider and visit type characteristics, although provider 
gender (female vs. males) and type of provider (other provider types vs. primary 
care providers) had an impact HPV vaccine initiation between publicly- and non-
publicly insured adolescents, having preventive visits best explained HPV vaccine 
completion among non-publicly insured adolescents.  
Both HPV vaccine initiation and completion gaps were explained by several 
population characteristics. HPV vaccine initiation gap between publicly and non-
publicly insured adolescents were explained by Catholic, mainline and Black 
Protestant religions, whereas completion gap was explained by living in communities 
with black protestant and other religions. Additionally, living in areas with more 
linguistically isolated households, living in areas with more population under age 25, 




initiation. However, living in areas below poverty and with more college graduates 
explained the observed gap in non-public insured completing the HPV vaccine 












This research study used HPV vaccine-ordering ratio compared to Tdap 
among VFC providers to identify regional variations in HPV vaccine ordering in 
Colorado for qualitative exploration of barriers and facilitators among the different 
providers. This study further estimated HPV vaccine uptake trends among 
adolescents who received the Tdap. When observed differences in HPV vaccine 
initiation and completion were present, a regression decomposition method was 
used to provide insight into the nature of the observed differences in outcomes, 
whether due to the characteristics of the groups (i.e. endowments) or unexplained 
factors such as cultural nuances. The main outcomes of interest for quantitative 
analysis were HPV vaccine initiation and completion among adolescents who were 
followed for a year post-Tdap vaccine receipt.  
This type of analysis has not been done in Colorado previously and this 
research provides an additional body of knowledge about HPV vaccine trends in 
Colorado and factors that drive differences in outcomes. Decomposition analysis of 
differences is important to understand the main determinants of differences 
(explained or unexplained) and to inform future interventions and research. 
Barriers and Facilitators to HPV Vaccine Uptake 
This research found that barriers to the HPV vaccine exist in Colorado even 
among the high practice-low PCSA practices as well as those in the low-practice, 
low-PCSA regions. Barriers discussed by these providers focused on provider, 
parental, and policy level factors. Parental factors identified as a barrier by 




 Vaccine hesitancy and refusal 
 Religious conservatism 
 Alternative vaccine schedules 
 Fear of inadvertent promotion of early sexual debut 
 Fear of vaccine side effects and ineffectiveness 
 Lack of trust in provider recommendations 
 Lack of regular visits for adolescents 
 HPV vaccine for boys 
 Parental consent for vaccines 
 Non-inclusive vaccine marketing 
 Vaccine related decision-making 
Participants also discussed provider factors that acted as barriers to HPV 
vaccine recommendation and provision. These included:  
 Limited provider persuasiveness 
 Clinic location and vaccines offered 
 Challenges in vaccine ordering and billing 
 Funding for vaccination efforts/cost of vaccines 
Although these barriers were identified and discussed by participants from all 
categories, there was a clear difference in the facilitators to HPV vaccine uptake as 
identified by participants in the different categories. Specifically, there was a notable 
difference in how participants discussed and addressed barriers to the HPV vaccine. 
Providers from high-practice, low-PCSA categories talked about being informed 




communicating with parents and adolescent children in unique ways. However, 
many facilitators identified by participants in the low-practice, high-PCSA category 
focused on parental factors, such as having vaccine-receptive populations, prior 
parental experience with HPV infection, and parents bringing their children to the 
clinic to fulfill the Tdap requirement. Although low-practice, low-PCSA sites identified 
facilitators to HPV vaccine provision, they did not discuss individual clinics making 
extra efforts that stood out from the other categories to improve HPV vaccine 
uptake. In addition, participants identified population characteristics as facilitators 
throughout these categories that remained consistent in their receptiveness to the 
HPV vaccine and overall provider recommendations, such as being publicly-insured 
or having Hispanic populations. Participants were unaware of their performance 
categories during the qualitative interviews, which provided for a more authentic 
reflection of their experiences and perceptions without the added pressure. 
 Opportunity for improved HPV vaccine uptake exist due to the dosage change 
for those who receive the vaccine before their 15th birthday. However, there was 
variation in knowledge regarding the new vaccine dosage recommendation and 
confusion regarding when to begin implementing the change.   
HPV Vaccine Initiation and Completion 
 Our findings from the logistic regression analysis showed that when 
comparing adolescent males to females, individuals who had male providers 
compared to female providers, and those who saw other types of providers 
compared to primary care providers were significantly less likely to receive at least 




visits compared to vaccine-only visits were significantly more likely to receive at least 
one dose of the HPV vaccine.  
Similarly, when comparing adolescent males to females, those who received 
care by male providers compared to female providers, and those who received care 
by other types of providers compared to primary care providers were less likely to 
complete the full dose of the HPV vaccine. Furthermore, Hispanic adolescents 
compared to non-Hispanics, those who had more preventative and sick visits 
compared to vaccine-only visits, and those with private as well as other insurance 
types compared to publicly-insured patients were more likely to complete the full 
three-dose HPV vaccine series. Finally, adolescents living in areas where a higher 
percent of population was living below the poverty level were less likely to initiate or 
complete the full dose of the HPV vaccine. 
Hispanic Decomposition on Medicaid-Insured Adolescents  
Medicaid-insured Hispanics were more likely to receive at least one dose and 
to complete the three-dose HPV vaccine series than Medicaid-insured non-
Hispanics. Among those who initiated the HPV vaccine, factors that significantly 
explained more HPV vaccine initiation of HPV vaccine among Hispanics compared 
to non-Hispanics included having preventative or sick visits compared to vaccine-
only visits, having male providers compared to female providers, and being seen by 
other types of providers compared to primary care providers. Among those who 
completed the three-dose HPV vaccine, having preventative visits compared to 
vaccine-only visits significantly explained the observed increased rate among 




visits but not vaccine-only visits typically did not complete the three-dose series 
because vaccine-only visits are typically for series completion. 
Insurance (Public vs. Non-Public) Decomposition on Adolescents  
We found that publicly-insured individuals were more likely to receive at least 
one dose of the HPV vaccine compared to non-publicly insured individuals. 
However, publicly-insured individuals were less likely to receive the full three-dose 
HPV vaccine series as compared to non-publicly insured individuals. This is 
consistent with other studies that looked at the HPV vaccine completion rate among 
private and public insured individuals (Simmons et. al., 2015). 
Some factors that significantly explained initiation of the HPV vaccine among 
publicly-insured compared to non-publicly insured individuals included being a male 
adolescent compared to female, having male providers compared to female 
providers, and having other types of providers compared to primary care providers. 
Similarly, completion of the three-dose HPV vaccine was higher among non-publicly 
insured than publicly-insured individuals. Some factors that explained the HPV 
vaccine completion rate among non-publicly insured included being an adolescent 
female compared to male, having male providers compared to female providers, and 
having primary care providers compared to other types of providers.  
Barriers to the HPV vaccine identified by Colorado VFC providers are 
consistent with nationally-available information on the HPV vaccine. For example, 
one of the top reasons parents gave as a reason for not vaccinating their adolescent 
children with the HPV vaccine was that there had not been a provider 




from low-practice, low-PCSA sites indicated, providers do not consistently 
recommend the HPV vaccine for all adolescents who come to their clinic. The 
reason these providers gave was that they trust that these children are not sexually 
active. This demonstrated a general lack of understanding about how the vaccine is 
protective before exposure and it created a missed opportunity. 
Providers identified several facilitators and opportunities for HPV vaccination 
rate improvement. Some providers discussed collaborating with local high schools to 
educate adolescents and their parents about HPV vaccine. Almost all providers said 
that the new two-dose HPV vaccine guideline should improve the HPV vaccine rate 
and would generate more enthusiasm from parents and adolescents. However, the 
dissemination of the new vaccine guideline was not consistent across providers, and 
some only learned about the dose change from the researcher. Inconsistently 
disseminated information remains a challenge. 
The quantitative results also showed a consistent decline in HPV vaccine 
initiation and completion as adolescents get older. Although the data showed 
significant differences in HPV vaccine uptake among ethnic groups and in the role of 
where adolescents live in the population, these factors were typically not amenable 
to changing. However, this research is an important addition that shows several 
factors that can be influenced to drastically improve the HPV vaccination rate in 
Colorado. 
Overall, these findings show the impact of adolescent gender, provider 
gender, the role of the primary care or other types of providers, and insurance status 




that male adolescents lag in HPV vaccination initiation and completion compared to 
females. One of the main reasons for the gender gap is the introduction of the HPV 
vaccine for males later than females. Additional barriers to HPV vaccine uptake 
among males is lack of parental awareness about HPV vaccine for boys (Nonzee, 
Baldwin, Cui, & Singhal, 2017). Although the trend in HPV vaccine is increasing in 
general, it is not where it needs to be compared to other adolescent vaccines. CDC 
2016 data show that only 56% of boys ages 13 to 17 received one or more doses of 
the vaccine, compared to 65% of girls nationally. And only 37.5% of boys in this age 
group completed the HPV vaccine series, compared with 49.5% of girls (Walker et 
al., 2017). Furthermore, new research in 2017 found that one in nine American men 
is infected with the oral form of HPV. This study estimated the rates for oral HPV 
infections at 11.5% of men (11 million men) and 3.2% of women (3.2 million women) 
(Sonowane et al., 2017). The incidence of oropharyngeal squamous cell carcinoma 
among men increased drastically from prior years (7.8 per 100,000) and has already 
surpassed the incidence of cervical cancer in women (7.4 per 100,000) (Mourad et 
al., 2017). The focus of HPV vaccine efforts should be both at preventing cancers 
that impact both male and female populations. Understanding the urgency of 
reducing HPV infection among boys and starting the HPV vaccine series when they 
are young, before sexual debut, is as crucial as it is for girls. Statewide efforts need 
to take place to reduce the gender gap in HPV vaccine recommendation and uptake 
among adolescent boys and girls. 
Significant difference in initiation and completion of the HPV vaccine series 




providers were less likely to initiate and complete HPV vaccine. Prior research has 
shown the role of provider gender in effects of preventive screening and counseling. 
One study concluded that female provider gender influences the provision of 
preventive screening and counseling (Henderson & Weiman, 2001). This aligns with 
our findings that adolescents who visited male providers were non-adherent. Even 
though our data did not explore reasons for the observed variation in male providers 
versus female providers in vaccination outcome for adolescent patients, several 
previous studies found that the gender of the physician influences the provision of 
preventive care. Specifically, female providers are found to engage in more 
communication that is considered patient-centered care (Roter, Hall, & Aoki, 2002), 
and influence provision of preventative care such as cancer screening (Osborn, Bird, 
McPhee, Rodnick, & Fordham, 1991; Levy, Dowling, Boult, Monroe, & McQuade, 
1992; Hall et al., 1990., Lurie et al., 1993). However, no studies have specifically 
analyzed the role of provider gender in influencing HPV vaccine uptake. 
Understanding and targeting factors that hinder HPV vaccine-related communication 
among providers, especially male providers, could be an important driver in reducing 
observed gaps in HPV vaccine provision and uptake.  
We also observed significant differences in HPV vaccine initiation and 
completion among primary care providers compared to other types of providers. The 
HPV vaccine was less likely to be provided by other types of providers compared to 
primary care providers. This is important because, if adolescents are visiting other 
types of providers for vaccines such as Tdap, targeting these providers to also 




needs or chronic conditions visit specialty providers more often to manage their 
chronic as well as preventive care needs. Furthermore, parents of children with 
chronic conditions reported lack of provider recommendation and low perceived 
susceptibility of their children to vaccine-preventable condition as reasons for not 
immunizing (Daley et al., 2005). It is important to raise awareness among other 
types of providers regarding the need for HPV vaccine recommendation to their 
adolescent population to reduce missed opportunities and to educate parents about 
the tangible probability of infection. Interventions aimed at helping providers better 
communicate HPV vaccine recommendations should also include these other types 
of providers in their messaging to help increase HPV vaccine uptake.  
Furthermore, this research showed unique findings in Colorado. It was found 
that adolescents living in areas with higher percentage of Hispanic population 
compared to non-Hispanics, those living in areas with higher percentages of income 
below the poverty level, and those living in areas with a higher institutionalized 
population were significantly less likely to initiate the HPV vaccine. This trend is 
opposite of what has been seen nationally where adolescents living below the 
poverty level had higher rates of HPV vaccine initiation (Walker et al., 2017). This 
discordance in results might be due to the fact that population-level poverty status 
was used for our analysis rather than individual adolescent poverty status. An 
adolescent could live in a community with more poverty but not be poor themselves.   
Additionally, quantitative analysis revealed that non-publicly insured 
adolescents were more likely to complete the three-dose HPV vaccine series than 




participants discussed that the publicly-insured population is more willing to allow the 
HPV vaccine. This perception might be true, but non-publicly insured adolescents 
are completing the vaccine series. There might be interest but lack of means among 
publicly-insured individuals might be hindering their HPV vaccine completion rates.   
Providers discussed a lack of awareness among parents regarding the HPV 
vaccine for boys. As our result show, there is agreement between qualitative and 
quantitative findings where adolescent male HPV vaccine initiation and completion 
lags behind that of girls. Additionally, the role of provider gender in HPV vaccine was 
not emergent in the qualitative research but was one of the prominent trends in the 
quantitative data. This shows the possible lack of awareness among providers and 
the role of provider gender in HPV vaccine recommendations. This mixed methods 
exploration identified similar, opposing and additional information that is useful to the 
HPV vaccine landscape.   
Limitations and Strengths 
This research study has various strengths and limitations. There are 
interrelated and complex factors that influence HPV vaccination trends. This work 
addresses provider perspectives, quantifiable patient, provider and population level 
characteristics and their influence on initiation and completion of the HPV vaccine.  
Strengths. We used in-depth qualitative interviews to understand VFC 
provider perceptions of barriers and facilitators to HPV vaccine. Hypotheses 
generated from those VFC provider interviews were tested using quantitative data to 
provide more generalizability with a larger sample size. The quantitative analysis 




perspectives and quantitative data are more generalizable. This allowed for a 
simultaneous in-depth look at what providers are saying and current HPV 
vaccination trends in Colorado. Several factors that are relevant in the current 
literature as impacting immunizations were included in the quantitative data analysis. 
This allowed for interpretation of findings in confirming or adding to current literature 
as well as providing new insight that should be further explored. 
This research study used regression decomposition, a method widely used in 
economics to differentiate between explained and unexplained factors in disparities. 
Furthermore, there currently are no published studies that utilized VFC vaccine 
ordering data to identify variations in HPV to Tdap ordering ratio and use qualitative 
key-informant sampling. There are no studies that analyze Colorado All Payer 
Claims data to understand adolescent HPV vaccine uptake. Thus, this work provides 
a combination of unique methodological approaches as well as data usage to show 
complexity of HPV vaccine uptake.   
Additionally, this work identified several barriers and facilitators to HPV 
vaccine uptake in Colorado. This has not been systematically explored to our 
knowledge. This work provides information for policy makers, practitioners and 
researchers to target intervention areas. Along with amenable factors identified 
through quantitative analysis, this work supports and provides more information and 
actionable data to individuals and agencies in Colorado who are interested in 
improving HPV vaccine uptake.  
Limitations. The qualitative research only targeted small number of VFC 




in Colorado. Although hypothesis generated from qualitative data were tested with 
larger sample size using APCD data, the analytical approach used in this research 
only estimated associations between observed covariates. It is possible that 
unobserved factors could influence outcomes of interest.  
Implications for Practice and Future Research 
This research provides more body of work where there is currently limited 
knowledge about HPV vaccine related practice among VFC providers and 
communities they serve. There is ongoing effort to improve VFC effectiveness in 
vaccine delivery. Understanding barriers and facilitators to current practice in 
Colorado informs a clear path for intervention. This work initially came about due to 
interest from CDPHE’s immunization branch to understand current barriers for 
improvement. This research providers a wealth of information that will be used to 
inform statewide HPV vaccine landscape. Additionally, results from this study could 
be used to inform current local efforts to improve HPV vaccine uptake such as 
Denver Metro Alliance for HPV Prevention and Colorado cancer coalition. These two 
efforts have made HPV vaccination priorities to eliminate HPV infection, disease and 
disability. This research results will provide information that is relevant to their 
ongoing work and provider new insights into barriers to HPV vaccine uptake. There 
are several opportunities for future research emanating from this work. These 
include: 
a. Further explore reasons for lower HPV vaccine provision among 
non-primary care providers for targeted intervention. Strong 




champion HPV vaccine uptake and resolve any systemic barriers 
faced.   
b. Confirm the role of provider gender in HPV vaccine provision. 
Further research is needed to confirm the role of provider gender in 
HPV vaccine uptake. If confirmed, further exploration to understand 
possible reasons is necessary to intervene.  
c. Conduct qualitative interviews with high-practice, high-PCSA 
sites. This research conducted qualitative interviews with only three 
out of the four categories. Conducting additional qualitative interviews 
with the high-practice, high-PCSA sites could yield additional insight to 
variation in HPV vaccine uptake among adolescents. 
d. Further explore unexplained factors, their role and impact on the 
HPV vaccine uptake. Regression decomposition analysis showed 
several factors that were unexplained by the observed data that 
influence HPV vaccine uptake. Understanding those factors is crucial  
in the ongoing effort to improve HPV vaccine uptake and 
recommendation, and to understand unobserved factors such as 
cultural values that influence the HPV vaccine rate.  
Recommendations 
 
Based on findings from this research, the following recommendations can increase 
HPV vaccine recommendation and uptake by adolescents: 
1. Respond to emerging epidemiologic trends. HPV infection and oral cancer 




parents and providers this trend and addressing the need for HPV vaccination 
among boys could improve the HPV rate in this group.  
2. Reminder / Recall. In response to adolescents who do not come to clinics 
when they are due for vaccines, reminder/ recall programs might play a larger 
role in bringing parents and their adolescents to clinics for well-child visit and 
vaccinations. Some parents might respond better to information that their 
child is due for well-child visit instead of vaccinations only to allow them to 
interact with providers.  
3. Invest in practice infrastructure and capacity. Lack of immunization 
providers in rural communities and resources should be addressed by 
improving practice infrastructure and capacity using resourceful methods to 
improve HPV vaccine uptake.  
4. Utilize innovative communication skills. Innovative communication skills 
that elicit behavior change by patients and providers such as Motivational 
Interviewing (MI) techniques should be used to influence HPV 
recommendation and uptake. Training providers to use MI techniques and for 
their vaccine discussion with parents could yield behavior change among 
hesitating parents. MI could also be used to target low performing providers to 
change their prescribing behavior.  
5. Find innovative approaches from public health and other fields. 
Informing low vaccine ordering practices their status compared to other 




done through sending letters from the state health department (which 
manages VFC vaccines) to let practices know that they are doing poorly. 
6. Utilize vaccine-ordering trends to make AFIX (Assessment, Feedback, 
Incentives, and eXchange) program visit. AFIX program conducts quality 
improvement visits to different VFC participating practices to improve 
immunization delivery among VFC providers. Utilizing vaccine ordering ratio 
yields important avenue for AFIX to be efficient in targeting low performing 
sites. This will help further understand and address systemic barriers faced by 
these sites. 
Conclusion 
There is evidence that shows the value of HPV vaccination in preventing HPV 
infections that cause cervical, throat, head, and neck cancers as well as genital 
warts. However, there are significant barriers to optimal immunization of adolescents 
with the HPV vaccine. There are continued disparities in initiation and completion of 
HPV vaccine among populations. Understanding what specific factors influence and 
explain HPV vaccine uptake in Colorado and beyond is crucial for intervening. 
Through identification of amenable parental, provider and system level factors, HPV 
vaccination could reach the rates of Tdap and other vaccines.   
This work builds on existing research and the body of knowledge about HPV 
vaccine-related barriers and facilitators. Researchers and health care professionals 
can utilize findings from this research study to further expand their research, create 
tailored interventions, or to inform their practice. While the findings from this 




vaccine current practice, further research needs to be done to understand 
unexplainable patient, provider, and policy level factors that influence HPV vaccine 
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Stata code used for generating variation and cut off points for qualitative 
interview sampling 
Used Quartiles i.e. 25th and 75th percentile.  
 
sum percenthpv if totaldosestdap >=24, d 
 
gen low_provder =% hpv ordered < 0.3376068 & totaldosestdap>=24 
gen high_provder=% hpv ordered >0.7945152 & totaldosestdap>=24 
gen low_pcsa       =% hpv ordered < 0.3542484 & totaldosestdap>=1 
gen high_ pcsa     =% hpv ordered > .6689151 & totaldosestdap>=1 
 
 
Sum  if low_provider==1 & low_pcsa==1 
Sum  if high_provider==1 & low_pcsa==1 
Sum  if low_provider==1 & high_pcsa==1 


















HPV Study Interview Guide V.1 
 
Interview guide 
Interviewer Name:                                                                                       Interviewee Name: 
 
Site:                                                                                                                 Date: 
 
Time Start:                                                                                                     Time End: 
 
Hello (Dr./Mr./Ms. insert interview participant name),  
My name is Roman Ayele and I am a PhD student at Colorado School of Public Health. I am 
conducting a series of interviews aimed at Understanding Provider Barriers to ordering 
and administering vaccine to adolescents in Colorado. The purpose of the interview is to 
help us understand provider practice and perspective to administering and recommending 
vaccines on the adolescent platform such as HPV, Tdap, Meningitis vaccines, facilitators and 
barriers to adequate immunization, and obtain general recommendations as to how to improve 
immunization rates. We will be interviewing providers from throughout Colorado. We are 
interested in any and all factors that you feel could be important for this topic. 
 
This interview should take 30 to 60 minutes, and my questions relate only to your professional 
experience as a Primary Care Provider/OBGYN and we won’t ask any information related to 
you that aren’t relevant to your work duties and responsibilities. Your decision to speak with 
me is voluntary.  You can also refuse to participate or answer any questions, and you may 
stop this interview at any time.  If, at a later time, you’d like to retract certain statements, you 
may do so.  Your information will be stored on a password-protected computer.   
 
And, lastly, this project will help to inform efforts to improve vaccination rates among 
adolescents in Colorado.  And, if you agree to participate, we’d like to record our interview, so 
that we can capture all of the important information that you share with us.  We will not identify 
you as a participant, nor will we identify your site in any of our reports.  We will aggregate the 
findings into a single report. Is this ok with you?  Y/N  If yes, we will ask you these questions 
again when the audio recording begins.  
 
We will now begin the audio recording: I have three questions for you.  The first is, are you 
willing to participate in this interview? Do you give us permission to record this interview? And, 
do you give us permission to contact you at a later time if we have additional questions? 
 
If you have questions about this QI project, you may contact me, Roman Ayele (720-402-
0489 and Roman.Ayele@ucdenver.edu) or our ethics review board COMIRB (303- 724-
1055 and COMIRB@ucdenver.edu).  
1. Tell me about your role in recommending and administrating vaccines and how long 
you have been doing this 
 
2. Focus on a specific visit and describe the vaccine related discussion you had with an 




I. How common are such discussions? 
II. Do they vary by vaccine type? 
 
3. What is your perception of the family's decision-making process? 
I. Does it vary by vaccine type? 
 
4. Are there families who specifically request HPV, Tdap, or Meningitis vaccines for 
their adolescents? 
 
5. Are there parents who refuse HPV, Tdap, or Meningitis vaccine for their 
adolescents? 
I. What are some of the reasons mentioned? (cost, sexual activity, religious or 
philosophical beliefs, vaccine safety) 
II. How do you address these concerns brought up by parents? 
 
6. Tell me about HPV, Tdap, Meningitis vaccines. When do you recommend 
adolescents get vaccinated? What dose do you recommend for adolescents? 
 
7. Do you endorse these vaccines to your adolescent patients/their parents?  Why or 
why not? 
I. Do your patients and\or their families know this?  
II. How do you tell them? 
8. Do you recommend these vaccines to all your adolescent patients who come to your 
clinic?  
I. Why or why not? 
9. Are you able to obtain a sufficient supply of adolescent vaccines for your patients? 
10. What are some of the barriers you face to providing HPV, Tdap, Meningitis vaccines 
to adolescents? 
11. What are the facilitators to administering HPV, Tdap, Meningitis vaccines to 
adolescents 






Current Procedural Terminology (CPT) codes for vaccine and well child visits 







 99411, 99412, 99420, 99429 
 In conjunction with diagnosis codes specified: 
 Prior to Oct 2015: 
o Preventive care ICD-9 codes:  V20.0, V20.2, V70.0, 
V70.3, V70.5, V70.6, V70.8, V70.9 
o Sick ICD-9 codes: Any code starting with 0, 1, 2, 3, 4, 
5, 6, 7, 8, 9, E 
 Oct 2015 and later 
o Preventive care ICD-10 codes: Z76.1, Z00.129, 
Z00.00, Z02.89, Z02.1, Z00.8, Z00.5 
o Sick ICD-10 codes:  Any code except those starting 
with “Z” 
o Vaccines: 
 Vaccine administration CPT Codes: 
 90471-90474, 90460, 90461 
 HPV Vaccine CPT Codes: 
 90649, 90650, 90651 
 Tdap Vaccine CPT Codes: 














Richard Lindrooth, PhD (Research Mentor) is a Professor and interim Chair in the 
Department of Health Systems, Management and Policy in the Colorado School of 
Public Health at the University of Colorado.  He is also a Co-Director of the 
Department's Health Service Research PhD program.  As a health services research 
methodology expert, he provided expertise on issues related to study design, data 
management, quality control, data analysis, and preparation of manuscripts.  
Catherine Battaglia, PhD, RN (Dissertation committee chair) is an Assistant 
Professor with the University Of Colorado School Of Public Health and is the Co-
Director of the Health Services Research PhD Program. She currently teaches 
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second year medical and physician assistant students work with a community-based 
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Sean O’Leary, MD (Research committee member) is an infectious disease doctor 
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